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SUMMARY
The purpose of this study was to develop a 
screening procedure for the detection of non-steroidal 
anti-inflammatory drugs (NSAIDs) in the urine of the 
racing greyhound. The study was divided into three parts, 
dealing with the evaluation and selection of an 
appropriate analytical methodology, the investigation of 
acidic endogenous components of greyhound urine and the 
analysis of selected NSAIDs in urine following 
administration at therapeutic levels to greyhounds.
(1) in the first part of the study, the analytical 
methods examined were isocratic high pressure liquid 
chromatography (HPLC) with ultraviolet (UV) detection, 
capillary gas chromatography (GC) with temperature 
programming and flame ionisation detection and gas 
chromatography-mass spectrometry (GC-MS). Twelve NSAIDs 
in common use in the UK were selected as test compounds 
for the evaluation of the separating ability, selectivity 
and sensitivity of detection of the three methods.
(a) HPLC : For one compound, phenylbutazone, the HPLC
capacity factor (k') was measured in seven reversed-phase 
solvent systems using an octadecylsilane column. The 
remaining compounds were examined on two selected 
systems. In addition, fluorescence spectrometry and 
electrochemical detection (ECD) were examined to assess 
their value as additional HPLC detection systems which 
might increase the selectivity or sensitivity of the
method. All of the test compounds were eluted from the 
column and could be detected by UV spectrometry at a 
sample size of 5 nanograms on-column. Five of the test 
compounds could be detected by fluorescence spectrometry 
and seven by E C D . However, none of the solvent systems 
examined resolved all of the test compounds from each 
other.
(b) GLC : Three chemical derivatives were evaluated to 
increase the thermal stability and improve the 
chromatographic behaviour of the test compounds - the 
methyl, trimethylsilyl and tertiary-butyldimethylsilyl 
derivatives. The retention indices of the three 
derivatives for each substance were recorded using a glass 
capillary column coated with dimethylsilicone (non-polar) 
stationary phase. Three compounds, all pyrazolidine 
diones, could be chromatographed without derivatisation 
but produced a mixture of products following reaction with 
the methylating agent, diazomethane. These were further 
examined by mass spectrometry.
(c) GC-MS : Gas chromatography with mass spectrometric
detection was carried out using similar GC conditions to 
those described above. Electron impact spectra were
recorded at 70 ev for each of the derivatives of the test 
substances and possible fragmentation reactions giving 
rise to the most prominent ions in the spectra were
proposed. The reaction products of pyrazolidinedione 
NSAIDs produced by reaction with diazomethane were
characterised by GC-MS and tentative structures were
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proposed in which methylene addition had occurred at the 
enol-oxygen atom and at the carbonyl group, to give enol 
ethers and oxiranes respectively.
It was concluded that GC-MS was the only method 
which would have sufficient selectivity and separating 
ability for use in a screening procedure and this method 
was used in the rest of the study.
(2) The second part of the study established the normal 
pattern of organic acids present in greyhound urine, which 
would be co-extracted with any NSAIDs present and might 
lead to interference in the detection and quantitation of 
the drugs.
Three different chemical derivatisation methods 
(methylation, trimethylsilylation and tert-butyl- 
dimethylsilylation) were evaluated using standards of 
acids normally present in human urine. Both gas 
chromatographic retention data and mass spectra were 
collected. The latter were examined to establish the main 
fragmentation pathways for each type of derivative.
Urine samples were collected from 3 dogs and l 
bitch, kept in registered kennels, at different times of 
the day and on successive days. Acid extracts were 
prepared for GC-MS analysis using a solid-phase method 
based on cross-linked polystyrene resin (XAD-2). A pooled 
extract was subdivided into portions and derivatised by 
four procedures including those listed above and also by 
combined methylation-trimethylsilylation. The four
derivatives were analysed by GC-MS and revealed complex
mixtures of acids, of which more than seventy components
were identified.
Although the tertiary-butyldimethylsilyl deriva­
tives gave excellent diagnostic ions, little data was
available in the literature to assist in the
identification of unknown acids. The methylated extract
presented the least complex chromatogram and methylation 
was used for subsequent analysis. The urinary acid
pattern varied between animals, according to the time of 
day and from day to day.
(3) In the third part of the study five test compounds
(ibuprofen, naproxen, ketoprofen, mefenamic acid and 
phenylbutazone) were administered at therapeutic levels to 
greyhounds. Blood and urine samples were collected
serially in the ibuprofen and mefenamic acid experiments. 
Urine samples only were collected for the remaining three 
compounds. urinary creatinine concentrations were 
measured for each sample.
The urinary components were extracted as before 
with XAD-2 resin and glucuronide and sulphate conjugates 
present in the samples were hydrolysed by incubation with 
helix-pomatia extract. Plasma samples were extracted
using heptane:ethyl acetate. All samples were methylated 
using diazomethane.
The five test compounds were detected and
quantified in the urine and plasma samples collected. 
Plasma drug concentration/time curves and excretion
profiles were obtained for ibuprofen and mefenamic acid.
Metabolites of ibuprofen and naproxen were observed in 
urine samples. The importance of parallel creatinine 
measurements to correct for variation in the urinary 
volume was shown in the naproxen study. The implications 
of the results with respect to the detection of these five 
drugs and the interpretation of their concentrations 
during a screening procedure at a race meeting are 
discussed.
C H A P T E R  O N E
INTRODUCTION
1.1 DRUGS IN SPORT
The abuse of drugs in sport is believed to have 
occurred as far back as the Third Century B.C., when
athletes, competing in the Olympic Games, used any means 
possible to improve their performances. In 1879, in the 
Six Day Cycle Race, French competitors are reported to 
have used caffeine, cocaine and strychnine, and Belgians, 
sugar soaked in ether, in order to improve their
performance. Whereas in amateur sporting events such as
the Olympic Games, honour and prestige are at stake,
greyhound and horse racing offer the incentive of prize 
money.
In 1967 the cyclist Tommy Simpson died while 
competing in the Tour de France, Simpson had over-exerted 
himself and put tremendous strain on his heart. 
Post-mortem findings revealed that he had taken
amphetamine, methamphetamine and alcohol. This was to be 
a final stimulus to the International Olympic Committee 
prior to the beginning of drug testing in human sport in
the Mexico Olympics in 1968.
Greyhound racing is a major spectator sport in
Great Britain, second only to football in the number of
participants. It is also a popular gambling sport 
accounting for approximately 25% of the £4 billion staked 
in Britain each year. Two types of greyhound tracks exist
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in the U.K; 37 tracks under the aegis of the National 
Greyhound Racing Club (N.G.R.C.), which corresponds to the 
Jockey Club of horse racing, and the independent "flapping 
tracks".
At N.G.R.C. tracks such as Shawfield in Glasgow and 
Powderhall in Edinburgh, dogs run under official rules and 
are subject to drug testing. The "flapping tracks" do not 
carry out drug testing procedures.
Pre-race drug screening of urine samples is carried 
out in a laboratory at the track on all competing 
greyhounds two hours before a race. Samples found to be 
positive at this stage are submitted for further 
examination to the Department of Forensic Medicine and 
Science at Glasgow university and the animal involved 
would be immediately withdrawn from the race. About 
80,000 pre-race samples are analysed each year. In 1988, 
622 samples were assessed as positive at the track 
laboratories and were submitted to Glasgow University for 
further analysis. of these samples 37 were found to 
contain a banned substance. Table l.l.l lists the 
frequency and the drugs detected.
The list of prohibited substances used 
internationally by many racing authorities, including the 
N.G.R.C., is comprehensive, and the intention is to ban 
the use of any drug in racing greyhounds at the time of 
competition. By contrast the stated intention of the 
Medical commission of the International Olympic committee 
is to ban those drugs which are likely to be harmful when
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TABLE 1.1.1: Drugs reported to be present in the urine of racing
greyhounds in Britain in 1988.
Number of
D R U G Occasions
Detected
Caffeine 13
Chlorpromazine A
Cyclizine A
Quinalbarbitone A
Quinine/Quinidine 3
Primidone and Phenobarbitone 1
Amphetamines 1
Ibuprofen 1
Caffeine, Theophyline and Diazepam 1
Millophylline 1
Diazepam and Diphenhydramine 1
P-Aminobenzoic Acid 1
Procaine 1
Glutethimide 1
misused, but with the minimum of interference with the 
normal therapeutic use of drugs. Non-steroidal 
anti-inflammatory drugs for instance, are banned in 
greyhound racing but are permitted to athletes.
Drugs may be used to try to increase or decrease
the performance of a greyhound but the desired effect is 
never guaranteed. A wide range of drugs has been detected 
in the urine of racing greyhounds, i n d u c i n g  stimulants
such as amphetamine and caffeine, sedatives such as 
barbiturates, phenothiazines, benzodiazepines and 
chlorbutanol, and also non-steroidal anti-inflammatory 
drugs such as phenylbutazone.
The preferred body fluid used for analysis in all 
species is urine. The collection of urine is non-invasive
and is easy to obtain. Greyhounds readily provide a urine
sample when released from their transporter. The 
authenticity of the urine sample must be ensured. 
Therefore, samples must be correctly labelled and 
contamination, or sample-switching must be avoided.
In the case of greyhound racing, the urine sample
is divided into two portions; one is analysed at the
track and the second portion is analysed at Glasgow 
University if the pre-race screening test is positive. 
The racing manager at the track can also request that a
post-race sample is analysed at the University if he 
suspects that an animal is not performing as he would have 
predicted.
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1.2 PHARMACOKINETICS AND DRUG METABOLISM
1.2.1 PHARMACOKINETICS
The disposition of a drug is controlled by three 
major processes: (i) absorption into the blood
(ii) distribution from the blood to peripheral tissues 
and (iii) elimination by both metabolism and excretion. 
Pharmacokinetics is a mathematical expression of these 
rate processes.
Figure 1.2.1 illustrates a typical plot of plasma 
concentration (Cp) versus time for a drug given by 
intravenous injection and orally. The terminal 
elimination rate of plasma concentration is the same 
irrespective of the route of administration. For most 
drugs the phase of elimination follows first order
kinetics.
Drugs, metabolites and their conjugates are removed 
from the body by various physiological channels of 
excretion including the urine, bile and faeces.
Successful clearance depends on physiological mechanisms 
of transport (heart, vessels, blood and circulation) and 
of excretion (kidney and bowel functions) and is related 
to the physico-chemical properties of the drug molecule, 
in particular water solubility and protein binding.
The main route of excretion is in the urine. Drugs 
appear in the glomerular filtrate but if they are
lipid-soluble they are readily reabsorbed in the renal 
tubules by passive diffusion. Metabolism of a drug often 
results in a less lipid-soluble compound, aiding renal
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FIGURE 1.2.1: Plot of plasma concentration versus time for a drug
given by intravenous injection and orally.
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excretion (see section 1.2.2). The pH of the urine will 
affect ionisation of weak acids or bases. Unionised drug 
is reabsorbed; ionised drug is cleared. Manipulation of
the urine pH is sometimes useful in increasing renal
excretion. For example, bicarbonate administration makes 
the urine alkaline; this ionises aspirin making it less
lipid-soluble and increasing its rate of excretion.
Bile is also a route of clearance. once excreted
the drug is cleared in the faeces, but some drugs are 
reabsorbed to a significant extent through entero-hepatic 
circulation (Figure 1.2.2). The effect is to prolong the 
presence of a drug in the body.
Some of the terms used in pharmacokinetics which
are relevant to later discussion are outlined briefly 
below. Reviews of all aspects of pharmacokinetics are 
discussed elsewhere [1-3].
(a) Half-Life: the half-life (t„) is the time
n
taken for the concentration of a drug in blood to fall by
half its original value (Figure 1.2.1). Measurement of
the t,, allows calculation of the elimination rate n
constant (k) from the formula:
k = 0 . 6 9 3 /117 
/2
(b) Elimination Rate Constant: the elimination rate 
constant (k) is the fraction of drug present at any time 
that would be eliminated in unit time. For example, 
k = 0.02 min-1 means that 2% of the drug present is 
eliminated in 1 minute.
FIGURE : 
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(c) Volume of Distribution: the volume of distribution
(VD ) is the apparent volume . into which a drug is
distributed.
(d) clearance: Clearance is the volume of blood or
plasma cleared of drug in unit time. Plasma clearance 
(clp) is given by the expression: Clp = vD k. and the
rate of elimination = Clp x Cp. Clearance is the sum of 
individual clearances, including metabolic and renal 
clearance.
1.2.2 DRUG METABOLISM
Since in greyhound racing the analyst is generally
supplied with a urine sample for analysis he must be aware
of the rates and products of metabolism of any drugs which 
might be present.
The metabolism of drugs (that is, the effect that 
an organism has on drugs), encompasses a wide range of 
chemical reactions. Drug metabolism is generally divided 
into two phases: Phase I (reactions on functional groups)
and Phase II (conjugation reactions)[4]. Phase I 
reactions include oxidation, reduction, hydrolysis and 
hydration and Phase II reactions include glucuronidation, 
sulphation, methylation and amino acid conjugation.
Drugs are often lipophilic in nature and in order 
to eliminate them from the body they have to be 
metabolised to a more water-soluble form.
Figure 1.2.3 gives a few examples of the type of 
reactions involved in the metabolism of drugs. Oxidation 
reactions can be divided into two types depending on the
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FIGURE 1.2.3: 
I . Oxidation involving cytochrome P-450
(a) The oxidative deamination of amphetamine
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(b) The side-chain hydroxylation of pentobarbital
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(c) The S-oxidation of chlorpromazine
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(d) The N-demethylation of diazepam
Cl ~ NCl
+ HCHO
II Other enzyme systems e.g. xanthine oxidase 
(a) The oxidation of caffeine
NH
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enzymes involved; oxidation performed by the microsomal 
mixed-function oxidase system (cytochrome P-450-dependent) 
and other oxidation systems. The mixed-function oxidase 
system performs many different functionalisation 
reactions; four examples are given in Figure 1.2.3. The 
other oxidation reactions are performed by a number of 
enzymes in the body not related to mixed-function 
oxidases, including alcohol dehydrogenase, xanthine 
oxidase and amine oxidase.
The main function of Phase I metabolism is to 
prepare a compound for Phase II metabolism and not to 
prepare the drug for excretion. Phase II is the true 
'detoxification' of drugs and gives products that are 
generally water-soluble and easily excreted.
In most cases the end products of Phase I 
metabolism is a chemically reactive functional group, such 
as -OH, -NH2 , -SH and -COOH. Drugs containing these 
functional groups can then be conjugated in Phase II 
reactions with compounds such as glucuronic acid, glycine, 
glutathione and sulphates.
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1.3 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
The non-steroidal anti-inflammatory drugs (NSAIDs) 
form part of a group of drugs used in the treatment of 
arthritis and have analgesic, anti-inflammatory and 
antipyretic properties. Their abuse in greyhound racing 
may be with the intention to alleviate the pain, swelling 
and stiffness of injured joints and may help a dog which 
is not quite at its peak to run a little better. They may 
also enable a lame dog to run. The use of NSAIDs is 
banned by the N.G.R.C. in greyhounds during competition.
The non-steroidal anti-inflammatory group of drugs 
contains a diverse range of structural types, but most are 
acidic and can be classified under three main headings: 
arylcarboxylic, arylalkanoic and enolic acids. Examples 
of each group are shown in Table 1.3.1. Representative 
members of each group were selected for inclusion in this 
study (indicated with *); these are the compounds most 
widely prescribed in Great Britain in the treatment of 
arthritis.
Despite the diverse structural range within the 
NSAID group their pharmacological properties are very 
similar. Their mode of action is complex but generally 
speaking they all inhibit the biosythesis and release of 
prostaglandins which are involved in the pathogenesis of 
inflammation and fever. The pharmacology of these drugs 
is well reviewed elsewhere [5] and will be discussed in 
subsequent chapters.
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TABLE 1.3.1: Non-steroidal anti-inflammatory drugs used in
treatment of arthritis.
ARYLCARBOXYLIC ACIDS
Salicylic Acids
Acetylsalicylate 
Diflunisal
Anthranilic Acids (Fenamates)
Etafenamic Acid 
Flufenamic Acid 
Meclofenamic Acid 
*Mefenamic Acid
ARYLALKANOIC ACIDS
Arylpropanoic Acids
*Fenbufen 
Fenprofen 
*Flurbiprofen 
*Ibuprofen 
Indoprofen 
*Ketoprofen 
*Naproxen 
Tiaprofenac
Idene and Indole Acetic Acids
*Indomethacin
*Sulindae
Arylacetic Acids
Alclofenac 
Diclofenac 
Fenclofenac 
Fentaizac
Heteroaryl Acetic Acids
Tolmetin
Zomepirac
ENOLIC ACIDS
Pyrazolidinediones
*Azapropazone
Feprazone
Kebuzone
^Phenylbutazone
*Sulphinpyrazone
Oxicams
*Piroxicam
the
* representative NSAIDs included in this study.
1.4 PROJECT AIMS
The purpose of this study was to develop a 
screening procedure to detect and identify non-steroidal 
anti-inflammatory drugs in the urine of the racing 
greyhound. In order to do this it was necessary to 
establish a method for systematic metabolism studies.
Since many NSAIDs and their metabolites resemble 
endogenous substances screening for NSAIDs in urine is a 
difficult problem requiring relatively sophisticated 
methodology.
Although the metabolism of NSAIDs has been 
extensively studied in rats, rabbits and humans, it was 
expected that due to the low fat and high muscle mass of 
the greyhound, the metabolism of these compounds may be 
quite different from other animals, both in terms of 
pharmacokinetics and the nature and relative amounts of 
the metabolites formed. A knowledge of these sets of 
information for each drug of interest is a necessary 
pre-requisite for the creation of an efficient drug 
screening procedure.
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C H A P T E R  T W O  
ANALYTICAL METHODS
2.1. INTRODUCTION
The purpose of this study was to develop a method 
to screen qualitatively and quantitatively for 
non-steroidal anti-inflammatory drugs (NSAIDs) in the 
urine of the racing greyhound. The twelve drugs which 
were chosen for study, as the most commonly prescribed 
representatives of the class of drugs in the U.K., were 
ibuprofen, flurbiprofen, naproxen, ketoprofen, fenbufen, 
mefenamic acid, indomethacin, sulindac, phenylbutazone, 
sulphinpyrazone, azapropazone and piroxicam.
Most NSAIDs can be quantified using 
spectrophotometric and/or spectrofluorometric techniques. 
These methods, however, were not suitable for this study 
because they are not specific due to interferences from 
metabolites, other drugs and endogenous co-extracted 
material from body fluids. Immunological methods also 
were not considered. it would be impossible to raise one 
antibody against a group of drugs with such diverse 
chemical structures. screening would require sets of 
antibodies for each chemical class (when screening for 
drugs of abuse, for instance, radioimmunoassays are run 
for opiates, eannabinoids and amphetamines). only 
chromatographic techniques will be considered here.
The literature contains many specific methods for
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the analysis of analgesics in various matrices including 
pharamaceutieals and body fluids but few studies include 
more than about ten NSAIDs [6-14] and even fewer assay 
several of the drugs in urine [6,7,15-17]. The methods
which assay the drugs in urine will be considered first.
Hunt and co-workers [6] developed a gas 
chromatographic screening procedure for a limited 
number of NSAIDs in horse urine. The drugs were 
solvent extracted from urine and were detected by gas 
chromatography (GC) with flame ionisation detection (FID) 
after on-column methylation using trimethylanilinium 
hydroxide as the methylating reagent. Fifteen NSAIDs were 
studied. Eight of the drugs were detected in horse urine 
(including mefenamic acid, ibuprofen, indomethacin,
naproxen and ketoprofen) after the animal had been 
administered with the drug. The other seven drugs 
(including flurbiprofen) detected by this method were 
simply added to the horse urine. Hunt and his colleagues 
used a packed GC column (equivalent to SE-30) and a 
temperature programmed run. The methylation procedure was 
found not to be sufficiently reproducible and could not 
therefore be used for quantitation. No metabolites were 
detected using this method. However, the authors
commented that to detect the metabolites hydrolysis of the 
urine would most likely be necessary.
The method of Hunt and co-workers was further
developed by Chalmers and colleagues in 1984 [7] and 
employed a combination of thin layer chromatography (TLC),
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high-performance liquid chromatography (HPLC), GC and 
gas-chromatography mass spectrometry (GC-MS). TLC was 
carried out using Kieselgei plates and a mobile phase of
ethylacetate:methanol:0.88 ammonia (8:l:l, v/v/v) and the 
plates were examined under uv light before overspraying 
the plates with acidic spray reagents. GC was effected 
with a packed column as before [6] but used both FID and 
nitrogen-phosphorus detection (NPD). The HPLC system was 
reversed-phase and consisted of a pre-column (Co Pell 
clg , 5cm x 4.6mm) and an analytical column of octadecyl 
silica (O D S ) (lopn, 22cm x 4.6mm), UV detection was at 
280nm. Gradient elution was carried out with an
acetonitrile/o. 1M acetic acid mix. The TLC and GC methods 
were successful in detecting the standard drugs, but the 
HPLC method failed to detect ibuprofen and a few of the 
other test compounds. The chromatographic systems were
less effective when used to assay the drugs in the 
presence of urine. Twenty-three out of the twenty-eight 
drugs assayed were detected using a combination of the 
three methods but the other five compounds were difficult 
to distinguish from co-extracted material present in the 
horse urine.
Each HPLC method in the literature which assays
NSAIDs in urine can only resolve a limited number of 
drugs. Three such methods have been developed by Upton 
and co-workers [15], Thomas and co-workers [16] and 
Ng [17] and are discussed below.
In 1980 Upton and co-workers [15] reported a
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sensitive HPLC method for five NSAIDs (including 
ketoprofen and naproxen) in plasma and urine. The drug 
conjugates were hydrolysed in 1M sodium hydroxide before 
analysis and extracted by solvent extraction. The method 
of detection was HPLC-UV (at 262nm) using a reversed-phase 
system consisting of an o d s  column (5)im, 4cm x 4.6mm) 
protected by a 4cm x 3.2mm pre-column and a mobile phase 
of 0.05M phosphate buffer (pH7) containing between 6 and 8 
percent (v/v) acetonitrile. This system could resolve 
naproxen, ketoprofen, ibuprofen, fenoprofen and probenecid.
Thomas and colleagues reported an HPLC method for 
the analysis of six NSAIDs (including indomethacin, 
ketoprofen, naproxen and phenylbutazone) in plasma or 
urine. Diluted urine, protein-free plasma or ether 
extracts were injected onto the ODS column (5cm x 5mm). 
The mobile phase was aqueous methanol adjusted to p H 3 . 
The methanol content and detection wavelength had to be 
altered to optimise the system for each drug.
Ng used a simple sample preparation of salt 
precipitation of proteins followed by HPLC-UV to analyse 
four NSAIDs (including indomethacin, phenylbutazone and 
sulindac). The HPLC consisted of an o d s  column 
(30cm x 3.9mm) and the solvents used as mobile phases were 
aqueous mixtures of acetonitrile and methanol acidified 
with phosphoric acid to p H 2 .2. similar to Thomas and 
co-workers’ method, Ng's mobile phase composition varied 
depending on the drug of interest.
other workers who have analysed ten or more
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NSAIDs have developed methods to analyse the drugs 
in blood [8] or plasma [9,13,14] or simply drug 
standards [10,11,12].
Recently Sharp reported [8] a GC-FID method which 
involved a single extraction with ethyl acetate for sixty 
acidic or neutral drugs in blood (including nine of those 
of interest in the present study). The samples were 
assayed either without derivatisation or with on-column 
methylation (using flash-heater methylation) on a fused 
silica capillary column with a split injector. A 
temperature programmed run was used. out of the nine 
drugs of interest which were examined, indomethacin and 
piroxicam were found to have poor chromatographic 
properties, ketoprofen, naproxen and phenylbutazone were 
found to give multiple peaks on methylation and sulindac 
did not chromatograph at all.
Two of the methods which assayed several NSAIDs in 
plasma were HPLC methods [9,14]. The HPLC assay of 
Nielsen-Kudsk [14] assayed fifteen NSAIDs, including nine 
of interest in this study. An ODS column (30cm x 3.9mm) 
with a methanol-phosphate buffer was used, the methanol 
content needing to be altered to obtain optimal 
separation and reasonable elution times as with other 
methods already discussed [16,17]. Owen and co-workers 
recently reported a rapid HPLC assay for the simultaneous 
determination of nine NSAIDs [9]. The system consisted of 
an ODS column (30cm x 3.9mm) and a phosphoric acid 0.03%, 
pH2.5 - acetonitrile (45:55, v/v) mobile phase. Ketoprofen
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and naproxen were not sufficiently separated with this 
system and the detection wavelength had to be altered to 
provide sufficient sensitivity to measure ibuprofen. The
authors noted that the metabolites of phenylbutazone, 
present in the plasma, would interfere in the elution of 
naproxen and ketoprofen.
Giachetti reported [13] a solvent extraction method 
from plasma of ten NSAIDs (including four of interest in
the present study) followed by capillary GC analysis of
the methyl esters. The methyl esters were formed using
anhydrous diazomethane in diethyl ether and a temperature 
programmed run and FID detection were used. This system
was able to resolve all the standards examined, but some 
of the later-eluting peaks (including indomethacin) were 
broad.
Some methods have presented retention data for ten 
or more compounds when considering interferences with 
specific assays. Two assays of this type have been 
reported; the analysis of ibuprofen in dog serum [11]
and the determination of naproxen in plasma [12]. The 
other NSAIDs mentioned in these two papers were
therefore non-extracted drug standards. Kearns and 
Wilson [11] found indomethacin to interfere in their 
ibuprofen assay which consisted of a solvent 
extraction followed by HPLC analysis on an ODS
column with a mobile phase of methanol-water-glacial 
acetic acid (pH3.4, 75:25:1, v/v/v). in the naproxen 
HPLC assay of Broquaire and co-workers [12]
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oxyphenbutazone and sulindac were reported to interfere 
with the analysis. in this assay an ODS column was also 
used and the mobile phase was acetonitrile-aqueous 
orthophosphoric acid (pH3f 45:55, v/v) .
In 1986 Stevens and Gill [10] reported HPLC 
retention data for over forty analgesics, including nine 
of those of interest. The authors reported that initial 
experiments with various eluents revealed that the 
analgesic drugs showed a very wide range of retention 
properties. Stevens and Gill found that a series of 
isocratic eluents were necessary to elute the compounds of 
interest with suitable retention characteristics. An ODS 
silica stationary phase was employed and three different 
isocratic eluents were used. The eluents were prepared 
from isopropanol, formic acid and an aqueous phosphate 
buffer. Nine of the compounds of interest were eluted
with the mobile phase isopropanol - potassium hydrogen 
phosphate (0.1M) - formic acid (154:1000:1, v/v/v).
There are other methods available which assay 
between three and ten NSAIDs. The majority of those
methods have been based on HPLC and are similar to the 
ones already mentioned in that they all employ a
reversed-phase system using an ODS column and an acidic 
mobile phase. some of these methods are isocratic [18-23] 
while others employ gradient elution [24] or some
modification of wavelength and/or mobile phase to enable 
detection of all the drugs examined [25,26].
Ford and co-workers [27] reported a rapid
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extraction method for acidic drugs in blood employing 
GC-NPD and GC-MS. The only drugs of interest which were 
examined were ibuprofen and phenylbutazone.
in this study it was decided to examine HPLC, GC
and GC-MS as possible methods for the analysis of the 
twelve NSAIDs. It was realised that isocratic HPLC alone 
would not be selective enough for the drugs of interest 
(a gradient system was not available) so different methods 
of detection, such as UV, fluorescence and electrochemical 
detection were examined. It was decided that a reversed- 
phase system with an acidic mobile phase would be 
necessary to elute the compounds and this has been 
demonstrated in the literature already mentioned.
A capillary GC method would also be examined. It
was thought that a capillary column would be necessary to
provide sufficient resolution of the twelve compounds. As
it would be necessary to derivatise some of the drugs of 
interest, different methods of derivatisation would be 
examined.
Finally it was thought that GC-MS would be 
necessary to give absolute identificaton of the twelve 
compounds, so GC-MS of the standards and their derivatives 
would be considered.
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2.2 CHROMATOGRAPHY ; GENERAL INTRODUCTION
2.2.1 HISTORY
Mikhail Semenovich Tsvet, a Russian botanist, was 
the pioneer of chromatography; he first described the 
method in 1903 [28] and gave a full account of it in 
German in 1906 [29]. Tsvet employed the technique to 
separate various plant pigments such as chlorophylls and 
xanthophylls by passing a solution of their compounds 
through a glass column packed with finely divided calcium 
carbonate. The separated species appeared as coloured 
bands on the column, which accounts for the name Tsvet 
chose for the method. Although the technique had been
used occasionally between 1910 and 1930 [30] it was not 
until 1931 when work was published by Kuhn and 
co-workers [31] that chromatography came into general use.
Martin & Synge published their first paper on
liquid-liquid partition chromatography in 1941 [32], It
was here that they first introduced the concept of 
gas-liquid chromatography. This idea, however, lay 
dormant until 1952 when James and Martin published the 
first report devoted to the subject of gas-liquid
chromatography [33]. They separated a series of fatty 
acids using a titration procedure as a detector employing 
a microburette. The microburette was eventually automated 
providing a very effective on line detector with an 
integral response [34].
High pressure or high performance liquid
chromatography (HPLC) was subsequently developed from work
- 24 -
on the theory of partition chromatography by Martin
and Synge [32] and from experience in gas-liquid
chromatography. Giddings [35] provided a major theoretical 
influence on the advance of HPLC, but instrumental
problems delayed its realization. The major experimental 
advances which brought about practical high pressure 
liquid chromatography systems, were made by Lipsky in 
1967 [36], Huber in 1967 [37] and Kirkland in 1969 [38].
The applications of chromatography have grown 
exponentially in the last forty years and the tremendous 
impact which these methods have had on science is attested 
by the 1952 Nobel Prize that was awarded to Martin and 
Synge for their discoveries in the field.
2.2.2 TYPES OF CHROMATOGRAPHY
Chromatography is essentially a technique for the 
separation of the components of mixtures by a continuous
distribution of the components between two phases, one of 
which (the mobile phase) is moving past the other (the 
stationary phase). The technique relies upon inter- 
molecular interactions in the mobile and stationary phases 
to cause differences in the migration rates of the 
components thus achieving a separation. Table 2.2.1 lists 
the types of interactions which are possible.
chromatography is generally divided into four 
types: adsorption, partition, ion exchange and molecular
exclusion, depending on the primary interactions operating 
in the system. However, the four types of chromatography 
cannot be so easily compartmented as described here. in
i
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TABLE 2.2.1: Types of interactions involved in chromatography
System
Primary
Interaction
Secondary
Interaction
Adsorption Hydrogen Bonding 
Dipole-Dipole
Ion-Ion Interaction 
Van Der Waals
Partition Van Der Waals Hydrogen Bonding 
Ion-Ion Interaction
Ion-Exchange Ion-Ion Interaction Hydrogen Bonding 
Van Der Waals
Molecular Exclusion Steric Exclusion
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reality there are no distinct boundaries and several 
different mechanisms, or secondary interactions, often 
operate simultaneously. in gas-liquid chromatography, for 
instance, active sites may be available on the support 
material to allow adsorptive processes to occur as well 
as partition. ion exchange chromatography involves 
hydrophobic interactions and specific adsorption processes 
as well as electrostatic ion interactions.
The choice of mobile phase in gas chromatography is 
fairly limited, an inert gas such as helium or nitrogen 
or argon/methane (for nitrogen-phosphorus detection, 
see Section 2.4.1(c)) is normally used. In liquid 
chromatography the number of mobile phases available is 
extensive, the choice depending on many factors. The 
total interaction of a solvent molecule with a sample 
molecule is a result of four major interactions: 
dispersion, dipole, hydrogen bonding (both proton donors 
and proton acceptors) and dielectric interactions. These 
interactions in combination determine a solvent's 
polarity. The polarity of solvents is typically expressed 
in an elutropic series in which the solvents are arranged 
in order of increasing polarity. Solvent strength 
increases with solvent polarity in normal-phase 
partition liquid chromatography and in adsorption liquid 
chromatrography, whereas in reversed-phase liquid 
chromatography solvent strength decreases with increasing 
polarity. Snyder and Kirkland [39] describe solvent 
selection in their book on modern liquid chromatography
1
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and give a table of solvent polarities.
Recently liquefied gases such as carbon dioxide, 
neon or ammonia have been used as a mobile phase: this is
known as supercritical fluid chromatrography [40].
(a) ADSORPTION CHROMATOGRAPHY
In adsorption chromatography the solute (the 
component to be isolated or measured) and the solvent (or 
mobile phase) compete for active sites on the stationary 
phase. Separations are achieved by the retention 
of a component resulting from its affinity for a 
particular site. The stationary phase is a solid and the 
mobile phase is gaseous or liquid. Adsorption 
chromatography, therefore, includes gas-solid and 
liquid-solid chromatography. Liquid-solid chromatography 
incorporates column chromatography, thin layer 
chromatography and high performance (pressure) liquid 
chromatography.
Gas-solid chromatography is useful for the analysis 
of gases; carbon disulphide [41], carbon dioxide [42], 
propellants [43], solvents [43] and volatile organic 
compounds [44], such as acetonitrile, benzene, carbon 
tetrachloride and styrene. The mobile phase is an inert 
gas such as helium or nitrogen and the stationary phase is 
an active solid. These solids may be inorganic materials, 
for example, synthetic zeolite molecular sieve, carbon 
molecular sieve, silica gel or graphitised carbon, or they 
may be organic polymers. The organic polymers include 
divinylbenzene cross-linked polystyrene co-polymers (the
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Chromasorb and Porapak series) and Tenax-GC, a porous 
polymer of 2 , 6-dipheny1-p-phenylene oxide.
in liquid-solid chromatography, either as column or 
thin layer, silica, alumina or cellulose are commonly used 
as the adsorbent. These adsorbents may have water on 
their surfaces, allowing partition and adsorptive 
processes to occur. The mobile phase can be a pure liquid 
or a mixture of solvents. The choice of solvent is 
determined by the sorption process employed and by the 
nature of the sample components.
Liquid solid chromatography has been employed 
in the analysis of many compounds including 
insecticides [45], antibiotics [46], porphyrins [47], 
flavanoids [48] and organometallic isomers [49].
Thin layer chromatography is used extensively by 
both synthetic and analytical chemists. It is a fast 
method of checking a reaction's progression and a simple 
method to assess a compound's purity and identity [50].
As discussed later in the theory of chromatography 
(Section 2.2.3), chromatographic efficiency increases with 
decreasing particle size of the sorbent. in order to 
achieve a practical flow rate under these conditions a 
positive pressure must be applied to the top of the 
column, this is known as high pressure liquid 
chromatography.
(b) PARTITION CHROMATOGRAPHY
Another form of chromatography is partition 
chromatography. in this case the solute is distributed
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between two immiscible phases according to its partition 
coefficient. Separations are achieved when the components 
of a mixture have different partition coefficients and so 
take different times to travel through the stationary 
phase. The stationary phase is a liquid and the mobile 
phase is gaseous or liquid. Partition chromatography 
includes gas-liquid and liquid-liquid chromatography. 
Liquid-liquid chromatography includes paper, column 
chromatography and high-pressure liquid chromatography.
In gas-liquid chromatography (GC) the mobile phase 
is an inert gas such as helium or nitrogen and the liquid 
stationary phase is coated on a solid support material for 
packed column chromatography. For capillary column 
chromatography the stationary phase may be located 
directly onto the walls of the column or onto a support 
which is bonded to the glass walls. The most common 
support material is calcined diatomaceous earth which is 
acid or base washed to remove impurities and sieved to 
remove fine particles. It can also be treated with a 
silanising reagent which reacts with the surface hydroxyl 
groups and reduces adsorption effects. There are a great 
number of liquid stationary phases available for GC 
covering a wide range of polarity. Some examples of 
stationary phases used in GC are given in Table 2.2.2.
in general, non-polar compounds chromatograph best 
on non-polar phases and polar compounds on polar phases. 
Gas-liquid chromatography has been applied to the analysis 
of many compounds including antifungals [51], amino
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TABLE 2.2.7: Examples of GC stationary phases
Class Structure Character Name
Methylsilicone
ch3
-0— Si— 0—
I
ch3
Non-polar 0V1
SE30
SP2100
Methylphenyl-silicone
ch3
• 0 — S i — o  —
I
c6h5
Medium-polar 0V17
SP2250
Trifluoropropyl-sill cone
ch3
- 0 — S i — 0 -
I
(ch2)2
cf3
Medium-polar QFl
OV210
SP2401
An
Cyanopropyl-methylphenyl-
silicone
ch3 ch3
I I
-Si— 0— Si— 0-
i I
(CH2)2 (ch2)2
ch2cn c6h5
Medium-polar OV225
Neopentylglycol
succinate
8
— o— ch2— c— ch2o— c— ch2—  
I
ch3
Polar NPGS
Polyethylene glycol CH2Oh[ch2OCH2]/7CH2OH Polar Carbowax
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acids [52], fatty acids [53] and there are numerous 
applications of GC to drug analysis; Clarke's "Isolation 
and Identification of Drugs" is an excellent reference 
source [50]. (Gas-liguid chromatography columns will be 
examined in more detail in Section 2.4.1).
Paper chromatography might appear to be a form of 
liquid-solid chromatography, however, due to water 
molecules associated with the cellulose fibres; it is in 
fact an example of liquid-liquid chromatography. Many 
applications of paper chromatography also call for the 
creation of an immobilised solvent layer within the paper 
fibres by dipping the paper in a suitable solvent 
mixture. As in liquid-solid chromatography a range of 
solvents with varying polarities can be employed in the 
elution of paper chromatography.
Liquid-liquid chromatography exists in two forms: 
normal (or straight-phase) and reversed-phase. The normal 
phase mode utilises a non-polar mobile phase and a polar
stationary phase. This type of system would retain polar
solutes and non-polar solutes would elute first. The
reversed-phase system employs a polar mobile phase and a 
non-polar stationary phase, when polar components elute 
first.
Classical liquid-liquid partition systems (in
either column chromatography or HPLC) require a column of 
more or less inert packing material that has been coated 
with a stationary phase. A typical normal phase system 
would use triethylene glycol coated on to a wide pore
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silica gel as stationary phase and triethylene-glycol- 
saturated hexane as mobile phase. This system has been 
used to separate phenols [54], steroids [54] and aromatic 
alcohols [55]. This type of system remains stable as long 
as the eluent is saturated with the stationary phase. 
Reversed-phase systems, where, for example, squalene (a 
non-polar stationary phase) is coated onto a silica based 
support and the samples eluted with a water/alcohol mobile 
phase are no longer used. The squalene, being non-polar, 
is not held strongly on the silica and results in a low 
bleed from the column.
The most widely used column packings for modern 
liquid chromatography are chemically-bonded packings 
prepared by bonding an organic moiety to the surface of an 
adsorbent. Halasze and Sebastian were the first to 
introduce bonded-phase materials in 1969 [56]. A wide
range of functional groups allows both normal and 
reversed-phase chromatography. Polar bonded-phase
packings (for example, silica) are used for normal-phase 
separations. The most popular reversed-phase stationary 
material is octadecyl silane (ODS) in which the c
18
group is bonded to a silica support via a silyl 
ether (siloxane) linkage. The mobile phase is a polar 
solvent such as methanol-water. other chemically-bonded 
stationary phases, for example, have c„ hydrocarbonO
chains, substituents containing aromatic moieties such as 
phenyl groups, or polar groups such as cyanopropyl and 
nitropropyl.
- 33 -
The literature covering separations of drugs, 
pesticides and many other compounds by bonded-phase 
materials, is now vast: examples are given in several
books on HPLC [50,57-60]. Further details of
liquid-liquid chromatography can be found in the text by 
Snyder and Kirkland [39].
Types of HPLC columns will be discussed in 
section 2.3.1.
(C) ION EXCHANGE
Ion exchange chromatography is based on the 
principle that oppositely charged ions are attracted to
each other. The functional groups on the packing material 
are groups such as amines or quarternary amines (for anion 
separation) and sulphonic acid or carboxylic acid (for 
cation separation). For example, an ion exchange column 
may contain sulphonate residues fixed to the stationary 
phase along with oppositely charged counter-ions, Na+ . 
The counter-ions are also normally present in the mobile 
phase as a salt, Nacl, for instance. The ionic sample
molecules, in this case, would be positively charged and 
are retained by exchange with the N a + ions. ion
exchange chromatography has been used to analyse many
biologically important substances [57,59].
(d) Molecular Exclusion
Molecular exclusion chromatography can be carried 
out in both gas chromatography and liquid chromatography, 
where it is also referred to as gel chromatography, gel 
filtration or gel permeation chromatography. This method
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separates molecules on the basis of molecular weight and 
size. The column packing in gel chromatography is porous 
with pores of a certain size. The larger molecules are 
eluted more quickly since the smaller ones diffuse further 
into the pores of the stationary phase and take a longer 
time to be eluted. Molecular exclusion is used, for 
instance, in the analysis of carbon monoxide by GC [61] 
but is mostly used in liquid chromatography of naturally 
occurring and synthetic polymers.
2.2.3 THEORY
(a) THEORY OF SEPARATION AND RETENTION CHARACTERISTICS
In most chromatography systems the stationary phase 
is retained inside a column. This is true for classical 
column, gas-solid, gas-liquid and high-pressure liquid 
chromatography. in the case of thin layer and paper 
chromatography, the stationary phase is an open bed. The 
theory discussed here refers to column chromatography but 
may also be applied to open bed chromatography.
In elution chromatography the sample is applied to 
the top of the column and immediately the components of 
the sample distribute themselves between the mobile and 
stationary phases. introduction of additional mobile 
phase (or eluent) forces the solvent containing a part of 
the sample down the column, where further partitioning 
between the mobile phase and fresh portions of the 
stationary phase occurs. Simultaneously, partitioning 
between the fresh solvent and the stationary phase takes 
place at the site of the original sample. continued
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additions of solvent carry solute molecules through the 
stationary phase in a continuous series of transitions 
between the mobile and the stationary phases. since 
solute movement can only occur in the mobile phase, the 
average rate at which a solute migrates depends on the 
fraction of time it spends in that phase. If the solute 
has a strong affinity for the stationary phase it will be 
retained longer. If, however, the solute has a low 
affinity for the stationary phase it will be eluted more 
quickly. Provided that the column is long enough these 
differences in affinity will result in the components of a 
mixture separating into bands. Theoretically the solute 
molecules should migrate through the stationary phase as 
symmetrical zones. If a detector that responds to solute 
concentration is placed at the end of the column and its 
signal plotted as a function of time (or volume of eluent) 
a series of symmetrical peaks would be obtained.
A plot of time (or volume) versus signal is known 
as a chromatogram and can be useful for both qualitative 
and quantitative analysis. The position of the peaks can 
help to identify the component and the areas under the 
peaks are related to concentration of the components 
(See Figure 2.2.1).
It is apparent that movement down a column 
increases the distance between two components. At the 
same time broadening of both bands occurs which lowers the 
efficiency of the column as a separating device. This 
band broadening is unavoidable, but fortunately occurs
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FIGURE 2.2.1: Chromatogram illustrating some of the terms used in
chromatography (explained in more detail in the text)
C/2
InjecHon 
Point- — '
Time of analysis 
or
Volume of mobile phase
tg retention time of unretained solute peak
V q retention volume of unretained solute peak
t^ retention time of peak A
V retention volume of peak A
■ *A -
t^ adjusted retention time of peak A
VE ■ VR - VQ adjusted retention volume of peak A
WB
peak width of peak B
WH
peak width at half peak height
»A peak height of peak A
hc/2 half peak height of peak c
- 37 -
more slowly than band separation. A useful theory of 
chromatography therefore must account for both the rate at
which solutes migrate and the rate of band broadening.
The rate or kinetic theory of chromatography describes the 
effects of variables on the band retention and band 
spreading characteristics of a system. Thermodynamics 
govern the speed at which any band of solute moves along 
the column and kinetics govern the rate at which a band
broadens as it moves down the column.
During the chromatography process, therefore, the 
sample components quickly distribute themselves between 
the mobile and stationary phases as soon as the sample is 
applied to the top of a column. shortly after the 
commencement of migration an equilibrium is achieved 
between the solute in the mobile phase, xm and the solute 
in the stationary phase, x s :
xm ^==^ xs
This equilibrium can be expressed quantitatively by 
means of a temperature-dependent constant, the partition
coefficient, K:
K = [X s ],
[Xm]
where
[Xs] is the concentration of the solute in the
stationary phase, and,
[Xm] is the concentration of the solute in the mobile
phase.
K is only a constant at low concentration ranges such as 
those generally found in chromatography. For wide
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concentration ranges the variation of K with solute 
concentration must be taken into account. Chromatography 
carried out under conditions such that K is constant is 
called linear chromatography.
During chromatography, molecules move while in the 
mobile phase at the mean linear speed of the mobile phase, 
V, and when in the stationary phase they do not move at 
all. The velocity of the centre of each band is therefore 
determined by the partition coefficient. it follows that 
the speed of the band of solute molecules. Vs, relative to 
the mobile phase is given by:
vs = fraction of solute in mobile
V phase at equilibrium
The fraction of molecules in the mobile phase is given by:
Qm 
Qm + Qs
where
Qm is the quantity of the solute in the mobile phase,
and,
Qs is the quantity of the solute in the stationary
phase.
Therefore,
Vs = Qm
V Qm + Qs
rearranging the above equation gives:
vs = l = l
V 1 + Qs/Qm l + k ‘
The ratio Qs/Qm is known as the capacity factor k 1. It is 
affected by the polarity of the solvent and the packing 
and is a measure of sample retention. The capacity
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factor, k', is a more practical quantity than the 
partition coefficient, K, and can be determined from the 
chromatogram (Figure 2.2.1), thus:
*' ■ VA - V 0
V 0
or
k ' - V  *0
where,
vo is the retention volume of an unretained peak
VA is the retention volume of peak A
ro is the retention time of an unretained peak
and.
is the retention time of peak A
V Q (or tQ ) can be measured by injection, for instance, 
of a dilute solution of sodium nitrite, in the case of 
HPLC, or methane for GC.
The two constants K and k f which describe the 
distribution of a sample component between the mobile and 
stationary phases can be related since.
Quantity = Concentration x Volume
Hence,
k ‘ = Qs/ = fxsivs = K V s  
w  [ X m j v m  v m
Since exact volumes of mobile and stationary phases for
columns are not known absolute retention values are seldom
reported. It is also difficult to obtain exact duplicates
of systems reported in the literature. Relative retention
values are therefore used since individual column
characteristics cancel out when retention values are
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divided. The relative retention value, alpha, is defined 
as the ratio of capacity factors for any two given peaks. 
Alpha is often referred to as the selectivity or 
separation factor and is affected by the chemistry of the 
whole system.
Instead of reporting absolute retention values, in 
GC Kovats indices [62] are used as a measure of a 
compound's retention. This system is based on a linear 
relation between the log of the partition coefficient of 
an aliphatic hydrocarbon in the stationary phase and the 
carbon number in a homologous series of test standards. 
The indices are normally used for isothermal 
chromatography. The expression for the Kovats index is 
given by:-
temperature
S t a t i o n a r y  
-phase
where
tr is the retention time of an unknown
tr(n) is the retention time of a normal alkane having n 
carbon atoms, and,
tr(n + l) is the retention time of a normal alkane having 
(n + l) carbon atoms.
Another retention index system, which normally is 
expressed in methylene Units (M.U) [63] is used with 
temperature programming and is given by an analogous 
expression:
M.u. = tt -ttJ M . * n
tr(n + l) - tr(n)
log tr - log tr(n)______
log tr(n+l) - log tr(n)
-
X 100
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The standardisation of HPLC retention data using 
relative retention times or capacity ratios is 
particularly difficult as the data can be highly 
irreproducible due to differences in nominally identical 
column packing materials or in environmental conditions. 
Attempts have been made to standardise HPLC systems with 
similar methods to the Kovats retention indices used in
GC. instead of using a series of alkanes, as used in GC, 
the system was based on 2-ketoalkanes [64] and more 
recently on a series of alkyl-arylketones [65,66].
(b) COLUMN EFFICIENCY
The efficiency of a separation depends on the
differences in the migration rates of the solutes and on 
the spreading of the solute zone. The rates at which the 
solutes travel depend on their partition coefficients and 
the resultant profile approximates to a normal Gaussian
distribution profile.
The peak maxima represent the k' values of each
component and approximate to the average rate of travel 
of the solute molecules. Ideally a peak would be sharp 
and symmetrical. However, peak broadening occurs 
when molecules with the same k ‘ value migrate at 
different velocities. Chromatographic peaks are generally 
broadened by three kinetically controlled processes; eddy 
diffusion, longitudinal diffusion and non-equilibrium mass 
transfer. The magnitudes of these effects are determined 
by such controllable variables as flow rate, particle size 
of the packing material and the thickness of the 
stationary phase.
A quantitative measure of efficiency is given by 
two expressions; N, the number of theoretical plates and 
H, the height equivalent to a theoretical plate. This 
concept of theoretical plates was originally developed by
chromatographic column as being composed of a series of 
discrete but continuous, narrow, horizontal layers called 
theoretical plates. At each plate, equilibration of the 
solute between the mobile and the stationary phase is 
assumed to take place. Movement of the solute and solvent 
is then viewed as a series of stepwise transfers from one 
plate to the next.
where,
t 1 is the adjusted retention time, and, 
w is the peak width.
The height equivalent to a theoretical plate, H, is given 
by:-
where L is the length of the column.
The number of theoretical plates, then, can be
calculated from the two time measurements t' and W; to
obtain H we must also know the length of the column.
The quantity H measures the efficiency of a given 
column (operated under a specific set of operating
Martin and Synge [32]. The theory envisages a
The number of theoretical plates, N, is given by*. -
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conditions) per unit length of column. The efficiency of 
a chromatographic column as a separation device improves 
as the number of equilibrations increases - that is, as 
the number of theoretical plates increases or the plate 
height decreases. The sharpness of a peak reflects the 
plate height.
Generally speaking, for a gas chromatographic 
packed column the efficiency would be about 500-2000 
theoretical plates, for a gas chromatographic capillary 
column it would be about 10,000-100,000 theoretical plates 
and for a 25cm reversed-phase high performance liquid 
chromatographic column the efficiency would be in the 
range 6,000-12,000 theoretical plates.
(C) BAND BROADENING
As previously mentioned chromatographic peaks are 
generally broadened by kinetically controlled processes. 
These processes are eddy diffusion, longitudinal diffusion 
and non-equilibrium mass transfer. A number of equations 
have been developed that relate efficiency to these band 
broadening factors. The earliest of these is known as the 
van Deemter equation and was derived for gas liquid 
chromatography. The van Deemter equation relates plate 
height to diffusion and average linear velocity, u,
H = A + (B/U)+ CU 
In this equation. A, B and c are associated with eddy 
diffusion, longitudinal diffusion and non-equilibrium mass 
transfer respectively.
Eddy diffusion arises from the numerous ways by
_ 44 -
which a molecule can find its way down a column. The 
lengths of these paths can differ and so two particles of 
the same species can actually take different times to 
emerge, thus contributing to band broadening. The 
quantity A includes factors such as particle size, column 
geometry and uniformity of the packing material. Band 
broadening due to eddy diffusion can be minimised by 
careful packing using small spherical particles with a 
limited size range.
Longitudinal diffusion occurs as molecules tend 
to diffuse from regions of high solute concentration to 
those of low solute concentration and this can occur in 
both the mobile and stationary phases. Longitudinal 
diffusion is more significant when the mobile phase is a 
gas since diffusion rates in the gas phase are several 
orders of magnitude greater than those in the liquid 
phase. Diffusion increases with time, thus broadening 
increases with decreased flow rate. The constant B in the 
van Deemter equation is related to the diffusion 
coefficient and is inversely proportional to the flow 
rate. Broadening due to longitudinal diffusion can be 
reduced by decreasing the temperature (thus reducing the 
diffusion coefficient) and increasing the flow rate.
The third process contributing to the van Deemter 
equation, non-equilibrium mass transfer, arises because 
true equilibrium between phases cannot be achieved due to 
the flow of the mobile phase. At the front of a band, 
where the mobile phase encounters fresh stationary phase.
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equilibrium is not instantly achieved and solute is 
carried further down the column than it would be had a
true equilibrium been established. At the rear of a band
solutes encounter fresh mobile phase and since equilibrium 
is not instant the tail of the band is drawn out. As a 
result, there is broadening at both ends of the bands. if 
the flow rate is decreased there is more time for 
equilibrium to be achieved and so the effects of 
non-equilibrium mass transfer become smaller. if the
channels through which the mobile phase flow and the 
stagnant pools of mobile phase on the stationary phase are 
as thin as possible, equilibrium will be more easily 
achieved. Equilibrium is also more closely approached at 
high temperatures and with low solvent viscosities.
Figure 2.2.2 illustrates the contribution of each 
term in the van Deemter equation as a function of the 
mobile phase velocity as well as their net effect on H. 
It can be seen that the optimum efficiency corresponds to 
the flow rate at the minimim point in the Net Effect curve, 
(d) RESOLUTION
Resolution is the term used to describe the
separating power of a column. Resolution, Rs, is defined 
as the distance between two adjacent solute zone centres 
divided by the average peak width, thus 
Rs = 2 (t * B - f A )
w + wA B
Resolution depends on the efficiency of 
relative retention characteristics of the
a column, the 
components and
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FIGURE 2.2,2: Plot of the van Deemter equation showing the
contribution of each term and the optimum mobile phase velocity.
Net
effect
Cu
CL 
!—  
LU 
X
B/u
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the capacity factor. These three terms can be related to 
resolution in the following equation:
Adjacent peaks which are incompletely resolved can be 
separated by reducing the band broadening, by using a 
longer column or one with more theoretical plates, or by 
increasing the separation of the peaks by varying the 
mobile or stationary phase to give different relative 
partition characteristics. Generally an increase in N, 
alpha or k' will give better resolution. However, as k' 
increases so does the transit time for the solutes through 
the system giving increased band broadening. in practice 
a good efficient column is used and then either the mobile 
or stationary phase is varied to achieve better resolution.
Another factor affecting peak shape and resolution 
is related to the capacity of the stationary phase and 
sample size. Exceeding the sample capacity causes 
overloading and therefore results in unsymmetrical peaks 
and loss of resolution.
It is difficult to quantify the criteria for
resolving two peaks but in general the peak separation 
should be greater than 2W,. apart with better than a
72
10% valley between the peaks.
In quantitative chromatography based on peak area
measurement, values of R ., < 1 should be avoided, forb
example, peaks D and E in Figure 2.2.1. A value of
Rs = l corresponds to about a 3-5% overlap of peaks.
Rs = % (alpha - l) 
alpha
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Higher values of Rs represent progressively smaller 
overlaps. values of Rs > 1.2 are desirable (for 
example, peaks A and B in Figure 2.2.1). Larger values of 
Rs then indicate better separations and smaller values of 
Rs indicate poor separations. For a given value of R s , 
band overlap becomes more serious when one of the two 
bands is much smaller than the other, see Figure 2.2.3.
- 49 -
FIGURE 2.2.3: Separation achieved and appearance of eluted peaks at
various levels of resolution Rg and differing peak intensities
R elative
peak
cones.
1:4 1:16
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2.3. HIGH PRESSURE LIQUID CHROMATOGRAPHY
2.3.1 INTRODUCTION
The theory of high pressure liquid chromatography 
(HPLC) has already been discussed in Section 2 .2 ; this 
section will deal with some of the practical aspects of 
HPLC.
HPLC is a complementary technique to gas 
chromatography (GC) in that HPLC can be used to analyse 
compounds which are polar and/or thermally labile. One of 
the limitations of HPLC is that the sample components must 
be soluble in a suitable solvent that can be employed as a 
mobile phase. A schematic diagram of a typical isocratic 
HPLC system is given in Figure 2.3.1.
Firstly, the mobile phase is degassed: this can be
done by ultrasonication, purging with helium or 
refluxing. The solvent is then pumped through a filter, 
the injection system, the column, the detector and then 
goes to waste or to a fraction collector.
The sample is flushed onto the column from the 
inlet system and the various components travel through the 
column at different rates, depending on their partition 
coefficients, and are separated. As in GC, the sample 
reaches the detector and generates an electrical signal 
which is amplified and recorded as a chromatogram.
injections of samples onto an HPLC column can 
either be made with a syringe or more commonly using a 
multiport valve with a sample loop. The column can be 
left at ambient laboratory temperature or housed in a
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column oven to maintain a constant temperature.
(a ) TYPES OF COLUMN
Conventional HPLC columns are made of stainless 
steel, are about 10 to 30cm in length and have internal 
diameters of 3 to 5mm. They are generally packed with 
5 to lOjim particles. in order to improve chromatographic 
performance particles of smaller diameters have been 
employed. stout [67] has demonstrated the use of columns 
with 3jim particles. since reducing the particle size 
increases efficiency, the shortening of columns is also 
possible. Smaller columns of 5cm or less in length, with 
3 to 5mm diameters and packed with 3 to 5jim materials are 
now commercially available. Another trend in column 
technology is the reduction of internal diameters and 
hence the development of microbore columns. Four types of 
microcolumns are recognised: open tubular [68,69];
packed microcapillaries [70]; microbore [71] and narrow 
bore [72]. The principle features of these columns are 
outlined in Table 2.3.1.
Microbore columns offer several advantages over the 
conventional columns such as low solvent consumption (flow 
rates of 50^il min-1 with microbore columns as opposed to 
lml min”1 with conventional columns), greater 
sensitivity and efficiencies and rapid separations. 
Scott et a_l. [74] reported the separation of seven 
compounds (phenylundecane, benzene, benzyl acetate, 
acetophenone, dimethylphenyl-carbinol, o C -phenyl-ethyl
alcohol and benzyl alcohol) in 30 seconds. several other
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applications have also been reported by Scott and 
co-workers [75-77], Apparatus for microbore columns has 
to be specially designed since amplifier time constant and 
detecter response become critical. Equipment of this type 
is not yet widely available and was not used in the 
present study. A review of advances in HPLC has been
given by Majors [78].
The mobile phase is generally a mixture of 
solvents, since it is difficult to achieve the correct 
polarity for elution with a single solvent. If the 
solvent composition remains the same throughout the 
analysis this is termed 'isocratic' elution and is used 
for simple mixtures of compounds. If a more complex 
mixture, for instance, one containing drugs and 
metabolites, was being analysed a gradient system could be 
employed. Gradient elution involves changing the 
proportions of the various solvents in a controlled manner 
with time: for this type of elution two pumps and a
mixing chamber are necessary. isocratic elution is the 
equivalent of isothermal analysis by GC and gradient
elution can be compared with temperature programming by GC. 
(b) DETECTORS
As for GC, there are a variety of detectors
available for HPLC [79]. The most commonly used 
detector is the uv-visible spectrophotometer which can 
detect compounds that absorb in the uv-visible 
wavelengths. Fluorescing compounds can be determined with 
a fluorescence detector. The electrochemical detector is
- 55 -
also available. This is suitable for use with compounds 
which can be readily oxidised or reduced within the 
voltage range of the electrode. The development of this 
technique has been reviewed by Bratin [80]. Radiochemical 
detectors and atomic absorption detectors can also be used 
with HPLC.
The mass spectrometer can also be used as an HPLC 
detector, but first the technical problem of interfacing 
the HPLC with the mass spectrometer has to be overcome. 
An interface design is required which allows only a small 
portion of the mobile phase into the source without 
disturbing the vacuum system. Reviews of various 
interfaces which have been tried have been given by Arpino 
and Guiochon [81,82] and McFadden [83]. Takeuchi and 
co-workers [84] and Herion [85] have demonstrated the 
direct coupling of micro HPLC with a mass spectrometer.
(C) PERIVATISATION
HPLC, generally negates the need to derivatise 
compounds but in some instances derivatisation can be used 
to increase the sensitivity and selectivity of a 
detector [86]. common examples include the formation of 
2,4-dinitropheny1 hydrazones of carbonyl compounds or 
dansyl derivatives of amines to increase the uv-extinction 
coefficient or provide a fluorescing derivative. Pre- and 
post-column der ivatisation have both been used in a 
dynamic manner.
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2.3.2 EXPERIMENTAL
(a) REAGENTS
1. Anhydrous di-sodium hydrogen orthophosphate, Analar 
(BDH Chemicals Limited, Poole, England).
2. Orthophosphoric acid, Analar (BDH Chemicals Limited, 
Poole, England).
3. Glacial acetic acid, Analar (BDH Chemicals Limited, 
Poole, England).
4. Acetonitrile, HPLC grade (Rathburn Chemicals 
Limited, walkerburn, Scotland).
5. Methanol, HPLC grade (Rathburn Chemicals Limited, 
walkerburn, Scotland).
(b) DRUG STANDARDS
Drug standards were kindly supplied by the following 
manufacturers -
1. Ibuprofen (The Boots company pic).
2. Flurbiprofen (The Boots company pic).
3. Naproxen (Syntex Pharmaceuticals Limited).
4. Ketoprofen (May and Baker Limited).
5. Fenbufen (Lederle Laboratories).
6. Mefenamic Acid (W.R. Warner and company Limited).
7. indomethacin (Berk Pharmaceuticals Limited).
8. sulindac (Merck Sharp and Dohme Limited).
9. Phenylbutazone(Ciba-Giegy Pharmaceuticals Division).
10. Oxyphenbutazone (Ciba-Giegy Pharmaceuticals
Division).
11. sulphinpyrazone (Ciba-Giegy Pharmaceuticals
Division).
12. Azapropazone (A.H. Robins company Limited).
- 57 -
13. Piroxicam (Pfizer Limited).
(C) APPARATUS
1. A Kratos Spectroflow 400 dual piston pump fitted 
with a Rheodyne 7120 injection valve with a 20ul 
sample loop.
2. A stainless steel column (250 x 4.6mm) packed with 
Hypersil 5pm ODS (HPLC Technology).
3. A Kratos spectroflow 757 variable wavelength 
detector (set at 230 n m ) .
4. A Bioanalytical Systems LC-4A amperometric detector 
with a TL-5 vitrified carbon working electrode, 
operating at +1 volt.
5. A Farrand Mark 1 spectrofluorimeter.
6. A Hewlett Packard diode array UV spectrometer was 
used to record the UV spectrum of each drug before 
HPLC was carried out.
(d) HPLC ELUENTS
The HPLC eluents used are listed in Table 2.3.2 -
Table 2.3.2: HPLC eluents
NUMBER C O M P O S I T I O N  (V/V)
1 Acetonitrile/Buffer*:70/30
2 Methanol/Buffer:70/30
3 Methanol/Aqueous Acetic Acid#:80/20
4 Methanol/Aqueous Acetic Acid:70/30
5 Methanol/Aqueous Acetic Acid:65/35
6 Methanol/Aqueous Acetic Acid/Acetonitrile:70/20/10
7 Methanol/Aqueous Acetic Acid/Acetonitrile:40/30/30
*Buffer 
to pH3
- 0 . 1M di-sodium hydrogen orthophosphate adjusted 
with orthophosphoric acid
#Aqueous Acetic Acid - 2% v/v glacial acetic acid in
distilled water.
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(e) PREPARATION OF STOCK SOLUTIONS
Stock solutions (img/ml) of each drug were prepared 
by dissolving the drug in mobile phase. Solutions for 
analysis were then prepared by making appropriate 
dilutions of the stock solutions in mobile phase.
- 59 -
2.3.3 RESULTS
Table 2.3.3 compares the effects of using several 
HPLC mobile phases on the capacity factors (k‘ values) of 
three drugs; phenylbutazone, indomethacin and ibuprofen.
initially seven mobile phases were examined with 
phenylbutazone. All of the mobile phases used eluted the 
drug; capacity ratios (k') ranged from 0.83 (with mobile 
phase 3) to 3.55 (with mobile phase 1). A complete list 
is given in Table 2.3.3.
The analysis was extended to indomethacin and 
ibuprofen for selected mobile phases as shown in
Table 2.3.3. Indomethacin and ibuprofen were also eluted 
with all the mobile phases tried.
Table 2.3.4 lists retention data following the use 
of mobile phase l and mobile phase 4 to analyse a wide 
range of NSAIDs. In both systems all of the drugs could 
be eluted within 5 minutes with mobile phase 1 and 10 
minutes with mobile phase 4.
UV detection was useful for all of the drugs
examined (Table 2.3.5). Full spectra are given in
Figures 2.3.2-2.3.5. With the exception of ibuprofen all 
of the drugs contain chromophores with high extinction 
coefficients. Typically detection limits were about 5ng
of drug on-column.
Fluorescence detection was found to be suitable 
only for ibuprofen, flurbiprofen, indomethacin, mefenamic 
acid and naproxen (Table 2.3.6) with detection limits 
similar to these obtained with the UV detector.
- 60 -
Electrochemical detection was applicable to seven 
of the test drugs as illustrated in Table 2.3.6. The 
detector was extremely sensitive to four of the drugs 
namely mefenamic acid, sulphinpyrazone, azapropazone and 
oxyphenbutazone. Limits of detection for these compounds 
were less than 1 ng on-column.
61 -
TABLE 2.3.3: Comparison of k ’ values for phenylbutazone, indomethanein 
and ibuprofen with several different mobile phases, recorded with a UV 
detector at 230nm. Column was 250 x A.6mm (i.d.) packed with 5um 
Hypersil ODS.
MOBILE PHASE
k ’
Phenylbutazone Indomethacin Ibuprofen
3 0.83 1.16 1.A1
6 0.97 - -
A 1.81 2.82 3.56
2 1.83 - -
5 2.02 3.76 A.55
7 2.03 2.A7 2.9A
1 3.55 2.A5 -
TABLE 2.3.A: HPLC data 
230nm. Column was 250
for some NSAIDs recorded 
x A.6mm (i.d.) packed with
with a UV detector at 
5um Hypersil ODS.
_______  k ’
y k u b
Mobile Phase 1 Mobile Phase A
Sulindac 0.68 1.03
Ketoprofen 1.08 1.06
Oxyphenbutazone 1.26 0.70
Azapropazone 1. A0 0.A2
Sulphinpyrazone 2.20 1.86
Flurbiprofen 2.22 2.82
Indomethacin 2.A5 2.82
Phenylbutazone 3.55 1.81
Mefanamic Acid A. 09 2.36
Ibuprofen A. A5 3.56
Naproxen - 1.27
Fenbufen - 2.A2
Piroxicam 1.05
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TABLE 2.3.5: UV absorbance data for some NSAIDs.
D R U G UV Max in nm (A
17o # 
1cm
Mefenamic Acid 236 (A17), 280 (314), 354 (274)
Ibuprofen 23A (A6)
Flurbiprofen 2A8 (768)
Naproxen 2A0 (667)
Ketoprofen 258 (651)
Fenbufen 230 (157), 286 (887)
Indomethacin 238 (A77), 258 (481)
Sulindac 236 (A3A) , 286 (369), 330 (324)
Phenylbutazone 2A0 (A67)
Sulphinpyrazone 252 (519)
Azapropazone 250 (1117)
Piroxicam 2AA (368) , 340 (462)
^FOOTNOTE A^°/lcm: the absorbance of lg of drug in 100 ml of 
solvent measured in a 1cm cell. The solvent in this case was mobile 
phase 4.
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TABLE 2.3.6: Comparison of UV, fluorescence and electrochemical
detection of some NSAIDs in mobile phase 1.
D R U G *
M E T H 0 D O F  D E T E C T I O N
UV
(230nm)
Fluorescence
(nm)
Electrochemical 
(+1 volt)
Ibuprofen X ** \&x 270 
J^emm 290
N D
Flurbiprofen XX ** Xex 290
^emm 320
N D
Naproxen X ** 320 
^emm 410
Ketoprofen XX N D N D
Fenbufen XX N D -
Mefenamic Acid XX ** Xex 365
\&mm 400
XX
Indomethacin XX ** Xex 305 
Xemm 375
X
Sulindac XX N D X
Phenylbutazone XX N D X
Oxyphenbutazone XX N D XX
Sulphinpyrazone XX N D XX
Azapropazone XX N D XX
Piroxicam XX N D -
** good response 
* poor response 
N D not detected
wavelength of excitation 
^emm wavelength of emission
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FIGURE 2.3.2: UV spectra of azapropazone, fenbufen and flurbiprofen.
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FIGURE 2.3.3: UV spectra of ibuprofen, indomethacin and ketoprofen.
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FIGURE 2.3.4: UV spectra of mefenamic acid, naproxen and phenylbutazone.
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FIGURE 2.3.5: UV spectra of piroxicam, sulindac and sulphinpyrazone.
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2.3.4 DISCUSSION
Reversed-phase HPLC was examined as a method of 
analysis since the NSAiDs in this study are all polar in 
nature. The drugs being considered are all acidic 
(see Table 2.3.7 for pka values) therefore the mobile 
phases tried were all acidic in order to suppress ion 
formation. If the drugs were ionised they would elute 
quickly and give poor peak shapes. Hence the use of ion 
pair chromatography for amines (basic drugs).
The ultimate aim of the HPLC analysis was to 
resolve completely the NSAiDs selected. There is an 
optimum range of values for k' in terms of resolution, 
separation time and band detection [39]; that range is 
l ^ k ^ 10. When k* is initially small (< l) 
resolution increases rapidly with increases in k', but 
when k 1 is greater than 5 resolution increases very little 
with increases in k ‘. Separations which involve k' > 10 
result in long separation times and excessive band 
broadening to the point where detection of small samples 
is impossible. The capacity factors for phenylbutazone 
ranged from 0.83 to 3.55 for the seven mobile phases 
chosen.
Capacity factors vary with the stationary and 
mobile phases, but in practice k' is controlled with 
solvent strength. When k ‘ values require to be increased 
a weaker solvent is used, and if k' values need to be 
reduced a stronger solvent is tried. solvent strength can 
be defined quantitatively by the solvent strength
- 69 -
TABLE 2.3.7: Dissociation constants for selected NSAIDs (ref 50)
D R U G pKa
Azapropazone not available
Fenbufen not available
Flurbiprofen not available
Ibuprofen 4.4, 5.2
Indomethacin 4.5
Ketoprofen not available
Mefenamic Acid 4.2
Naproxen 4.2
Oxyphenbutazone 4.7
Phenylbutazone 4.4
Piroxicam 6.3 (2:1 dioxane-water)
Sulindac 4.7
Sulphinpyrazone 2.8
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0
parameter E Solvent strength is listed for several 
solvents in Snyder and Kirkland's book [39]. Solvents 
with low polarities and low E° values are weak
solvents; for example, methyl acetate and acetone.
Solvents with high polarities and high E° values are 
strong solvents; for example, acetonitrile and methanol. 
Water has the highest polarity and E° in the series. A 
binary or tertiary solvent has a combination of the
solvent strength parameters of the solvents involved.
The changes in k' with various solvents can be seen 
in Table 2.3.3. Mobile phases 3, 4 and 5 have decreasing 
solvent strength, and the k' values for the three drugs 
increase as a result.
Methanol is a stronger solvent than acetonitrile 
and this is illustrated when mobile phases 1 and 2 are 
compared. The k' value for pheylbuta2one with a
methanol/buffer mobile phase is 1.83 and is 3.55 with an 
acetonitrile/buffer mobile phase. Finally, comparing 
mobile phase 5 and 7, we would expect mobile phase 5 to 
give smaller k' values since it is a stronger solvent; 
the k' value for mobile phase 6 for phenylbutazone is 0.97 
and is 2.03 for mobile phase 7. Mobile phases 3 and 6 
which resulted in k' <T 1 were thought to be unsuitable 
in terms of their resolving potential.
Mobile phases 1 and 4 were used to examine a wider 
range of NSAiDs (see Table 2.3.4). Both systems were 
found to be satisfactory for the analysis of individual 
standard drug substances with respect to sensitivity, peak
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shape and k ‘ values. However, systems of these types did 
not provide sufficient resolution to permit unambiguous 
identification of unknown NSAiDs. It would most likely be 
necessary to use a gradient system in order to separate 
this range of compounds within a reasonable time. The 
problem of resolution would become more complex when urine 
samples containing metabolised drugs were analysed. The 
selectivity of the system could be improved by employing 
various detector systems in series, for example UV with 
fluorescence detection or UV with electrochemical 
detection.
Fluorescence was found to be suitable for 
flurbiprofen, naproxen, mefenamic acid and indomethacin in 
agreement with previous work described in the 
literature [87-90]. ibuprofen was also found to fluoresce.
The most intense fluorescence is generally found 
in structures with aromatic character [91]. Most 
unsubstituted aromatic hydrocarbons fluoresce in solution 
and the quantum efficiency usually increases with the 
number of rings and their degree of condensation.
Substitution on the aromatic ring also causes 
changes in the fluorescence efficiency. The addition of 
an electron withdrawing group such as -wo 2 ' -C02H,
-CHO or an halogen, dramatically reduces the fluorescence, 
while the introduction of an electron releasing group, such 
as -NH2 , -OH, -OCH3 or -CH3 increases the fluorescence.
Molecules that possess rigid structures also favour 
fluorescence. in this case the planarity inhibits the
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loss of absorbed energy by other radiationless pathways.
It is, however, difficult to formulate absolute 
rules to say whether a substance will fluoresce or not. 
In the case of the drugs examined in Table 2.3.6 we may 
have expected none of them to fluoresce since they all 
contain both electron withdrawing and releasing groups. 
It is often best to use an empirical approach rather than 
a predictive one when assessing fluorescence detection for 
HPLC.
Electrochemical detection coupled to HPLC is now 
used to monitor a wide range of organic molecules [92]. 
Both electro-oxidation and electro-reduction are possible 
although electro-reduction is technically more difficult 
due to high background currents caused by dissolved oxygen 
and other reducible trace impurities [93].
Organic oxidations can be performed on most
electron-rich compounds. common reactions include phenol 
oxidative couplings, oxidation of primary and secondary 
alcohols to aldehydes and ketones, respectively, Kolbe 
de-carboxylation of carboxylic acids, oxidation of primary 
and secondary thiols, hydroquinones, indoles and
xanthines [94-96].
The electrochemical analysis was performed using
mobile phase l which contained o . 1M phosphate buffer since 
it is essential for electrochemical detection that the 
solvent is electrically conductive.
Electrochemical oxidation was found to be
particularly suitable for mefenaraic acid, sulphinpyrazone.
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azapropazone and oxyphenbutazone. indomethacin, sulindac 
and phenylbutazone also give a response but the detector 
was less sensitive for these substances under the 
conditions used. These seven drugs contain functional 
groups with an oxidation potential within the range of the 
electrode used. None of the other drugs examined in 
Table 2.3.6 gave a response under the conditions used. A 
change in mobile phase or electrode potential could 
facilitate a response but this was not investigated 
further.
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2.3.5 CONCLUSION
HPLC was found unsuitable as a screening procedure 
for NSAiDs. An isocratic system such as the one used in 
the evaluation is suitable for the analysis of specific or 
known groups of compounds but does not provide sufficient 
resolution to analyse the twelve test compounds. it 
should also be noted that there are many other NSAIDs on 
the market which, in the presence of their metabolites and 
other urinary components, poses an insurmountable problem 
with respect to specificity. This problem could be 
reduced by the use of a gradient system to improve 
resolution, although these systems have in the past been 
unreliable and non-reproducible.
Alternatively, increased specificity could be 
achieved by using different detectors in series thereby 
increasing the amount of information avaiable on the 
compounds eluted from the column. Although the use of 
electrochemical and fluorescence detectors, for instance, 
does go some way to improving the selectivity of the 
system, they would not give an unambiguous identification 
of the NSAiDs and metabolites in authentic samples.
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2.4. GAS LIQUID CHROMATOGRAPHY
2.4.1 INTRODUCTION
Gas liquid chromatography (GC) has already been 
described as an example of partition chromatography in 
section 2.2 and an outline of the chromatographic process 
has been given.
A schematic diagram of a typical gas chromatograph 
is shown in Figure 2.4.1. The mobile phase or carrier gas 
flows through the gas purifier, flow controller, injector, 
column and detector. The sample is introduced by micro­
syringe through a rubber septum into the heated injector 
where it is immediately vaporised and transported onto the 
column. The various components travel through the column 
at different rates dependent on their vapour pressures and 
become separated. The partitioning behaviour of the 
sample between the mobile and stationary phases is very 
temperature-dependent, therefore the column is housed in 
an oven and the temperature is carefully controlled. When 
the sample components pass the detector (of which there 
are many types) at the end of the column they generate 
electrical signals which, after amplification, are fed to 
a recorder which presents the signals versus time as a 
chromatogram. This plot is useful for both qualitative 
and quantitative analysis.
Analysis can be performed isothermally or using a 
temperature programme. in the isothermal mode the column 
temperature remains constant throughout the analysis, 
whereas a temperature programme increases the column
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temperature in a uniform manner at a few degrees per 
minute. For the analysis of simple mixtures an isothermal 
run will suffice, but for the analysis of more complex
mixtures a temperature programmed run may be necessary.
(a) SAMPLE INLET SYSTEMS
The introduction of a sample into a GC system is 
important as it affects the overall efficiency of the
separation procedure and the accuracy and precision of the 
results. Liquid sample introduction has always been a
problem in gas chromatography for a number of reasons. The 
sample must be introduced instantaneously into the system 
and then be evaporated rapidly, without decomposition,
into the smallest possible gas volume. This "gas plug"
must then be transferred into the column without loss. 
Also, the total amount introduced should not exceed the 
sample capacity of the column. In packed columns the 
sample capacity is high therefore the problems are less
than for open-tubular (or capillary) columns.
There are a number of injection systems available
for capillary column GC [97] and these include split 
systems, splitless systems and on-column sample 
introduction. The GroB splitless injector was the type
of injector used in this study and is illustrated in
Figure 2.4.2. In this type of injector the injector
housing contains a glass liner. The column is placed
inside the injector housing and projects into the glass 
liner. The column is no more than 10mm from the syringe 
needle, providing an all-glass system with minimum dead
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FIGURE 2.4.2: The GroB splitless injector
ON/OFF TOGGLE 
OR SOLENOID 
VALVE (CLOSED 
FOR 20 TO 30 
SECONDS AFTER 
INJECTION)
NEEDLE VALVE
SPRING 2 to 5 cm min 
SEPTUM PURGE
GLASS LINER
CARRIER IN
PRESSURE
REGULATOR
PRESSURE GAUGE SOLVENT VENT 
30 to 50 cm3 min’NARROW BORE LINER - UNPACKED 
(HIGH IMPEDANCE COLUMNS)
INNER STEEL LINER
WIDE BORE LINER - UNPACKED 
(LOW IMPEDANCE COLUMNS)
GRAPHITE SEAL SPLIT LINE 
NEEDLE VALVE
CHARCOAL TRAP
COLUMN
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volume. When the syringe plunger is depressed the sample 
is transported onto the column with the carrier gas. 
Small sample volumes of no more than ljal are used. If a 
larger volume was injected the sample would diffuse in the 
injector and lead to inefficient sample application and 
band broadening. This type of injector may be used to 
take advantage of the solvent effect (condensation of the 
solvent at the top of a cold column) to concentrate the 
solute at the top of the column. However, for high-
boiling solutes, especially when temperature program GC is 
used, the solute zone remains sharp and minimal band 
broadening occurs. This is important as it may be very 
inconvenient to cool the column, say, to 40° to condense 
methanol, or require subambient cooling for diethyl ether,
(b) TYPES OF COLUMN
There are two main types of column in GC: the
packed column and the capillary column. Packed columns 
are generally made of glass or metal, are l-5m in length 
and 3-6mm in diameter. The efficiency of the packed 
column is low, usually 500-2000 theoretical plates. The
packing consists of an inert support coated with a thin
film of liquid stationary phase. A table of some 
stationary phases available is given in Section 2.2 
(Table 2.2.2). Capillary columns have been made of 
copper, stainless steel, glass and more recently vitreous 
silica. capillary columns are usually i0-50m in length 
and O.l-O.5mm in diameter, they have higher efficiencies 
than packed columns and are suitable for the analysis of
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complex mixtures. Capillary columns can be classified 
into two groups: micropacked columns and open-tubular
columns. Micropacked columns range in length from 5-25m 
have diameters of 0.6-lmm and have high efficiencies of 
about 50,000 theoretical plates. open-tubular columns 
have an unrestricted flow through the bore of the column, 
they are 10-loom in length, have internal diameters of
0.1-0.5mm and have high efficiencies of 10,000 to 100,000 
theoretical plates. They can be further subdivided 
according to the method of supporting the stationary phase:
(i) bonded phase columns (BPC)
(ii) wall coated open-tubular columns (WCOT)
(iii) support coated open-tubular columns (SCOT)
(iv) porous layer open-tubular columns (PLOT)
(i) BONDED PHASE COLUMNS (BPC)
in these columns, the stationary phase is formed
polymerisation of siloxane monomer on the inner surface of 
the capillary tube: covalent bonds form between the wall
and the polymeric phase, thereby bonding it as a 
physically stable film on the surface.
BPC's are the most commonly used columns today. 
They are normally made of fused silica and have several 
advantages over the other open-tubular columns. 
Rearrangement of the bonded stationary phase film is 
virtually impossible so the column efficiency will be 
retained much longer than in other types of column, 
contaminated columns can be washed with solvent to return 
them to their original performance. Pure vitreous silica
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columns overcome many of the adsorption problems of glass 
or stainless steel columns once the surface has been 
deactivated. vitreous silica columns also have much 
higher tensile strength and flexibility, although the 
exterior surface must be protected from oxidation and 
scratching, both of which weaken the column. Polyimide is 
the material usually used to coat the outer surface of the 
column. Fused silica capillary columns are 10~50m in 
length and have internal diameters of 0.l-0.5mm. A wide 
range of chemically bonded phases are now available 
including non-polar, medium polar and polar phases.
(ii) WCOT COLUMNS
WCOT columns have a thin film (0.i-0.5^im) of 
stationary phase coated on the inside wall of the 
capillary tubing. Glass rather than stainless steel 
capillary tubing is used because of its relative 
inertness. wide-bore columns (0.5mm i.d.) have about half 
the efficiency of narrow bore columns (0.25mm i.d.) but
usually they are easier to install and are less critical 
with respect to the effects of dead volume as the flow 
rate is higher. Both 0.25 and 0.5rnm i.d. columns can be 
used with on-column injectors. wide bore columns have 
more stationary phase and therefore a higher capacity than 
narrow bore columns. Wide bore columns also have the 
advantage that direct injection techniques without 
splitting may be used.
(iii) SCOT COLUMNS
SCOT columns are 0.5mm i.d. glass capillary
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columns. The inner wall is coated with a layer of fine 
particle support material which in turn is coated with a 
thin film of stationary phase. The thicker effective film 
of stationary phase on a SCOT column permits a higher 
sample capacity than that of the WCOT columns, but SCOT 
columns are less efficient. Smaller diameter (0.3mm i.d.) 
SCOT columns are also available which have efficiencies 
approaching that of the WCOT columns.
(iv) PLOT COLUMNS
p l o t  are similar to the SCOT columns, but have a 
porous layer on the inner wall of the glass capillary 
tubing, which is then coated with stationary phase.
(C) DETECTORS
There are various detection principles used for GC 
analysis [98] and these include:
(i) the flame ionisation detector (FID)
(ii) the nitrogen-phosphorus detector (NPD)
(iii) the electron capture detector (ECD)
(iv) the flame photometric detector
(v) the thermal conductivity detector (TCD)
(vi) the mass spectrometer (GC-MS)
(i) FLAME IONISATION DETECTOR (FID)
The FID is the most widely used GC detection 
system. The detector consists of a small hydrogen flame 
in an electrode gap. organic compounds eluting from the 
column burn and form ions. The ion formation is a complex 
process, in which direct ionisation plays only a small 
part. The ions then travel to the collector electrode and 
thus a current is observed.
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(ii) NITROGEN-PHOSPHORUS DETECTOR (NPD)
The NPD is used specifically to detect nitrogen and 
phosphorus-containing compounds. The detector is a 
modified FID containing a bead of an alkali metal salt. 
When heated the bead gives off alkali metal vapours.
Decomposition products of N or P-containing compounds can 
accept electrons from alkali atoms causing ionisation and 
a large current increase. Precise control of the hydrogen 
and air flow rates allows the detector to respond 
selectively to N or P-containing compounds. Halogen and 
sulphur-containing compounds can also be detected under 
the correct flame conditions. Alkali metal salts used 
are caesium bromide, rubidium silicate, chloride or
sulphate and potassium chloride or carbonate.
When compared with FID the NPD is approximately fifty 
times more sensitive to nitrogen compounds and five
hundred times more sensitive to phosphorus compounds.
(iii) ELECTRON CAPTURE DETECTOR (ECD)
This detector contains a radioactive fl-emitter 
3 6 3( H or Ni) which ionises the carrier gas (usually 
argon/methane) forming slow electrons. When a sample
capable of capturing electrons enters the detector it 
reacts with the electrons to produce negative ions. These 
negative ions combine with the positive gas ions. The 
number of free ions and electrons is therefore depleted in 
the presence of the sample and the current is reduced. 
ECD's are highly sensitive to molecules with 
electrophores, for example, halogen-containing compounds, 
conjugated carbonyls, nitrate esters and organometallics.
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(iv) FLAME PHOTOMETRIC DETECTOR
The flame photometric detector is another type of 
flame detector and is specific for phosphorus and 
sulphur-containing compounds. The principle of operation
is the measurement of radiation emitted by excited species 
in the flame. in a hydrogen flame, sulphur and phosphorus
form excited species which emit radiation at 394nm and
526nm respectively.
(V) THERMAL CONDUCTIVITY DETECTOR (TCP)
The TCD is based on the principle that the filament 
will lose heat at a rate which depends on the composition 
of the surrounding gas. The change in temperature of the 
filament will give rise to a change in its electrical 
resistance. The detector contains two filaments, one in 
the gas flow from the column (the detector cell) and the 
other in the carrier gas flow (the reference cell). The 
two filaments form the arms in a Wheatstone bridge 
circuit. When no sample is eluted carrier gas passes 
through both cells, therefore, the bridge is balanced.
When sample is eluted the resistance in the sample cell 
changes, an imbalance of the bridge occurs and is 
registered. The carrier gas used is either helium or 
hydrogen which both have high conductivities. The 
detector responds to any compound having a different 
thermal conductivity from the carrier.
(Vi) MASS SPECTROMETRY (GC-MS)
The mass spectrometr ic detector is the most 
specific and sensitive detector available and will be 
discussed in detail in Section 2.5.
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(d) PERIVATISATION
For a compound to be suitable for GC analysis the 
sample must be easily vaporised without decomposition. 
There are many compounds which do not fulfil this
criterion but a chemical derivative of the compound may be 
suitable for GC analysis. The main reasons for
derivatisation are as follows:-
1. to increase volatility of the sample;
2. to increase thermal stability of a compound;
3. to introduce functional groups which increase the 
sensitivity in selective detectors; and,
4. to improve separation and reduce tailing by masking 
polar groups.
The derivatisation reaction used should be rapid 
and quantitative and it should be possible to
chromatograph the reaction mixture directly without
pre-isolation of the derivative.
An extensive literature is available for chemical 
der ivatisation [99-102], but some examples will be given 
here. Derivatisation methods can be classified into groups 
according to the reagents used and the reactions achieved, 
for example, silylation, acylation and alkylation. in the 
present study, silylation and alkylation reactions were 
used and these will be considered in more detail.
(i) SILYLATION
Silylation involves the replacement of an acidic 
hyrogen in the sample molecule with an alkylsilyl group 
such as the trimethylsilyl (TMS) group. The derivatives
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are generally less polar, more volatile and more thermally 
stable than the parent compound. Water decomposes both 
TMS reagents and derivatives and solvents such as water 
and alcohols with active hydrogens should be avoided. 
Non-polar solvents such as hexane produce slow reactions, 
however. Pyridine is the commonly used solvent. it is an 
acid scavenger and basic catalyst. DimethyIformamide, 
dimethylsulfoxide, tetrahyrofuran and acetonitrile are 
also used. Examples of some reagents are N,o~bis 
(trimethylsilyl)acetamide (BSA), N,0-bis (trimethylsilyl) 
trifluoroacetamide (BSTFA), N-trimethylsilylimidazole 
(TMSI), trimethylchlorosilane (TMCS) (also used as a 
catalyst with BSTFA) and hexamethylsilazane (HMDS). using 
these reagents esters are formed from carboxylic acids, 
ethers from alcohols and N-TMS derivatives from amines. 
Some examples of reactions are given in Figure 2.4.3.
N- Methyl -N- (tert - butyldimethylsilyl) trifluoro- 
acetamide (MTBSTFA) is another silylation reagent. It 
donates a tert-butyIdimethylsilyl moiety instead of the 
trimethylsilyl group. The advantage of this reagent is 
that both it and the derivatives it produces are less 
prone to hydrolysis than the other silylation reagents and 
derivatives already mentioned. An example of a reaction 
is given in Figure 2.4.3. Additional advantages of this 
derivative occur in GC-MS.
(ii) ALKYLATION
Alkylation is the addition of an alkyl group to an 
active functional group. Esterification of carboxylic
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FIGURE 2.4.3: Silylation reactions using various reagents,
(a) Silylation using BSTFA.
OSi(CH3)3 
R-OH ♦ F3C-C = NSi(CH3)3
5-20 minutes 
60° C. 
pyridine
0
* I
R-0-Si(CH3)3 + F3C-C-NH-Si(CH3)3
or
F3C-CONH2
(b) Silylation using TMCS
R-C^ + Cl— Si(CH3)3 
OH
5-20 minutes 
60° C 
pyridine
R-CC + HCl
^0-Si(CH3)3
(c) Silylation using MTBSTFA
0 ch3 ch3
R-OH + F3C-C-N-|i-C-CH3
Chb CH3 ch3 
5-20 minutes 
room temperature 
acetonitrile
CH3 CH3 0
I I I
R-O— Si — C — CH3 + F3C-C-NH-CH3
ch3 CH3
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acids to form methyl esters is one of the most useful 
reactions. The ester is less polar, more thermally stable 
and more volatile than the acid therefore facilitating GC 
analysis. A number of methods are available for 
methylating compounds and these are discussed in detail in 
Blau and K i n g ’s book [99]. Examples of some methylating 
reagents are an ethereal solution of diazomethane, a 
methanolic solution of boron trifluoride in ether and 
methanolic HC1. Figure 2.4.4 illustrates mechanisms for 
the reaction of these three reagents with a carboxylic 
acid.
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FIGURE 2.4.4: Methylation reactions using various reagents.
Acid Catalysed Methylation Methylation with Diazomethane
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EXPERIMENTAL
REAGENTS
Diethyl ether, Pronalys AR grade (May & Baker, 
Dagenham, England).
Methanol, HPLC grade (Rathburn Chemicals Limited, 
Walkerburn, Scotland).
Ethyl acetate (Ratherburn Chemicals Limited, 
Walkerburn, Scotland).
Digol, Analar grade (BDH Chemicals Limited, Poole, 
England).
Potassium hydroxide, Analar grade (BDH Chemicals 
Limited, Poole, England).
Diazald, N-methyl-N-nitroso-p-toluenesulfonaraide
(Aldrich chemical Co.Ltd Limited, Gillingham, 
England).
Boron trifluoride etherate, redistilled (Sigma 
Chemical Company Limited, Poole, England).
Acetyl chloride (Sigma Chemical company Limited, 
Poole, England).
b s t f a  + 1% TMCS, Tri-Sil-Z, m t b s t f a , HMDS, Pyridine 
(Pierce, Life sciences Laboratory Limited, Luton 
England).
DRUG STANDARDS
As in Section 2.3.2 (b)
APPARATUS
A Pye unicam model 204 gas chromatograph fitted 
with an all-glass GroB splitless injector and a 
flame ionisation detector.
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2. A wall-coated open-tubular column (24m, 0.5mm i.d.,
1.10mm o.d.) with a liquid stationary phase of
CP-SIL5 at a film thickness of 0.8ipm.
(d) CHROMATOGRAPHIC CONDITIONS
The chromatographic conditions employed were as
follows:- 
column:
Carrier Gas:
Make-up G a s : 
injector Temperature: 
Detector Temperature: 
column Temperature:
(e ) PREPARATION OF
(i) DIAZOMETHANE
Diazald* (1.8g) was placed in a dry flask. Diethyl
ether (30ml), digol (4.5ml) and potassium hydroxide
solution (6ml; 30% v/v) were then added to the flask
consecutively. The flask was then placed in a water bath
at 6 0 ° c .  The diazomethane produced was collected via a
side arm in the flask which was inserted into a 10ml
*This reagent is toxic and a potent carcinogen. Solutions of the gas 
are unstable and potentially explosive. The preparation and handling 
of the reagent were therefore carried out with care in a fume 
cupboard.
WC O T , 24m, 0.5mm i.d., 1.lmm o.d.
with a liquid stationary phase of 
CP-SIL 5 at a film thickness of 
0. 8 ljim.
Nitrogen (2mL/min).
Nitrogen (30mL/min)
275°C.
300°C
Programmed from 80° to 280°C at 
a ramp rate of 4°/minute with 
initial and final isothermal periods 
of 2 minutes.
DERIVATISING REAGENTS
- 92 -
volumetric flask, containing diethyl ether (lml), 
submersed in an ice-bath. The diazomethane solution 
remained stable for about one week when kept at 4°C.
(ii) BORON TRIFLUORIDE ETHERATE/METHANOL
Boron trifluoride etherate (3ml) was added to 
methanol (15ml, HPLC grade) and kept at 4°C until used.
(i i i ) ACETYL CHLORIDE/METHANOL
Acetyl chloride (3ml) was added dropwise to
methanol (15ml, HPLC grade) in a round-bottom flask.
(iv) HMDS, PYRIDINE, TMCS
HMDS, dry pyridine and TMCS were pre-mixed in the 
ratio of 3:2:1, v/v/v. The solution was centrifuged
before use to remove precipitated silica.
(f ) PREPARATION OF DERIVATIVES OF NSAIDS
(i) METHYLATION WITH DIAZOMETHANE
Methyl esters of the drug standard were prepared by
adding a few drops of a solution of diazomethane, in 
diethyl ether, to about lmg of drug standard in methanol 
(lml). Diazomethane was added dropwise until the solution 
remained yellow. The reaction was found to be complete on 
addition, but was allowed to stand at room temperature for 
15 minutes before evaporating to dryness under a stream of 
nitrogen. The residue was redissolved in 5ml of ethyl 
acetate and about 0.5pl was used for GC analysis.
(ii) BORON TRIFLUORIDE ETHERATE/METHANOL
Boron trifluoride etherate/methanol 1:5 v/v (500yil) 
was added to about lmg of drug standard in a reaction 
vial. The vial was sealed and the reaction mixture heated
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at 60° c . The reaction was found to be complete after 
l hour. The solution was evaporated to dryness under a 
stream of nitrogen. The residue was redissolved in 5ml of 
ethyl acetate and about 0.5jil was used for GC analysis.
(iii) METHYLATION WITH ACETYL CHLORIDE/METHANOL
Acetyl chloride/methanol 1:5 v/v (500pl) was added 
to about lmg of drug standard in a reaction vial. The 
vial was sealed and the reaction mixture heated at 
60°C. The reaction was found to be complete after l 
hour. The solution was evaporated to dryness under a 
stream of nitrogen. The residue was redissolved in 5ml of 
ethyl acetate and about 0.5pl was used for GC analysis.
(iv) SILYLATION WITH BSTFA + 1% TMCS
BSTFA + 1% TMCS (lOOpl) and acetonitrile (lOOpl)
were added to a vial containing about lmg of drug 
standard. The vial was sealed and the reaction mixture 
heated at 6 0 ° c  for 2 0  minutes. After this time 
acetonitrile (5ml) was added to the reaction vial and 
about o.spl was used for GC analysis.
(V) SILYLATION WITH TRI-SIL-Z
Tri-Sil-Z (lOOpl) was added to a vial containing
about lmg of drug standard. The vial was sealed and the 
reaction mixture heated at 60°c for 20 minutes. After
this time acetonitrile (5ml) was added to the reaction 
vial and about o.5pl was used for GC analysis.
(Vi) SILYLATION WITH HMDS, PYRIDINE. TMCS
An aliquot of the HMDS, pyridine, TMCS mixture 
(lOOpl) was added to a vial containing about lmg of drug
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standard. The vial was sealed and heated at 60°C for 10 
minutes. After this time acetonitrile (5ml) was added to 
the reaction vial and about o.5pl was used for GC analysis.
(vii) tert-BUTYLDIMETHYLSILYLATION WITH MTBSTFA
MTBSTFA (lOOpl) and acetonitrile (lOOpl) were added 
to a vial containing about 50pg of drug standard. The 
vial was sealed and the reaction mixture heated at 6 0 ° c  
for 30 minutes. After cooling about o . 5 p l  was used for GC 
analysis.
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2.4.3 RESULTS
(a) GC ANALYSIS OF SELECTED NSAIDs
Ibuprofen, flurbiprofen, naproxen, ketoprofen, 
fenbufen and mefanamic acid did not chromatograph as their 
free acids. These six drugs were therefore derivatised and 
chromatographed successfully as their methyl esters, silyl 
esters and tert-butyldimethylsilyl esters. Figure 2.4.5 
illustrates the resolution obtained with the three 
derivatives and Table 2.4.1 compares their retention 
indices. Methylation was performed using diazomethane, 
silylation with BSTFA + 1% TMCS and t er_t-butyl dime thy 1-
silylation with MTBSTFA.
Piroxicam, indomethacin and sulindac did not 
chromatograph at all under the conditions used.
Phenylbutazone, sulphinpyrazone and azapropazone 
are discussed in section 2.4.3(b).
(b) GC ANALYSIS OF PHENYLBUTAZONE, SULPHINPYRAZONE AND
AZAPROPAZONE
Phenylbutazone, sulphinpyrazone and azapropazone 
chromatographed successfully as the free compounds and had 
retention indices of 2381, 2252 and 2427, respectively.
Figure 2.4.6 illustrates a chromatogram obtained with a 
mixture of the three compounds.
Using ibuprofen as a model compound, ibuprofen, 
phenylbutazone and sulphinpyrazone were reacted with 
diazomethane, boron trifluoride/methanol and acetyl 
chloride/methanol. The products were analysed by GC and 
the results are given in Table 2.4.2.
Ibuprofen gave one peak with a retention index of
- 9 6 -
1529 with all four methylation procedures. This 
corresponded to the methyl ester of ibuprofen.
Phenylbutazone was not derivatised using boron 
trifluoride/methanol or acetyl chloride/methanol. The peak 
observed at 2381 corresponds to phenylbutazone itself. 
Phenylbutazone, however, formed several peaks when reacted 
with diazomethane. Three peaks were present after 
methylating for only 10 seconds in diazomethane, one peak 
corresponding to the free phenylbutazone. After reacting 
for 15 minutes, the phenylbutazone peak was no longer 
present. Figure 2.4.7 illustrates the progress of the 
reaction.
Sulphinpyrazone did not react with boron 
trifluoride/methanol, the peak observed at 2252 
corresponding to sulphinpyrazone. Two peaks were observed 
after reacting sulphinpyrazone with diazomethane, one 
corresponding to sulphinpyrazone. several peaks were 
observed when sulphinpyrazone was reacted with acetyl 
chloride/methanol. The reactions of phenylbutazone, 
sulphinpyrazone and azapropazone with diazomethane were 
studied using GC-MS. The results are given in 
Section 2.5.3(b).
Ibuprofen, phenylbutazone and sulphinpyrazone were 
reacted with BSTFA + l% TMCS; Tri-Sil-Z; HMDS, pyridine, 
TMCS (3:2:1) and MTBSTFA. The reactions products were 
analysed by GC and the results are given in Table 2.4.3.
Ibuprofen gave one peak at 1615 with BSTFA + 1%
TMCS and HMDS, pyridine, TMCS (3:2:1) corresponding to its
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silyl ester. Ibuprofen did not react with Tri-Sil-Z 
gave one peak at 1845 with MTBSTFA corresponding to 
tert-butyIdimethylsilyl ester.
Phenylbutazone and sulphinpyrazone were found 
to react with any of the silylating reagents under 
conditions used.
and
its
not
the
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TABLE 2.4.1: Retention indices of selected NSAIDs after methylation,
silylation and tert-butyldimethylsilylation.
D R U G
R E T E N T I O N  I N D I C E S
COMPOUND AFTER COMPOUND AFTER COMPOUND AFTER
METHYLATION1 SILYLATION2
t-BUTYLDIMETHYL-
SILYLATION3
Ibuprofen 1529 1615 1842
Flurbiprofen 1893 1971 2225
Naproxen 1981 2051 2302
Ketoprofen 2092 2161 2437
Fenbufen 2315 2440 2748
Mefenamic Acid 2072 2164 2435
1 Methylation was carried out with diazomethane (room
temperature, 15 minutes).
2 Silylation was carried out with BSTFA + 1% TMCS (60*0,
20 minutes).
3 tert-Butyldimethylsilylation was carried out with MTBSTFA
(60°C, 30 minutes).
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FIGURE 2.4.5: GC analysis of products obtained after reacting a
mixture of NSAIDs with (a) diazomethane (b) BSTFA + 1% TMCS and 
(c) MTBSTFA.
Peak identifications are: 1, ibuprofen; 2, flurbiprofen; 3,
naproxen; 4, ketoprofen; 5, fenbufen; and 6, mefenamic acid.
Chromatographic conditions used are described in the text.
(a) Methyl Esters.
6
-Time mins
20 25 30 35
(b) 1 Silyl Esters
•Time mins
30 3520 25
(c) tert-Butyldimethylsilyl Esters.
4&6
m
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FIGURE 2.4.6: Typical chromatogram obtained with a mixture of
phenylbutazone sulpinpyrazone and azapropazone.
Chromatographic conditions used are described in the text.
478
phenylbutazonesulphinpyrazone
azapropazone
SCfiN
HUE
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FIGURE 2.A. 7: GC analysis of products obtained after reacting
phenylbutazone with diazomethane for (a) 10 seconds, and
(b) 15 minutes.
Chromatographic conditions used are described in the text.
Reaction of phenylbutazone with diazomethane for 
10 seconds.
Phenylbutazone
+
20 22 24 25 26 28 30
t  Time mins
(b) Reaction of phenylbutazone with diazomethane for 
15 minutes.
Phenylbutazone
Time mins
22 24 25 26
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2.4.4 DISCUSSION
In order to have sufficient resolving power to 
analyse NSAiDs in urinary extracts it was thought that a 
capillary column would be necessary. A fused silica 
column was not available so a wide bore (0.5mm i.d.) wall 
coated open-tubular column was chosen. This type of 
column had a high capacity and was resistant to water; it 
gave good resolving power and also allowed direct 
splitless injection to be used. If the samples to be 
analysed contained small amounts of drugs and/or 
metabolites it would be preferable to have as much of the 
sample on the column as possible, rather than losing a 
large percentage of it as would happen with a split 
injector system. The stationary phase chosen was CP-Sil 5 
which is 100% dimethyl polysiloxane, a non-polar phase.
A temperature programmed run was chosen in order to 
give reasonable analysis times for a group of drugs with a 
wide range of retention indices.
A flame ionisation detector was used since it would 
be able to detect all of the drugs that emerged from the 
column. As with HPLC the analysis specificity could be 
improved by using different detectors, such as an NPD or 
ECD. These detectors were not tried, but reports have 
appeared in the literature which claim to detect the 
methyl ester of ketoprofen by ECD [103] and several 
authors report methods for indomethacin, also by 
ECD [104-106]. Phenylbutazone and indomethacin have also 
been reported to have been detected by NPD [7].
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Out of the twelve test drugs which were examined
only phenylbutazone, sulphinpyrazone and azapropazone were 
successfully chromatographed without derivatisation. Many 
literature methods are available for the GC analysis of 
phenylbutazone and sulphinpyrazone. However, Leach [107] 
noted that azapropazone oxidises at room temperaure within 
l hour. Samples containing azapropazone must, therefore, 
be analysed immediately or stored at -20°c. The
chromatogram in Figure 2.4.6 illustrates that 
phenylbutazone, sulphinpyrazone and azapropazone all gave 
tailing peaks. This is most likely due to deterioration 
of the GC column. since sulphinpyrazone is the heaviest 
of these three molecules it would be expected to elute 
last, but it has the shortest retention time. This is 
probably due to thermal decomposition of the compound 
(this was confirmed by GC-MS analysis).
in order to chromatograph the other nine drugs as 
part of a drug screening procedure derivatisation by 
methylation, silylation and tert-butyldimethylsilylation 
were evaluated. Methylation, with ethereal diazomethane,
silylation, with BSTFA + 1% TMCS and tert-butyldimethyl-
silylation, with MTBSTFA were all successful for six of 
the drugs. These drugs all contain carboxylic acid 
functional groups, namely: ibuprofen, flurbiprofen,
naproxen, ketoprofen, fenbufen and mefanamic acid. in all 
cases the methyl esters eluted first followed by the silyl 
esters and lastly the tert-butyldimethylsilyl esters. 
This was to be expected as a result of the relative
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increases in molecular weight provided by the 
derivatives. The necessity to derivatise these carboxylic 
acids agrees with many other authors [7,8,108]. However, 
ibuprofen, naproxen, ketoprofen, mefanamic acid and 
indomethacin have been chromatographed on fused-silica 
capillaries as their free acids [8,109]. only ibuprofen 
chromatographed well and the other four compounds were 
said to have poor chromatographic properties.
Piroxicam, indomethacin and sulindac were not 
chromatographed by GC at all in this study. sharp [8] 
reported piroxicam to have poor gas chromatographic 
properties and most literature methods of this drug 
have been by HPLC [110,111]. Several papers have agreed 
that indomethacin either forms several products on GC 
analysis [6,7] or has poor gas chromatographic 
properties [8,108]. Hunt and co-workers [6] identified 
the structures of the products produced by indomethacin 
under GC conditions. Sharp [8] also agrees with this 
present work in not successfully chromatographing sulindac 
by GC.
The six drugs containing carboxylic acid functional 
groups reacted quantitatively with diazomethane to form 
their methyl esters. When phenylbutazone and
sulphinpyrazone were reacted with diazomethane multiple 
products were formed. since this would be an undesirable 
complication to interpreting a GC chromatogram other 
methylating reagents were examined. Neither
phenylbutazone or sulphinpyrazone reacted with boron
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trifluoride/methanol. Phenylbutazone did not react with 
acetyl chloride/methanol but sulphinpyrazone formed 
several products with this reagent.
Silyl derivatives of phenylbutazone and sulphin­
pyrazone were not formed under the conditions used. This 
was perhaps not surprising because neither of these drugs 
have functional groups obviously amenable to silylation. 
However, the proton at C-4 is acidic and C-methylation has 
been noted at this position during the metabolism of 
phenylbutazone [112]. It was therefore necessary to 
establish the chemical form in which the drug and/or 
metabolites would be observed in the course of a routine 
drug screen.
2.4.5 CONCLUSION
since only three out of the twelve NSAiDs examined 
could be chromatographed by GC as the free compounds, a GC 
screening procedure would have to involve a derivatisation 
step. if silylation or tert-butyIdimethvlsilylation were 
used nine out of the twelve compounds would be detected, 
ibuprofen, flurbiprofen, naproxen, ketoprofen, fenbufen 
and mefenamie acid would be detected as their silyl or 
tert-butyldimethylsilyl derivatives. Phenylbutazone,
sulphinpyrazone and azapropazone would not react and would 
be detected as the free compounds.
If methylation was used as the der ivatisation 
procedure, ibuprofen, flurbiprofen, naproxen, ketoprofen, 
fenbufen and mefenamie acid would be detected as their 
methyl esters. It has been shown that phenylbutazone and 
sulphinpyrazone form multiple products when reacted with 
diazomethane or acetyl chloride/methanol. These reagents 
could therefore cause problems in quantitation of these 
compounds in a screening procedure. Although, on this 
occasion, it was shown that boron trifluoride/methanol did 
not react with phenylbutazone or sulphinpyrazone there is 
the possibility that these compounds may, to some extent, 
form derivatives with this reagent.
Piroxicam, indomethacin and sulindac did not 
chromatograph under the conditions used and would, 
therefore, not be detected in a GC screening procedure.
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2.5 GAS CHROMATOGRAPHY/MASS SPECTROMETRY
2.5.1 INTRODUCTION AND THEORY
Mass spectrometry is the basis of the most specific 
and sensitive detector available for gas chromatography. 
It is possible to give an unambiguous indentification of a 
compound with lng or less of material.
The technique relies upon the ionisation and 
subsequent fragmentation of molecules and results in a 
mass spectrum, a graph of mass to charge ratios of the
fragments plotted against relative abundance. Functional
groups in the molecule direct the fragmentation. It is 
possible to deduce a possible structure from the 
fragmentation pattern and in many cases the molecular 
weight of the compound can be determined.
The basic components of a mass spectrometer are 
shown in Figure 2.5.1.
Throughout this study the mass spectrometer used 
was the VG 16F single focussing magnetic sector 
instrument. The technique and basic components of the
mass spectrometer described here will be those of the VG
16F.
(a) SAMPLE INLET SYSTEMS
In order to minimise the number of collisions 
undergone by ions and thus maximise the number of ions 
reaching the detector the interior of a mass spectrometer 
is under high vacuum (10-6 torr). Sample inlet systems 
must therefore allow the introduction of a sample without 
significant loss of vacuum, especially in the mass 
analyser and detector regions of the spectrometer.
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FIGURE 2.5.1: Schematic diagram of a mass spectrometer system.
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There are four inlet systems available on the VG 
16F mass spectrometer; the septum inlet, the direct probe 
and two gas chromatographic inlets.
(i) THE SEPTUM INLET
The septum inlet is for the introduction of
volatile liguids or gases. This inlet consists of a loornl 
reservoir and a molecular leak which meters the sample to 
the ion chamber at a constant volume rate. This inlet is 
particularly useful for the introduction of 
perfluorokerosene to calibrate the instrument. The
reservoir is normally heated to about 150°C.
(ii) THE DIRECT PROBE
The direct insertion probe is used for the 
introduction of solid samples (~30jig or less). The
solid sample is placed in a small quartz capillary tube
and inserted through a vacuum lock close to the ion
source. Due to the low pressure in the chamber and
heating by contact with the source (250°c) the sample 
vaporises. The probe can also be heated directly to aid 
vaporisation.
(iii) GAS CHROMATOGRAPHIC INLETS
There are two gas chromatographic inlets on the VG 
16F. one is used for a capillary column and the other for 
a packed column. A capillary column has a gas flow rate
of about l to 2 ml/min which the vacuum pumps can easily 
pump away. The capillary column can therefore be inserted 
directly into the ion source. Packed columns have gas
flow rates of about 20 to 30ml/min and they require a
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molecular separator to prevent all the effluent entering 
the ion source, thus maintaining the vacuum. only the jet 
separator will be discussed here as it is the one 
installed in the VG 16F.
The single-stage jet separator consists of two 
aligned orifices, the gap between the orifices being 
evacuated by a rotary pump. As the effluent from the 
chromatographic column passes through the first orifice 
the lighter molecules of carrier gas (usually helium) have 
less momentum and tend to diffuse: these are then pumped
away. Those heavier sample molecules have more momentum
and so continue to the second orifice.
The two-stage jet separator consists of two
single-stage separators in series.
(b) IONISATION METHODS
Various methods exist to produce ions in mass 
spectrometry. One of the most popular techniques is 
electron impact (El). In the ion source (see Figure
2.5.2) electrons are emitted from a hot filament and are 
accelerated across the ion chamber to the collector 
anode. The vaporised sample molecules are bombarded by
this stream of high energy electrons (70eV) and are
consequently ionised. since only about lOeV is required 
for ionisation of organic molecules some of the remaining 
energy absorbed by the molecules is used to break bonds, 
thus forming fragment ions. Both positive and negative
ions are produced. Positive ion mass spectrometry is the
most popular as these ions are produced in much larger
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numbers than are negative ions (by a factor of about
3 . . .
10 ). only positive ion mass spectrometry will be
considered here.
The simplest ionisation reaction is the loss of an 
an electron resulting in the molecular ion (M+). The 
abundance of the molecular ion in the mass spectrum varies 
with the structure; depending on the inherent stability of 
the molecule, it can be a dominant ion, a weak ion or 
completely absent. The molecular ion can then rearrange or 
fragment into smaller ions which subsequently fragment 
themselves (see Figure 2.5.3). The resulting positive ions 
move out of the ionisation chamber through the slits and 
an ion lens system into the mass analyser, under the 
influence of a small positive repelling potential in the 
source.
The most important piece of information which may 
be obtained from a mass spectrum is the molecular weight. 
Certain classes of compounds do not show molecular ions 
and in other cases it is not always possible to identify 
the molecular ion. in order to resolve these problems a 
group of 'soft ionisation' techniques have been developed. 
These techniques generate a quasi-molecular ion and 
fragmentation is minimal. 'Soft ionisation' methods 
include chemical ionisation, secondary ion mass 
spectrometry (SIMS), fast atom bombardment (liquid SIMS), 
field ionisation, field desorption and atmospheric 
pressure ionisation.
Chemical ionisation is the most popular "soft
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FIGURE 2.5.3: Ionisation by electron impact.
The source pressure is kept sufficiently low that ion decompositions 
are unimoleeular. M represents the gaseous molecules and D1-D6 
represent the daughter ions formed.
M + e ”  -------  [ M ] *  + 2 e“
Excited
V
D1+ + D2‘
D3+ D 4
/ \ 
D5+ D6
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ionisation" method. Chemical ionisation utilises a reagent
gas such as methane or isobutane which is present in a
large excess. Electron impact causes mainly ionisation of
the reagent gas and primary ions are produced. These
primary ions then react with more reagent gas to produce a
number of chemically reactive species such as CH+ and
5
C^H^, in the case of the reagent gas being methane
(See Figure 2.5.4). These secondary ions can then act as 
Bronsted Acids and donate protons to the sample molecules, 
resulting in (M + 1)+ quasi-molecular ions. These quasi- 
molecular ions may have sufficient energy to fragment, but 
in practice few fragmentation and rearrangement ions are 
observed. Chemical ionisation results in mass spectra with 
the quasi-molecular ion as the most intense ion in the
spectrum.
Chemical ionisation then is a complementary
technique to electron impact ionisation. Figure 2.5.5 
illustrates the mass spectra of proline obtained by both 
electron impact and chemical ionisation techniques.
(C) MASS ANALYSER
The ions formed in the source are repelled through 
the source slit by a small potential difference between 
the slit and the repeller. These ions are then 
accelerated towards the mass analyser by a high potential 
difference (about 4 Kv) between the source block and the 
accelerating slit.
The linear ion beam leaving the ion source is 
separated into groups of ions of different mass to charge
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FIGURE 2.5.4: Chemical ionisation with methane.
M represents the gaseous molecule and MH+ is the quasi-molecular ion 
which is detected.
ci-u
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C H ^  + CH^ CH3+ + CH4
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CH5+ + M ------- *  MH+ + CH4
quasi-m olecular
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FIGURE 2.5.5: Mass spectrum of prolific (a) by electron impact and
(b) by chemical ionisation.
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ratios by the mass analyser. There are four different 
types of mass analysers commonly used in organic 
chemistry; the single focussing magnetic deflection mass 
analyser, the double focussing mass analyser (which 
contains a magnetic sector and an electrostatic sector), 
the quadrupole analyser and the time of flight analyser. 
Only the single focussing magnetic sector instrument will 
be discussed here as this is the type of mass analyser 
present in the VG 16F.
The most important parameter determined by the 
analyser is the mass resolution (R) which is defined as:
* = S-A m
where m is the mass of the first peak in a consecutive 
pair of ions and A m the difference in the masses of the 
two peaks. The peaks are considered to be resolved if 
they are separated by a valley of 10% the peak height. 
Mass spectrometers may be of low, medium or high
resolution.
Low resolution instruments have a resolution of the 
order of 1000, that is, they can distinguish ions of 1000 
and 1001 amu or 100.0 and 100. l amu. single focussing 
magnetic sector and quadrupole mass spectrometers are low 
resolution instruments. Medium to high resolution 
instruments range from 10,000 to 150,000 and have
double-focussing mass analysers.
The principle of the single-focussing magnetic
sector instrument is shown in Figure 2.5.6. ions formed 
in the source are accelerated through a voltage V
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FIGURE 2.5.6: Schematic diagram of single-focussing magnetic
deflection mass analyser.
* r* is the radius of curvature of the magnetic sector.
M a g n e t i c
f i e ld
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Col lectorS o u r c e
S 2
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(V = 2000-8000V) toward the source slit which is at earth 
potential. The fall in potential energy for the ions is
equal to their gain in kinetic energy, summarised in 
Equation 1, where e is the charge on an electron, Z is the 
number of such charges on an ion, v  is the accelerating 
voltage, m is the mass of the ion and v is the velocity of 
the ion.
For an ion to reach the collector slit and be
recorded it must traverse a path of radius of curvature r 
through the magnetic field of strength B. The equation of
motion of the ion (Equation 2) expresses the balance
between the centripetal force (or angular momentum) and 
the centrifugal force caused by this field.
ZeV = y2mv  Equation l
2mv /r = B z v e ................Equation 2
Combining Equations l & 2 gives the basic mass
spectrometer Equation 3,
m / = B 2r2e ............... Equation 3
z 2V
Thus by keeping r constant and by varying either the field 
strength or the applied voltage (as in th VG 16F) ions of 
different m/z ratios separated by the magnetic field can 
be made to reach the collector. The resolution of a 
magnetic sector mass spectrometer is determined 
principally by the radius of curvature and by the width of 
the source and collector slits.
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where k is a constant and s1 and s2 are the widths of 
the source and collector slits. Decreasing the slit 
width, therefore, increases the resolution but also 
decreases the instrument's sensitivity.
Typical ion currents recorded in mass spectrometry 
are in the range 10"10 to io~19 amps. These low 
currents are amplified by an electron multiplier before
they reach the electronic amplifier.
Due to the amount of data generated by a mass
spectrometer and the need for fast data acquisition and
processing a computer is generally interfaced to the mass
spectrometer. Chromatograms can be obtained from the
output of the mass spectrometer by either recording the
total ion current (TIC) or by recording a selected ion
(known as Selected Ion Recording, SIR, or Selected ion
Detection, SID) .
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2.5.2 EXPERIMENTAL
(a) REAGENTS
1. Diethyl ether, Pronalys AR grade (May and Baker, 
Dagenham, England).
2. Methanol, HPLC grade (Rathburn Chemicals Limited, 
Walkerburn, Scotland).
3. Ethyl acetate (Rathburn Chemicals Limited, 
walkerburn, Scotland).
4. Digol, Analar grade (BDH Chemicals Limited, Poole, 
England).
5. Potassium hydroxide, Analar grade (BDH Chemicals 
Limited, Poole, England).
6. Diazald, N-methyl-N-nitroso-p-toluenesulfonamide
(Aldrich chemical company Limited, Gillingham, England).
7. BSTFA, + 1% TMCS, MTBSTFA and Pyridine (Pierce,
Life Sciences, Laboratory Limited, Luton, England).
(b) DRUG STANDARDS
As in section 2.3.2(b).
(c) Apparatus
1. A Perkin-Elmer sigma 3B gas chromatograph fitted 
with a GroB split/splitless injector interfaced 
via a direct inlet to a VG 16F single-focussing 
magnetic sector mass spectrometer and a VG series 
2000 data system. Electron impact mass spectra 
were recorded repetitively (cycle time 2.5 seconds).
2. A wall coated open tubular column (24m, 0.5mm i.d., 
l.lmm o.d.) with a liquid stationary phase of 
CP-SIL5 at a film thickness of 0.81 i^m.
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(d) GC-MS CONDITIONS
The GC-MS conditions employed were was follows:- 
Column: WCOT, 2 4m, 0.5mm i.d., l.imm o.d.
with a liquid stationary phase of 
CP-SIL5 at a film thickness of
0.81pm.
carrier Gas: Helium (2ml/min)
injector Temperature: 275°c
Column Temperature: Programmed from 80°c to 280°c at
a ramp rate of 4°/minute with 
initial and final isothermal periods 
of 2 minutes, 
ionising Energy: 70ev
source Temperature: 2 4 0 ° c
(e) PREPARATION OF DIAZOMETHANE 
As in Section 2.4.2 (e)(i).
(f) PREPARATION OF DERIVATIVES OF NSAIDS
(i) METHYLATION WITH DIAZOMETHANE
As in Section 2.4.2 (f)(i) except that the reaction
products produced with phenylbutazone, sulphinpyrazone and 
azapropazone were diluted in methanol instead of ethyl 
acetate before injection.
(ii) SILYLATION WITH BSTFA + 1% TMCS
As in section 2.4.2 (f)(iv).
(iii) tert-BUTYLDIMETHYLSILYLATION WITH MTBSTFA 
As in section 2.4.2 (f)(vii).
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2.5.3 R E S U L T S
(a) MASS SPECTRAL ANALYSIS OF SELECTED NSAIDS 
Ibuprofen, flurbiprofen, naproxen, ketoprofen,
fenbufen and mefenamie acid were derivatised and analysed 
by GC-MS as their methyl esters, trimethylsilyl esters and 
tert-butyldimethylsilvl esters. The mass spectral data 
obtained are listed in Table 2.5.1 and the full spectra
are given in Figures 2.5.7-2.5.12.
(b) MASS SPECTRAL ANALYSIS OF PHENYLBUTAZONE,
SULPHINPYRAZONE AND AZAPROPAZONE
Phenylbutazone, sulphinpyrazone and azapropazone
were analysed by GC-MS. The mass spectral data obtained
is listed in Table 2.5.2 and the full spectra are given in 
Figure 2.5.13.
(C) MASS SPECTRAL ANALYSIS OF THE REACTION PRODUCTS OF
PHENYLBUTAZONE. SULPHINPYRAZONE AND AZAPROPAZONE
WITH DIAZOMETHANE
Phenylbutazone, sulphinpyrazone and azapropazone
were reacted with diazomethane as described in Section
2.5.2(f)(i) and the reaction products analysed by GC-MS.
The chromatograms obtained for the reaction 
products of phenylbutazone and azapropazone with 
diazomethane are given in Figure 2.5.14.
The retention indices and the mass speetrometric 
data of the reaction products obtained for the three drugs 
are listed in Table 2.5.3 and the full spectra are given
in Figures 2.5.15-2.5.19.
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FIGURE 2.5.7: Mass spectra of the methyl, trimethylsilyl and
tert-butyldimethylsilyl esters of ibtiprofen.
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FIGURE 2.5.8: Mass spectra of the methyl, trimethylsilyl and
tert-butyldimethyls ilyl esters of flurbiprofen.
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FIGURE 2.5.9: Mass spectra of the methyl, trimethylsilyl and
tert-butyldimethyls ilyl esters of naproxen.
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FIGURE 2.5.10: Mass spectra of the methyl, trimethylsilyl and
tert-butyldimethylsilyl esters of ketoprofen.
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FIGURE 2.5.11: Mass spectra of the methyl, trimethylsilyl and
tert-butyldimethylilyl esters of fenbufen.
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FIGURE 2.5.12: Mass spectra of the methyl, trimethylsilyl and
tert-butyldimethylsilyl esters of mefenamic acid.
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FIGURE 2.5.13: Mass spectra of phenylbutazone, sulphinpyrazone and
azapropazone.
E73 230iui.il*! i 1
Phenylbutazone —  MW 308-39
105
CL m
130
119 183
150
uiiL
270
o
I me 21*
252
265
293 % 380 ^0  ^368 a I.
50 108 150
Sulphinpyrazone — MW 404 49
250 350
189
Azapropazone —  MW 300 - 36
- 137 -
FIGURE 2.5.14: Chromatograms obtained for the reaction products of
phenylbutazone and azapropazone with diazomethane.
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FIGURE 2.5.15: Mass spectra obtained for the reaction products 1 and 2
of phenylbutazone with diazomethane.
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FIGURE 2.5.16: Mass spectra obtained for the reaction products 3 and 4
of phenylbutazone with diazomethane.
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FIGURE 2.5.17: Mass spectrum obtained for the reaction product of
sulphinpyrazone with diazomethane.
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FIGURE 2.5.18: Mass spectra obtained for the reaction products 1, 2
and 3 of azapropazone with diazomethane.
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FIGURE 2.5.19: Mass spectra obtained for the reaction products 4 and 5
of azapropazone with diazomethane.
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2.5.4 DISCUSSION
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(a) MASS SPECTRAL ANALYSIS OF SELECTED NSAIPs
The mass spectra of the methyl esters of
ibuprofen, flurbiprofen, naproxen, ketoprofen, 
fenbufen and mefenamic acid showed several
similar characteristics. All of the esters had 
a prominent molecular ion except fenbufen which
had a molecular ion of 1% relative intensity.
Two common fragmentations seen in the 
spectrum of methyl esters were M-31 and M-59.
These were due to loss of a methoxy group and
loss of a earbomethoxy group. The six NSAlDs
discussed here all exhibited an [M-59I+ peak,
although [M-6l]+ was of a higher relative
abundance in both the fenbufen and mefenamic
acid methyl ester spectra. This ion would arise
from a proton transfer along with loss of the
earbomethoxy group. The loss of 31 amu was seen 
in both the fenbufen and mefenamic acid methyl 
ester spectra.
The mass spectra of the silyl esters of
five of the NSAlDs discussed here had a
molecular ion. Ketoprofen did not exhibit a
molecular ion. All of the six NSAlDs had a
[M-15 ]+ ion. This is usual for silyl esters
and corresponds to the loss of a methyl moiety
from the silyl group. All spectra of
- 144 -
compounds had ions at m/z 73 and 75. These ions
often formed the base peaks of the spectra, but 
were of low diagnostic significance. They have
been shown [113] to have the structures 
illustrated in Figure 2.5.20.
only the tert-butyldimethylsilyl (BDMS) 
esters of naproxen and mefenamic acid exhibited 
molecular ions, the other four NSAlDs having 
[M-l ]+ peaks. in all cases the base peak in 
the BDMS ester spectrum was the [M-57]+ ion,
formed by loss of the tertiary butyl group.
The spectra of aromatic compounds often 
contained some or all of the following 
characteristic ions: m/z 77, 91 and 105. The
formation of these ions is shown in Figure 3.4.1 
and 3.4.2. These three ions can be found in
many of the spectra of the methyl, silyl and
BDMS esters of the NSAlDs discussed here.
IBUPROFEN
Cleavage of the 2-methyl-propyl side chain 
was evident in two of the ibuprofen spectra: 
m/z 177, [M-43]+ in the methyl spectrum and
m/z 234, [M-44]+ in the silyl spectrum. The
ion at m/z 161 was present in all three spectra 
and was due to loss of the earbomethoxy group,
[M-59]+ in the methylated compound, loss of
the earboxy-silyl-ether group, [M-ll7]+ in the
FIGURE 2.5.20: Ions found in the mass spectra of silylated compounds.
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silylated compound and loss of the carboxy-tert-
butyl-dimethyIsilyl ether group, [M-159]+ in the
BDMS ester. The base peak in the silyl ester
spectrum was in fact m/z 160, formed by loss 
of the 117 group mentioned above along with a
proton transfer.
The cluster of ions present in all three
spectra at m/z 117/118/119 was due to cleavage
of the 2-methyl-propyl side chain along with 
loss of the carboxy ester group. The ion at
m/z 117 was most abundant in the silyl spectrum
because it was also due to the presence of the
[co2si(CH3 )3]+ ion.
FLURBIPROFEN
The base peak in the spectrum of the
methyl ester of flurbiprofen was at m/z 199 and
was due to loss of the earbomethoxy group. The 
BDMS ester spectrum also contained ions at
m/z 198/199 but neither of these ions were of
high relative abundance in the silyl ester 
spectrum. Loss of the earboxy-silyl-ether group
was, therefore, not a favoured fragmentation of 
the silyl ester of flurbiprofen.
Peaks found at m/z 183/184 in the methyl
and the BDMS spectra were due to losses of the 
earbomethoxy and the carboxy-tert-butyldimethylsilyl- 
ether groups respectively.
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A dominant ion at m/z 180 which appeared 
in the spectrum of the silyl ester of 
flurbiprofen could be due to loss of the
carboxy-silyl-ether group and a fluorine atom. 
The 180 ion was of low relative intensity in
the methyl ester and BDMS ester spectra, but
ions at m/z 178/179 were of high relative 
intensity. These ions could have been formed by
loss of a fluorine atom along with a 
earbomethoxy group (or a carboxy-tert-butyldimethyl- 
silyl-ether group in the case of the BDMS
ester) and a one or two proton transfer.
NAPROXEN
The ions at m/z 185/186, 184/186 and
184/185/186 appeared in the methyl, silyl and
BDMS ester spectra respectively. These ions
arose due to losses of the carboxy-ester groups
in all three cases. An ion at m/z 170 also 
appeared in the three spectra and this was most
likely due to loss of the carboxy-ester group 
and a methyl group. Loss of the carboxy-ester
group and a methoxy group was shown by the
presence of peaks at m/z 153/154 in the three
spectra.
KETOPROFEN
The base peak in the methyl spectrum of
ketoprofen at m/z 209 was due to loss of the
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earbomethoxy group. The base peak in the silyl
ester spectrum appears at m /2 282 (M-44) and was
presumably due to loss of carbon dioxide. The
mass spectrum of the BDMS ester of ketoprofen 
exhibitied a base peak at 311 which was the 
[M-57 ]+ ion. The peak at m/z 191 in the
methyl spectrum could have been due to the loss
of a benzyl group. Apart from the usual
aromatic ions at m/z 77 and 105 the other ions
in the three ketoprofen ester spectra were of 
low relative intensity.
FENBUFEN
The peak at m/z 181 appeared in the three
fenbufen spectra and was due to the [C(rH_-C.Hyi-C0]t * 6 5 6 4
ion. The peak at m/z 237 in the methyl spectra
was due to loss of the methoxy group. This
peak was also present in the silyl and the
BDMS ester spectra. The cluster of ions at
m/z 151/152/153 present in all three spectra were
due to the [C6H 5-C6H 5 ]+ ion.
MEFENAMIC ACID
Nitrogen containing compounds such as 
mefenamic acid must follow the nitrogen rule: 
the molecular weights of compounds containing
only c ,  H, N and O are odd when the number of
nitrogens is odd and are even when the number
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of nitrogens is even. The molecular ions in 
the three spectra of mefenamic acid all appeared 
at odd numbers, since mefenamic acid contains 
one nitrogen atom.
The ions present in the remainder of the
three spectra were very similar to each other. 
Peaks at m/z 22 3 in the methyl and silyl 
spectra and m/z 224 in the BDMS spectra were of
high relative intensity and were due to loss of 
the ether groups. The peak at m/z 208 present 
in the methyl and silyl spectra and that at
m/z 207 in the b d m s  spectra was due to further
loss of a methyl group from the 223/224 ion.
The peak at m/z 194 also appeared in all
three spectra and could have been due to the 
loss of the carboxy-ether groups along with
proton transfers. Finally the peak at m/z 180 
again appeared in the three spectra and was due 
to loss of the carboxy-ether group and a methyl
group.
(b) MASS SPECTRAL ANALYSIS OF PHENYLBUTAZONE.
SULPHINPYRAZONE AND AZAPROPAZONE
The mass spectra of some medicinal 
pyrazolidinediones have been studied. Yen and
co-workers [114] include phenylbutazone in their
analysis, while unterhalt [115] and Locock and his
colleagues [116] discuss phenylbutazone,
oxyphenbutazone and sulphinpyrazone.
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In the spectra obtained in this study
molecular ions were observed at m/z 308, 404 and
300 for phenylbutazone, sulphinpyrazone and 
azapropazone respectively.
unterhalt observed [115] that phenylbutazone,
oxyphenbutazone and sulphinpyrazone undergo the
McLafferty rearrangement to give a radical ion
at m/z 252 (m/z 268 for oxyphenbutazone). Locock
and co-workers studied the metastable ions 
present in all three spectra and concluded that 
this is a direct fragmentation from the 
molecular ion with the loss of the elements of
butene or C^H._S0CHCH„ in the case of
b 5 Z
sulphinpyrazone. These fragmentations are
presented in Figure 2.5.21. The McLafferty
rearrangement product (m/z 252) is also present 
in the spectra of sulphinpyrazone obtained during 
this study (Figure 2.5.13).
A minor fragmentation pathway for the
molecular ion of phenylbutazone (also substantiated
by the presence of metastable ions) is the loss
of a propyl radical from the butyl side chain
of the molecular ion to give an ion at
m/z 265. in the spectrum of sulphinpyrazone,
strong peaks at m/z 278 (100%) and at m/z 279
(127) represent the loss of C &H 5SOH and
c H SO from the side chain of the
6 5
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FIGURE 2.5.21: The McLafferty rearrangement reactions of
phenylbutazone and sulphinpyrazone.
N
C.
-C4Hj HO. N
N
C
M-(m/z 308) m/z 252
CH2CHSOC5H5
Mf  (m/z 404)
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sulphinpyrazone molecular ion.
If azapropazone were to undergo a 
McLafferty rearrangement, an ion would be 
expected at m/z 258, and in fact an ion at
m/z 257 is present in low abundance (1%).
Locock and co-workers have commented that
the most characteristic fragments in the mass
spectra of all the pyrazolidinediones which they
studied were a series of peaks at m/z 182, 183
and 184 (198, 199 and 200 in oxyphenbutazone) .
The ions m/z 182, 183 and 184 are present in
the mass spectra of phenylbutazone and 
sulphinpyrazone (Figure 2.5.13). The ion at
m/z 183 is the base peak in the phenylbutazone
spectrum. Locock and co-workers have shown that 
this ion arises from the radical ion (m/z 252)
by hydrogen transfer as depicted in Figure 2.5.22. 
The peak at m/z 182 can be attributed to the
formation of the azobenzene radical ion
<C 6H 5N 2C6H 5 )+-
Other ions present in the spectra of
phenylbutazone and sulphinpyrazone, which may
arise from the azobenzene radical are the result
of the loss of a phenyl radical C6H 5 » t0
give c H N + (m/z 105) which subsequently
6 5 2
may lose nitrogen to give C 6H5 (m/z 77).
The base peak in the spectrum of
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FIGURE 2.5.22: The formation of the m/z 183 ion in phenylbutazone.
H
H c = c = o
m/z 183
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azapropazone at m/z 160 and the collection of 
ione at m/z 188/189/190 may be formed as 
indicated in Figure 2.5.23. The ion at m/z 145
could be formed from the ion at m/z 160 by
loss of a methyl group.
(C) MASS SPECTRAL ANALYSIS OF THE REACTION PRODUCTS
OF______ PHENYLBUTAZONE ,_SULPHINPYRAZONE____________AND
AZAPROPAZONE WITH DIAZOMETHANE
Phenylbutazone was reacted with diazomethane 
in methanol and the reaction products were
examined by GC-MS. Four reaction products, whose
spectra are indicated in Figures 2.5.15 and
2.5.16, were observed. Two products (1 and 3)
have molecular ions at m/z 322 (i.e.
phenylbutazone + 14) and the other two
products (2 and 4) have molecular ions at m/z 336
(i.e. phenylbutazone + 28). structures have been
tentatively assigned to the four reaction 
products as indicated in Figure 2.5.24.
Reaction products l and 2 both show the 
loss of the butyl side chain (M-56) similar to
phenylbutazone itself, while 3 and 4 have M-43
ions, corresponding to loss of a propyl group
(part of the butyl side chain). The change in
the fragmentation of the side chain in products 
3 and 4 suggests that the reaction with
diazomethane has altered the structure of the
molecule at the carbon atom holding the side
chain, which would be true if an enol ether
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FIGURE 2.5.23: Possible cleavages of azapropazone to form the ions at 
m/z 160 and 189.
(CH3)2N 
160
(ch2)2ch3
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FIGURE 2.5.24: Suggested structures of the four reaction products of
phenylbutazone with diazomethane.
Reaction Product 1
C^Hg
Reaction Product 2
Reaction Product 3
Reaction Product 4
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had been formed. since a vinyl bond would be 
more difficult to break than an alkyl bond, the
loss of the butyl side chain would be less
likely to occur when a vinyl bond is present. 
The presence of the vinyl bond would therefore 
explain the loss of a propyl group from the
butyl side chain.
Bauer and co-workers [117] discuss the 
formation of oxiranes by the addition of 
CH2N 2 to the carbonyl function of alpha-oxo 
acids when reacted with diazomethane. Bauer
suggests that this occurs via a Zwitterion which 
is able to stabilise itself by elimination of 
N 2 and ring closure to form the oxirane ring
as shown in Figure 2.5.25. It is possible that
oxiranes could be formed when pyrazolidinediones 
are reacted with diazomethane to give the
structures indicated in Figure 2.5.24.
The favoured reaction product is number 3.
Figure 2.5.26 suggests possible fragmentations of
the structure to give the m/z 188, 160 and 146
ions.
Sulphinpyrazone produced one reaction product 
when reacted with diazomethane in methanol. The 
mass spectrum of the reaction product does not
contain a molecular ion, but has a base peak at 
m/z 292. By comparison with the mass spectrum of 
sulphinpyrazone which has a base peak at m/z 278, 
[M-126] due to loss of the C ^ S O H  group it
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FIGURE 2.5.25: The formation of an oxirane, when an alpha-oxo acid is
reacted with diazomethane.
0
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FIGURE 2.5.26: Predicted fragmentation of reaction product
from phenylbutazone).
h5C6\ /CeH5 
N-N
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can be inferred that the molecular weight of the
reaction products is 418. The reaction product
is therefore a mono-methyl derivative of sulphin­
pyrazone. it is, however, difficult to predict 
its structure since there are very few diagnostic 
ions in the spectrum.
Azapropazone was also reacted with
diazomethane in methanol; the chromatogram obtained
from the reaction mixture (Figure 2.5.14) contained 
five major peaks. The early eluting, broad peak 
may be due to a pyrolysis product whose 
structure is given in Figure 2.5.27.
The other four peaks all have molecular
ions at m/z 314 in their mass spectra suggesting
that there are four different reaction products
which all have one extra methyl group. These
products could be similar to those suggested for 
phenylbutazone and tentative structures are given 
in Figure 2.5.28. unlike phenylbutazone, azapropazone 
is not symmetrical about the pyrazolidine ring and 
each mono-derivative is a different geometric
isomer. While it is difficult to assign
structures to each product in the absence of
further spectral data, the presence of (M-42) ions
in products 2 and 4 suggests that these are
oxirane derivatives while the presence of an
(M-29) ion in products 3 and 5 suggests that
these are enol ethers, following the same argument 
used for the products obtained from phenylbutazone.
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FIGURE 2 5.27: Pyrolisis product of azapropazone
ch3
N ^ N  
H3C' v  
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M* 188
CH3
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FIGURE 2.5.28: Suggested structures of the four reaction products of
azapropazone with diazomethane.
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2.5.5 C O N C L U S I O N
Ibuprofen, flurbirpofen# naproxen,
ketoprofen, fenbufen and mefenamic acid could be 
uniquely identified from each other as the 
methyl, trimethylsilyl or tert-butyIdimethylsilyl 
derivatives. Phenylbutazone, sulphinpyrazone and 
azapropazone could be analysed and identified. 
However, when these three drugs were reacted 
with diazomethane, as they could be in a 
screening procedure, they produced multiple 
reaction products which would complicate the 
analysis. These drugs would also be difficult to 
quantify if reacted with diazomethane.
Phenylbutazone, sulphinpyrazone and azapropazone 
did not react with the silylation reagents used in 
section 2.4. If a derivatisation reaction was used in 
a screening procedure silylation would not affect the 
pyrazolidinediones and they could be identified as the 
free drug.
The proposed structures for the reaction 
products of the pyrazolidinediones with diazomethane 
need to be confirmed by further work. Sufficient 
quantities of the various products would have to be 
synthesised and identified using elemental analysis, 
high resolution mass spectrometry and nuclear magnetic
resonance spectroscopy.
Another approach which may help to identify the 
reaction products would be to examine the mass spectra
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of the reaction products produced using 
[2H 2 ]-diazomethanef although it should be noted
that the fragmentations of the pyrazolidinedione 
reaction products are not simple reactions. Many 
appear to involve rearrangements and hydrogen transfers 
and the interpretation of deuteromethyl derivative 
spectra may be complex.
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C H A P T E R  T H R E E
URINARY ACID PROFILE IN THE RACING GREYHOUND
3.1 INTRODUCTION
Dope testing in the racing greyhound is carried out 
using urine and since the anti-inflammatory drugs being 
examined were all acidic in nature it was essential to 
establish the normal urinary acid profile of the greyhound 
before attempting to assay the NSAiDs. The human urinary 
acid profile is already well documented [Ref. 118 and the 
references cited therein] since the identification and 
quantification of organic acids in human urine is used as 
a method of diagnosis for a group of hereditary diseases 
known as organic acidurias. These diseases, resulting 
from inborn errors of metabolism, are caused by the 
diminished activity or complete absence of a specific 
enzyme or enzyme co-factor which leads to the accumulation 
and increased excretion of acidic metabolites. Today some 
sixty different organic acidurias are known, involving a 
total of more than two hundred different acidic 
metabolites [119]. Phenylketonuria and maple syrup urine 
disease are two examples of organic acidurias occurring 
as inborn errors of metabolism [izo]. if left untreated 
both of these diseases result in mental retardation. 
Phenylketonuria is caused by a deficiency in the 
activity of phenylalanine-4-hydroxylase. since the normal 
conversion of phenylalanine to tyrosine is prevented.
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the alternative pathway to phenylpyruvic acid and
its metabolites is utilised and they are excreted
in abnormally high concentrations in the urine 
(Figure 3.1.1). Maple syrup urine disease is revealed by 
high concentrations of 2-oxocarboxylic acids in the urine 
caused by a defect in the metabolism of the amino acids 
valine, leucine and isoleucine (Figure 3.1.2).
urinary organic acids are the water-soluble end 
products or intermediates of the metabolism of amino
acids, carbohydrates, biogenic amines, steroids, lipids 
and many other endogenous compounds. They may also be 
derived from exogenous sources such as food additives and 
drugs. They are a complex mixture of polar and moderately 
polar hydroxy-, keto-, mono-, di- and tri-carboxylic
acids, aromatic and heterocyclic compounds as well as 
glycine and other conjugates which differ widely in their 
chemical properties and concentration in normal urine. 
Liebich has summarised the acids which have been
identified in human urine and has classified them into
seven major groups [120]. Table 3.1.1 lists the seven 
groups and gives some examples of urinary acids.
GC-MS has been the dominant technique used in the 
field of urinary organic acid analysis [121-124], though
some workers have used GC alone and utilised retention 
indices from two columns of different polarities to
establish the identity of the acids [119,125,126]. 
Lefevere and co-workers, however, report that it is 
impossible to make an unambiguous identification based on
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FIGURE 3.1.1: Metabolism of phenylalanine in man, showing the normal
pathway to acetoacetic acid and the alternative pathway to 
phenylpyruvic acid and its metabolites.
H O c H2 - c H - COO H 
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FIGURE 3.1.2: Metabolism of valine, leucine and isoleucine in man
showing the normal pathways and the alternative pathways to the
2-oxocarboxylic acids observed in patients with Maple Syrup Urine 
disease.
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TABLE 3.1.1: Organic acids found in urine and serum.
DICARBOXYLIC ACIDS 
Oxalic acid 
Methylmalonic acid 
Succinic acid 
Glutaric acid 
Adipic acid 
Pimelic
OXOCARBOXYLIC ACIDS 
Glyoxylic acid 
Pyruvic acid 
2-Oxobutyric acid
4-Oxovalerie acid 
2-Oxoglutaric
2-Oxoadipic acid
HYDROXYCARBOXYLIC ACIDS AND LACTONES 
Hydroxyacetic acid 
Lactic acid
3-Hydroxyvaleric acid 
Malic acid
D-Glucono-1,5-Lactone 
Tartaric Acid
AROMATIC ACIDS AND PHENOLS 
Phenol
Benzoic Acid 
Vanillic acid 
Phenylacetic acid 
Mandelic acid 
Phenyllactic acid
FURANCARBOXYLIC ACIDS
5-Methylfuran carboxylic acid 
Furan-2,5-dicarboxylic acid 
5-Hydroxymethyl furan carboxylic acid
3-Carboxy-4-methyl-5-(4-oxo-pentyl)-2-furanpropionic acid
NITROGEN-CONTAINING ACIDS 
N-Methylleucine 
Pyroglutamic acid 
Nicotinic acid 
3-Indoleacetic acid 
Anthranilic acid 
3-Indolelactic acid
ACID CONJUGATES
Propionylglycine 
Isovalerylglycine 
Hippuric acid
3-Hydroxyhippuric acid 
N-Isovalerylglutamic acid 
N-Phenylacetylglutamic acid
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retention indices alone and that a final confirmation by 
GC-MS is necessary [119],
There have been some reports on the applications of
HPLC to the study of organic acids in particular disease
states [127,128], but Chalmers and Lawson [118] report 
that these methods have no particular advantage over the
conventional GC procedure.
3.1.1 ISOLATION OF URINARY ORGANIC ACIDS
Various methods have been used to isolate organic 
acids from urine and these have been reviewed by several 
workers [120,122,123]. solvent extraction and the use of 
anion-exchange procedures (an example of solid phase 
extraction) have been the most popular. solvent
extraction of acidified salt-saturated urine with ethyl or 
methyl acetate and/or diethyl ether has been preferred for 
routine clinical use [125,126,129,130]. These procedures, 
however, are not quantitative and polar compounds, such as 
di- and tricarboxylic acids and polyhydroxy acids are 
poorly extracted [131]. solvent extraction also 
co-extracts interfering neutral compounds, such as urea 
and glycerol.
Anion-exchange using, for instance, DEAE-Sephadex 
has also been used by many workers [131, 132, 133]. This 
method is more quantitative than solvent extraction, 
gives better reproducibiltiy and eliminates interfering 
neutral compounds. Anion-exchange, however, requires the 
time—consuming lyophilisation of the aqueous pyridinium 
acetate solution which is used as the eluent. Large
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amounts of sulphate and phosphate are also eluted in 
anion—exhange and these "interfere with subsequent gas 
c hr oma t o g r a p h y .
Most of the current applications of solid phase 
extraction use chemically modified silica and alumina 
which resemble chemically bonded phases for HPLC in their 
mode of action (or retention mechanism). Sorbents of 
different types are available to emulate straight phase, 
reversed phase, ion-exchange and affinity chromatography 
(not yet commercially available), depending on their 
substituents [134,135]. Appropriate choices of sorbent 
and solvents used in sample loading, sorbent washing and 
analyte elution permit solid phase extraction to be highly 
selective and often to provide extracts of sufficient 
purity for direct analysis by chromatographic methods 
following suitable derivatisation if necessary. Dalsh and 
Leonard reported [136] a solid phase extraction method for 
the extraction of organic acids from plasma. Recently 
Rumsby and co-workers reported [137] the use of a similar 
solid phase extraction method for the extraction of 
organic acids from various biological fluids including 
urine.
Another example of a solid phase extraction 
technique is the use of cross-linked polystyrene/divinyl 
benzene (XAD-2) resin. Its application is well recognised 
in analytical toxicology and it has been used in the 
isolation of drugs from various body fluids including 
urine [138-147]. These resins have also been utilised to
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extract urinary organic acids [124,148].
For urine analysis the resin can be introduced 
directly into the urine or the sample may be
passed through a column of the resin. Dieterle and
co-workers [149] have also used micronised XAD-2 resin to 
form the support for preparative high-resolution liquid 
chromatography. This method was used to isolate the
urinary glucuronides of sulphinpyrazone and also achieved 
a separation of a standard mixture of phenylbutazone and 
four of its metabolites.
in this project Amberlite XAD-2 resin was chosen as 
the solid phase for the extraction of the NSAlDs, organic 
acids and their metabolites from urine. Amberlite XAD-2 
retains organic substances by virtue of hydrophobic/ 
lipophilic interactions on the resin surface. Aromatic 
substances are particularly well retained. Elution of 
adsorbed species requires the use of an organic solvent to 
break the lipophilic interactions, usually ethanol or 
methanol. unlike other adsorbents based on silica or 
alumina there are no secondary ion exchange interactions 
present.
The use of XAD-2 resin for the isolation of drugs 
and metabolites from urine has several advantages over 
conventional solvent-solvent extraction; XAD-2 resin 
yields extracts which are free from emulsions and eluates 
do not require to be dried prior to evaporation. Eluates 
from XAD-2 resins are also free from inorganic phosphates 
and sulphates which could interfere with any subsequent 
enzyme hyrdrolysis step, for example, using glucuronidase.
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3.1.2 DERIVATISATION OF URINARY ORGANIC ACIDS
Urinary organic acids are frequently highly polar, 
have low volatilities and are thermally unstable; they 
are therefore not suitable for direct analysis by GC and 
are normally derivatised first. The relative merits 
of various derivatisation procedures have been 
reviewed [118,122,123] and those commonly consist of 
the formation of esters of the carboxyl functions and 
ethers of free hydroxyl groups. Trimethylsilylation with 
BSTFA or BSA [119,124,125,131-133] and methylation with 
diazomethane [130,150-153] are the most commonly followed 
derivatisation procedures and are discussed briefly below. 
Keto-acids may require additional modification, normally 
by preparing an oxime derivative, to avoid formation of 
isomeric enol ethers and subsequent complications in the 
analysis.
Trimethylsilyl (TMS) derivatives are easy to 
prepare and most of them have good chromatographic 
properties. In addition, useful diagnostic ions are 
frequently obtained in the mass spectra of these 
derivatives. However, they are not stable during storage 
and the mass fragmentation pattern in some instances can 
be difficult to interpret especially in the case of 
unidentified substances. TMS reagents form derivatives 
with carboxyl groups, hydroxyl groups and phenolic groups 
of organic acids. Keto-acids have a tendency to yield 
multiple derivatives (enol-trimethylsilyl ethers) with 
silylation and are more easily determined if double
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derivatives, such as oxime-TMS [154], methoxime-TMS [155] 
and ethoxime-TMS [156] are prepared.
Methyl esters of organic acids can also be readily 
prepared and have excellent chromatographic properties. 
They are not prone to hydrolysis like the corresponding 
TMS derivatives. The mass spectra of methyl esters are 
often easier to interpret and display ions which are more 
characteristic of the parent substance than those of the 
TMS derivatives. Diazomethane reacts with carboxyl 
groups, phenolic hydroxyls and the sulphydryl group of
thiols. Diazomethane, though, has been found to produce a 
mixture of products when reacted with alpha-, beta-
unsaturated acids and alpha-keto acids [157] and this 
complicates the interpretation of the spectra.
in this study four different derivatisation 
procedures were evaluated for the analysis of urinary
acids in the racing greyhound by GC-MS. Having established 
the normal urinary composition and the derivatisation 
procedure which gave the simplest chromatographic profile, 
it would then be possible to establish screening
procedures for NSAIDs and their metabolites in urine.
3.2
3.2.1 
1 .
2 .
3 .
4 .
5 .
6 .
7 .
8 .
9 .
1 0.
11.
3.2.2
human
Poole,
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EXPERIMENTAL
REAGENTS
Amberlite XAD-2 resin, 80-100 mesh (BDH Chemicals 
Limited, Poole, England).
Acetone, reagent grade (BDH Chemicals Limited, 
Poole, England).
Ethanol, glass distilled (J. Burrough, London). 
Methanol, HPLC grade (Rathburn Chemicals Limited, 
Walkerburn, Scotland).
Hydrochloric acid (BDH Chemicals Limited, Poole, 
England).
Ethyl acetate (Rathburn Chemicals Limited, 
Walkerburn, Scotland).
Diethyl ether, Pronalys AR grade (May and Baker, 
Dagenham, England).
Digol, Analar grade ((BDH Chemicals Limited, Poole, 
England).
Diazald, N-methyl-N-nitroso-p-toluenesulfonamide
(Aldrich Chemical Company Limited, Gillingham, 
England).
Potassium hydroxide, Analar grade (BDH Chemicals 
Limited, Poole, England).
BSTFA + 1% TMCS (Pierce, Life Sciences Laboratory 
Limited, Luton, England).
ORGANIC ACID STANDARDS,
organic acids, known from previous work to occur in 
urine, were obtained from BDH chemicals Limited, 
England.
1 . 0-Anisic 2 . cis-Aconitic
3 . Adipic 4 . Ascorbic
5 . Azelaic 6. Benzoic
7 . iso-Butyric 8 . n-Butyric
9 . iso-citric 10. Fumaric
(tri-sodium salt)
11. 2-Furoic 12 . Glucuronic
13 . Glutaric. 14. Glyeollic
15. n-Hexanoic. 16. Hippuric
17. 3-Hydroxyben2oic. 18 . 4-Hydroxybenzoic
19 . Indole-3-yl-aeetic. 20. Lactic
21. DL-Malic. 22 . oxalic
23 . Pimelic. 24 . succinic
25 . Tartaric. 26 . Vanillic
27 . iso-Valeric
Salts of acids were treated with hydrochloric acid (1M) 
and the free acid was extracted into an organic solvent. 
The organic layer was removed and evaporated to dryness 
before derivatisation as described in section (c).
3.2.3 APPARATUS
1. Perkin-Elmer sigma 3B gas chromatograph fitted with 
a Groft split/splitless injector interfaced via a direct 
inlet to a VG 16F single-focussing magnetic sector mass 
spectrometer and a VG series 2000 data system. Electron 
impact mass spectra were recorded repetitively (cycle time
2.5 seconds).
2. A wall coated open tubular column (24m, o.5mm i.d., 
l.lmm o.d.) with a liquid stationary phase of 
CP-SIL5 at a film thickness of 0.81pm.
3. A Bucchi rotary evaporator.
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3.2.4 GC AND GC-MS CONDITIONS
Gas chromatography and gas chromatography-mass 
spectrometry were carried out on systems similar to those 
described in Sections 2.4.2 and 2.5.2, respectively.
3.2.5 PREPARATION OF DERIVATIVES OF STANDARD ACIDS
(a) METHYLATION WITH DIAZOMETHANE
An ethereal solution of diazomethane (see 
Section 2.4.2(e)) was added dropwise to methanol (lml) 
containing about lmg of acid standard until the solution 
remained yellow. The solution was allowed to stand at room 
temperature for 15 minutes before evaporating to dryness 
under a stream of nitrogen. The residue was redissolved in 
5ml of ethyl acetate and about 0.5jil was used for analysis.
(b) SILYLATION WITH BSTFA + 1% TMCS
BSTFA + 1% TMCS (loo^il) and pyridine (20pl) were
added to a vial containing about lmg of acid standard. The 
vial was sealed and the reaction mixture heated at 6 0 ° c  
for 20 minutes. After this time hexane (5ml) was added to
the reaction vial and about 0.5jil was used for analysis.
(C) tert-BUTYLDIMETHYLSILYLATION WITH MTBSTFA
MTBSTFA (100^11) and acetonitrile (lOO^pl) were added 
to a vial containing about 50^ig of acid standard. The 
vial was sealed and the reaction mixture heated at 6 0 ° c  
for 30 minutes. After cooling about 0.5pl was used for
analysis.
3.2.6 COLLECTION OF URINE SAMPLES
A metabolic unit was set up in order to carry out 
this study, to administer therapeutic doses of drugs to
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greyhounds and to collect urine samples in a controlled
manner. The study was licenced by the Home office and the 
metabolic unit was situated at the university of Glasgow 
Veterinary School. The upkeep of the unit was funded by 
the National Greyhound Racing Club of Great Britain.
Four greyhounds (3 male and l female) were housed 
at the unit. The animals were cared for and blood and
urine samples were taken by kennel nurses. The greyhounds
were fed a normal diet of tinned dog food and biscuits.
Urine samples were collected by two procedures, 
either in a metabolic cage or by using a collection vessel 
during normal urination. The metabolic cage was about
2 x 2 x l  metres in size and consisted of stainless steel 
supports covered in wire mesh. The floor of the cage,
which was raised about 20cm off the ground, was also made 
of wire mesh (Figure 3.2.1). Under the flooring was a 
funnel made of stainless steel which collected urine 
passed by the animal in the cage. Urine samples were
collected in a stainless steel jug, then transferred to
polypropylene containers for carriage. Samples were
stored at -20°C until analysed.
The second method of urine collection, outside the 
cage, was much simpler and involved the animal nurse 
collecting urine in a stainless steel jug while the animal
was urinating.
When an animal had been administered a drug and the
reguired number of urine samples had been taken, a washout 
period of about three weeks was allowed before dosing
again.
FIGURE 3.2.1: Illustration of a metabolic cage.
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COLLECTION OF BLANK URINE SAMPLES
Normal 24 hour urine samples were collected 
from the four greyhounds which were medication-free and
were kept in individual metabolic cages for 24 hours.
Twenty-four hour urine collections were analysed for 
individual dogs or as a pooled urine sample. Urine 
samples were collected separately from male and female 
dogs in the morning and evening on three successive days 
to observe variations.
3.2.7 PREPARATION OF AMBERLITE XAD-2 RESIN COLUMN 
Amberlite XAD-2 resin (ca 20g) was slurry packed in
water into a glass column (bed volume 30ml) and washed 
several times with acetone (total volume approximately
500ml) to remove any styrene present. The column was then 
washed with distilled water (approximately 200ml), ethanol 
(approximately 200ml) and distilled water (approximately
200ml) before use.
3.2.8 ISOLATION OF URINARY ORGANIC ACIDS
An aliquot of urine (20ml) was adjusted to pH l 
with 1M hydrochloric acid and passed through a freshly 
prepared column of XAD-2 resin (20gf bed volume 30ml) at a 
flow rate of 4ml/minute. The column was allowed to drain 
and was washed with distilled water (200ml) at the same 
flow rate. The column was allowed to drain once more and 
organic material retained on the resin was eluted with 
ethanol (100ml) at a flow rate of 2ml/minute. The extract 
was evaporated to near dryness on a rotary evaporator. 
The residue was then transferred quantitatively to a vial
- 1 8 1  -
and evaporated to dryness under nitrogen.
3.2.9 PREPARATION OF DERIVATIVES OF URINARY ACID EXTRACTS
(a) METHYLATION WITH DIAZOMETHANE
Urine extracts were dissolved in methanol (500^11) 
and treated with a freshly prepared ethereal solution of 
diazomethane (500pl). The solution was left at room 
temperature for 15 minutes. After this time the solution 
was evaporated to dryness under a stream of oxygen-free 
nitrogen. The sample was then redissolved in methanol 
(25Op 1) before analysis.
(b) SILYLATION WITH BSTFA -t- 1% TMCS
Dried extracts of urine were treated with 
BSTFA + 1% TMCS (200^1) and dry pyridine (50^il) in a vial. 
The vial was sealed and heated at 6 0 ° c  for l hour. This 
solution was then injected directly into the GC.
(C) METHYLATION/SILYLATION
Dried extracts of urine were dissolved in
methanol (500^1) and treated with an ethereal solution of 
diazomethane (500^il). The solution was left at room
temperature for 15 minutes then evaporated to dryness 
under a stream of oxygen-free nitrogen. The sample was 
then treated with BSTFA + 1% TMCS (200pl) and dry 
pyridine (SO^il). The vial was sealed and heated at 60°c 
for l hour. The solution was then injected directly into 
the GC.
(d) tert-BUTYL-DIMETHYLSILYLATION WITH MTBSTFA
Dried extracts of urine were treated with
MTBSTFA (200j2l) and acetonitrile (50pl) in a vial. The
-  1.8 2  -
vial was sealed and the reaction mixture heated at 6 0 ° c  
for 1 0  minutes. This solution was then injected directly 
into the GC.
3.2.10 IDENTIFICATION OF ORGANIC ACIDS IN URINE EXTRACTS
organic acids in urine extracts were identified by 
comparison of their retention indices and mass spectral 
data with those of authentic acid standards run under the 
same conditions. When standards were not available 
identification was on the basis of the mass spectrum alone 
or from published gas chromatographic retention time and 
mass spectral data [118,152,158,159].
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3.3 RESULTS
3.3.1 URINARY ACID STANDARDS
The retention indices and mass spectral 
data obtained after methylation, silylation and 
ter_t-butyldimethylsilylation of several standard acids, 
which are known to occur in human urine, are
given in Tables 3.3.1, 3.3.2 and 3.3.3, respectively,
seventeen of the acids were successfully methylated
and twenty-three successfully trimethylsilylated. A 
selected group of fourteen acids was also converted to 
tert-butyldimethylsilyl ethers (Figure 3.3.1, p225).
3.3.2 NORMAL URINARY ACID PROFILE OF THE RACING GREYHOUND 
The average normal urinary acid profile of
the racing greyhound was determined by GC analysis of
a methylated extract of a pooled urine sample 
(Figure 3.3.2, p226). The chromatogram revealed a complex 
pattern of about seventy components present in varying 
quantities.
Samples of urine taken from two animals (l male and 
1 female) at different times of day and on different days 
were similarly analysed and showed variations between 
animals, according to the time of day and from day to 
day. An overall pattern, however, could be recognised as 
seen in the various chromatograms illustrated in 
Figures 3.3.3 to 3.3.5, pp227-230.
3.3.3 COMPARISON OF DERIVATIVES AND IDENTIFICATION OF 
GREYHOUND URINARY ACIDS
A pooled urine sample was extracted by the method 
described in section 3.2.8. The final extract was
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divided into four aliquots and was derivatised by 
four methods; methylation, trimethylsilylation, combined 
me t hy 1 a t i o n /1 r ime t hy 1 s i ly 1 a t i o n a nd ter t-bu ty 1 d ime t hy 1 - 
silylation. The chromatograms obtained are compared in 
Figures 3.3.6 to 3.3.9, PP231-234.
The gas chromatographic and mass spectral data 
obtained for the four derivatives examined are listed in 
Tables 3.3.4 to 3.3.7. The peak numbers given in these 
tables correspond, as indicated, to the peak numbers in 
Figures 3.3.6 to 3.3.9. Compounds have been indentified 
by comparison with an authentic standard where available 
and the remaining peaks have been tentatively identified 
on the basis of their mass spectra or from published 
gas chromatographic retention times and mass spectral 
data [118.152,158,159].
A summary of the acids identified in the methylated 
and silylated extracts of greyhound urine is given in 
Table 3.3.8. Compounds which have been identified by 
comparison with an authentic standard are marked with *. 
This table groups acids of similar types together, and 
illustrates the structures of the acids identified.
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TABLE 3.3.8: Organic acids identified by GC-MS in the urine of the 
racing greyhound.
NAME OF ACID
, . Retention Retention
STRUCTURE OF ACID Indice of Indice of
Weight of ._ . . . Methylated Silylated
Free Acid 1 2
Derivative Derivative
ALIPHATIC MONOCARBOYYLIC ACIDS 
Caprylic CH3(CH2)5 C0 0 H 144 1 2 4 7 ( 1 8 )
Laurie CH3(CH2)iqC00H 245 1 6 2 0 ( 5 2 )
Palmitic CH3(CH2)i 4COOH 256 1 8 7 0 ( 3 3 )  2 0 1 5 ( 7 3 )
Oleic or Isomer 2 0 3 3 ( 4 8 )
CH3 (CH2 )7CH:::CH(CH2)7C00H 296
Oleic or Isomer 2 0 4 0 ( 4 9 )
Heptadecanoic CH3(CH2)tsCOOH 284 2 1 1 1 ( 7 6 )
Stearic CH3(CH2)16C00H 298 2 0 6 3 ( 5 1 )  2 5 3 3 ( 8 3 )
C^Monounsaturated CH3(CH2 )7CH":CH(CH2)aCOOH 3 10  2 1 4 5 ( 5 7 )
ALIPHATIC DICARBOXYLIC ACIDS_ 
Oxalic HOOC COOH 90 1 0 7 9 ( 2 ) *
or
1 0 8 1 ( 3 ) *
Glutaric HOOC(CH2)3COOH 132
CH3
2 - M e t h y l - G l u t a r i c  H O O C -C H 2 - C H 2 CH COOH 146
1 3 0 7 ( 2 6 ) *
1 3 9 7 ( 3 4 )
TABLE 3.3.8: Continuation (a)
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NAME OF ACID STRUCTURE OF ACID
„ , , Retention RetentionMolecular „ ,,
Weiuht of Indlce of indice of
Free Acid Methylated Sllylated
Derivative"*" Derivative
3-Methyl-Glutaconic CH3 144
h o o c - c h 2 - c = c h - c o o h
Peak 1 
1410(35)
Peak 2 
1450(38)
Adipic
Pimelic
Suberic
Azelaic
H00C(CH2kC 00H
HOOC(CH2)5COOH
HOOC(CH2)6COOH
HOOC(CH2)7COOH
146
160
174
188
1475(39)*
1571(47)*
1385(8) 1666(54)
1485(15)* 1766(61)*
ALIPHATIC TRICARBOXYLIC ACIDS
. , . . .  H 0 0 C .  .COOHcis-Aconitic
h 2c^ ^ h
H 00C
HYDROXY-ALIPHATIC CARBOXYLIC ACIDS
OH 
I
H3C - C - C O O H
I
H
Lactic
3-Hydroxy-iso- 
Valerie
CH3
I
h3c - c - c h 2 - c o o h
OH
OH
174
90
OH
4-Hydroxy-Butanoic H2£_ C H 2 - C H 2C00H 1 0 4
CH3
2-Hydroxy-2-Methyl- H3C— CH2—C— COOH 118
Butanoic I
OH
OH
3-Hydroxy-But-2-enoic H3C — C =  CH — COOH 1 0 2
Hydroxy-Heptanoic ,
CH3 -C H (C H 2)^COOH
OH
Ou -Hydroxi-Tri.n« CH2(ch,5 ch2CH(CH2)2COOH
120
146
210 1570(24)
1727(57)*
1079(2)*
1161(11)
1169(12)
1189(14)
1208(16)
1390(33)
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TABLE 3.3.8: Continuation (b)
Retention Retention
NAME OF ACID STRUCTURE OF ACID  ^ Indice of Indice ofWeight of ed d
Free Acid 1 2
Derivative Derivative
AROMATIC ACIDS AND PHENOLS
Benzoic COOH 122 1073(1)* 1228(17)*
Phenylacetic H2C —COOH 136 1139(2)
Phenylpropanoic H2C— CH2COOH 150 1234(3)
Methyl Cinnamate
3- or 4-Methoxy- 
Phenylacetic
C T "
H2C - C 0 0 H
'OCH3 
OCH3
COOH 148
166
1321(6)
1371(7)
2-Hydroxy-Benzoic
COOH
OH 138
1431(37)
3-Hydroxy-Phenyl-
Acetic
H2C-COOH 
'OH
152 1436(9) 1536(45)
3-Phenyl-Lactic
OH 
I
H2C - C - C 0 0 H  
H
166 1558(46)
4-Hydroxy-Benzo i c
COOH 138 1598(49)*
OH
TABLE 3.3.8: Continuation (c)
NAME OF ACID STRUCTURE OF ACID
Molecular 
Weight of 
Free Acid
Retention Retention 
Indice of Indice of 
Methylated Silylated
Derivative'*' Derivative^
4-Hydroxy-
Phenyl-Acetic
H2C —COOH 152 1448(11) 1606(50)
4-Hydroxy-
Phenyl-Propanoic
OH
h 2c - c h 2co oh 166 1613(51)
H
5-(3- or 4-Methoxy- /r“A |
Phenyl)-4-Hydroxy- H3C 0 C M C ^ h C O Q H
224
Valeric OH
1492(16)
3-Hydroxy-Phenyl-
Propanoic
H2C —CH2 —COOH 166 1695(55)
2,5-di-Hydroxy-
Benzoic
(Gentisic)
COOH
HO'
OH
154 1718(56)
4-Hydroxy-3- 
Methoxy-Phenyl- 
acetic 
(Homovanillic)
h 2c - c o o h
o c h 3
182 1515(17) 1736(58)
3,4-di-Methoxy-
Benzoic
COOH 182 1521(18)
TABLE 3.3.8: Continuation (d)
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NAME OF ACID STRUCTURE OF ACID
Molecular 
Weight of 
Free Acid
Retention 
Indice of 
Methylated
Retention 
Indice of 
Silylated
1 . 2
Derivative Derivative
4-Hydroxy-
Phenyl-Propanoic
h 2c - c h 2- c o o h 166 1535(19)
2-Keto,3- 
Hydroxy-3(4- 
Methoxyphenyl)- 
Propanoic
OH
OH 0 
I I 
H - C - C - C O O H
210 1541(20)
0CH3
3- or 4-Hydroxy- 
Mandelic
OH
HO
j^jjp^-COOH
168 1762(60)
3,4-di-Methoxy-
Phenylacetic
4-Hydroxy-
Phenyl-Lactic
H2C —COOH
'0CH3 
o c h 3
OH
I
h 3c - c - c o o h
196
182
1552(21)
1888(66)
3-(4-Hydroxy- 
Phenyl)-2- 
Prope.no ic
OH
HC =  CHCOOH 164 1908(68)
4-Hydroxy-3-
Methoxy-Phenyl-
Lactic
OH
OH
I
h 3c - c - c o o h  
^ och3
OH
212 1998(72)
TABLE 3.3.8: Continuation (e)
- 2 2 1  -
NAME OF ACID
. Retention Retention
STRUCTURE OF ACID * Indice of Indice of
Weizht of„ 8 7 . .  Methylated Silylated
Free Acid 1 2
Derivative Derivative
3,4-Dimethoxy- 
Cinnamic
h 3co
COOH 2 0 8  1 8 0 2 ( 3 1 )
0CH3
4-Hydroxy-3-
Methoxy-Cinnamic
H3CO
COOH 194 2 0 5 2 ( 7 5 )
NITROGEN-CONTAINING ACIDS 
Glycine • NH2-  CH2 -  COOH 89 1125(7)
3-Methyl-
Quinoline
CH3 143 1269(4:
2-Amino-Benzoic COOH
J s^ N H 2
U
137 1294(5) 1581(48)
Indole-3-Acetic
Indole—3— 
Carboxylic
•CH2C00H
I
■COOH
175
161
1755(28)*
1790(29)
2-Carboxy-4-
Methoxy-
Quinoline
OCH3
N "‘COOH
203 1853(S2)
/
TABLE 3.3.8: Continuation (f)
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NAME OF ACID
_ Retention Retention
MOlPCtl 1 3T*
STRUCTURE OF ACID “ 7 t Indice of Indice of
Weight of t . j
Free Acid M®thylated Silylated
Derivative-*- Derivative^
Indole-3-Lactic
ACID CONJUGATES
Isoleucine-N-
Acetyl
Pyroglutamic
OH
0  H H
H3C - C - N - C - C O O H
I
H - C - C H 3
I
c h 2
I
c h 3
° Y n y C00H
205
173
127
1937(40) 2148(78)
1421(36)
1489(40)
N-(2-Furanyl- 
carbonyl)-Glycine
rx^ 0 ^ C - N - C H 2C00H
I I 
0  H
169 1453(12)
0  H
II I 0 0 7
Phenylpropanoyl- H2C — CH2 — C — N — CH2COOH 
Glycine
Hippuric
N-Phenylacetyl-
Glycine
0  H
0 H
h2c-c-n-ch2cooh
179
193
1561(23)
1616(26)* 1800(63)*
1666(27) 1832(64)
0  H
4-Methoxy-Phenyl- h 2C — CH2 — C — N “ CH2C00H 
Propanoyl-Glycine
207 1891(36)
OCH3
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TABLE 3.3.8: Continuation (g)
NAME OF ACID
„ . „ Retention RetentionMn i pv 11 1 a r*
STRUCTURE OF ACID „ 7 7 Indice of Indice ofWeight of ^. , Methylated Silylated
i? 17 ©  6  JV C  1  Cl ^  ^
Derivative Derivative
4-Methoxy-Hippuric 0  H 209
I I
C - N  —CH2C00H
1905(37)
4-Methoxy-Phenyl-
acetyl-Glycine
4-Hydroxy-Phenyl-
acetyl-Alanine
o c h 3
0  H
I I
h 2c - c - n - c h 2c o o h
0  H 
I I
H2C —C —N —CHC00H
I
c h 3
223
223
1920(38)
1964(42)
2-,3- or 4-Methoxy- 
Phenylacetyl-Glycine
0  H
h2c - c - n - c h 2c o o h  2 2 3 2012(45)
vo c h 3
4-Hydroxy-
Hippuric
0  H
C - N - C H 2C00H
195 2181(80)
0 H
2-,3— or 4—Hydroxy- h^C- *C~N — CH2C00H
Phenylacetyl-Glycine
209 2024(46)
'OH
TABLE 3.3.8: Continuation (h)
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NAME OF ACID STRUCTURE OF ACID Molecular 
Weight of 
Free Acid
Retention 
Indice of 
Methylated
Derivative1
Retention 
Indice of 
Silylated
Derivative2
Phenylacetyl-
Cysteine
0
I
h2c — c — 
0
H
1
N-CHC00H
ch2
1
SH
239 2066(52)
0  H
I I
3,4-di-Methoxy- C - N - C H 2COOH 239 2081(53)
Hippuric
3-Ethanoyl-
Quinoline-Glycine
0  H
I I
c h 2c - n - c h 2cooh
230 2113(55)
H
N-Acetyl-Tryptophan  ji— CH2 — C — NH2 246 2287(63)
*N COOH
I
C-CH3
I 
0
Indole-Acetyl-Glycine 0 H 2 3 2  2363(65)
II I
c h 2c —n —c h 2coohCO
* Identified by comparison with an authentic standard
1 Number in parenthesis corresponds to the peak number m  Figure
3.3.3(a) and Table 3.3.4.
2 Number in parenthesis corresponds to the peak number m  Figure
3.3.3(b) and 3.3.5.
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FIGURE 3.3.1: Chromatogram of standard acid mixture as their BDMS
derivatives.
1511 21-16
Identity of peaks; A = n-Hexanoic acid
B = Benzoic acid
C = Lactic acid
D = Oxalic acid
E = o-Anisic acid
F = Succinic acid
G = Adipic + Glutaric acids
H = 3-Hydroxy-Benzoic acid
I = Pimelic acid
J = Hippuric
K = 4-Hydroxy-Benzoic acid
L = Azelaic acid
M = iso-Citric acid
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FIGURE 3.3.2 ' Chromatogram obtained for the analysis of a methylated
extract of a pooled sample of greyhound urine.
B L K  0 - 8 9 3  S O M E  BLK EXT. 13MRY8S 2 0 - M R Y - 8 S
R ! T IC
C B U 7 W R R
S . F . - 2 280838
7 0 6
3 4 7 3? :
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FIGURE 3.3.3a: Chromatograms obtained for the analysis of methylated
extracts of urine samples taken from a female greyhound at different
times.
D a y l, am 
Female Greyhound
I J U  I I I I
Day 1, pm 
Female Greyhound
fimelr
! s
Day2, am 
Female Greyhound
Timeli
-  22 8
FIGURE 3,3.3b: Chromatograms obtained for the analysis of methylated
extracts of urine samples taken from a female greyhound at different
t imes.
Oay2 , pm 
Female Greyhound
Fimelm
§36ZL
» - —
Day 3. am 
Female Greyhound
T'T”
I
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FIGURE 3.3.4: Chromatograms obtained for the analysis of methylated
extracts of urine samples taken from a male greyhound at different 
t imes.
Day1, am 
Male Greyhound
Tiroelm*
I I M
Day1, pm 
Male Greyhound ns)
Tlme(<
- 2 3 0  -
FIGURE 3.3.5: Chromatograms obtained for the analysis of methylated
extracts of urine samples taken from a male greyhound at different
times .
"T"
/V
0ay2, pm 
Male Greyhound
I \ r f
Day 3, am 
Male Greyhound
.Timelmrs)
Day 3, pm 
Male Greyhound
- 2 3 1  -
FIGURE 3.3.6: Chromatogram obtained for the analysis of a methylated
extract of a pooled sample of greyhound urine. The peak numbers
correspond to those in Table 3.3.4.
BLK3 199-520 METHYLRTED BLK
R i T ] C
C H L tU P C f lL
S3
CO
4 3 4
BLK3 5 1 9 - 8 4 0  METHYLRTED BLK
R l T IC  
C R L iU P C R L
<33
S3
;bs
7 2 4
7 0 2
57 58
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FIGURE 3.3.7: Chromatogram obtained for the analysis of
trimethylsilylated extract of a pooled sample of greyhound urine,
peak numbers correspond to those in Table 3.3.5.
BLKl 9 9 - 4 5 0  S]LYLHTED BLK
R IT 1 C
20)
221
3 3 9
3 7 7 ,1B0
2SS
BLKl 449-800 S1LYLBTED BLK 
R i T I C
60 63 66
S 0 2  S 2 2 S 3 4  S S B 6 7 4S 8 0
S 7 1
471 56 59 61
6 3 1 7 6 3
03
a
The
- 23 3 -
FIGURE 3.3.8: Chromatogram obtained for the analysis of a
tert-butyldimethyls ilylated extract of a pooled sample of greyhound
urine. The peak numbers correspond to those in Table 3.3.6.
BLK2 120-500 W B S T F R ' D  BLK 
m nc 
ai.iurcBL
2 6 0
2S7
201
15 17
337/ I ■434
;i 3 6 9
BLI\2 500-880 MTBSTFR'D BLK
f i t  t i c
cnuurcnu
03
03
8 0 S
7 6 7
6 2 0
6 7 3
S6S 41
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FIGURE 3.3.9: Chromatogram obtained for the analysis of a methylated/
silylated extract of a pooled sample of greyhound urine. The peak:
numbers correspond to those in Table 3.3.7.
BLK4 100-500 I1ETIIYLBTED/S] LYLflTED 
ni tic 
cnuunry.
CDco
3 6 7
203
3 9 1
2 2 3
2 3 9
co
B L K 4  5 0 0  - 7 6 0  HETHYLFITED/Sl LYLftTED
n> nc 
iTi.itrcnL
fo
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3.4 DISCUSSION
3.4.i URINARY ACID STANDARDS
A selection of organic acid standards known 
to occur in human urine [118] was reacted with three 
derivatisation reagents; seventeen acids were detected 
as their methyl derivatives, twenty-three as their 
trimethylsily1 (TMS) derivatives and fourteen as their 
tert-butyldimethylsilyl (BDMS) derivatives.
The methylated acids appeared to be stable but the 
silylated derivatives hydrolysed on evaporation of the 
reagents. When silylation of the acids was first examined 
in this project the reagents were evaporated and the 
residue redissolved in hexane before analysis. Since the 
evaporation step resulted in the hydrolysis of the 
silylated derivatives it was decided to omit this step and 
inject the standards directly in the reagent. The BDMS 
derivatives were also injected directly in the reagent.
A summary of the retention data obtained for the 
three derivatives is given in Table 3.4.1. This table 
illustrates that for each acid listed the methyl 
derivative elutes first, followed by the TMS derivative 
and lastly the BDMS derivative. The lengthening in 
retention time is due to an increase in molecular weight; 
methylation increases the molecular weight of a 
monocarboxylic acid by 14 units, silylation increases it 
by 72 units and tert-butyIdimethylsilylation increases it 
by 114 units. This effect is exemplified in the 
increasing retention times of the various derivatives of
- 236 -
TABLE 3.4.1: Gas chromatographic retention indices for the methylated, 
silylated and tert-butyldimethvl silylated derivatives of standard 
organic acids.
N A M E  O F  
A C I D
SATURATED MONOCARBOXYLIC ACIDS 
n-Butyric 
iso-Butyric 
iso-Valeric 
n-Hexanoic
2-Furoic
SATURATED DICARBOXYLIC ACIDS 
Oxalic 
Succinic 
Glutaric 
Adipic 
Pimelic 
Azelaic
UNSATURATED OXOCARBOXYLIC ACIDS 
cis-Aconitic 
Fumaric
HYDROXY ALIPHATIC CARBOXYLIC ACIDS 
Glycollic 
Lactic 
Malic 
Tartaric 
Citric
AROMATIC ACIDS 
Benzoic 
An i s i c
3-Hydroxy Benzoic
4-Hydroxy Benzoic 
Vanillic
N-CONTAINING ACIDS 
Indole-3-Acetic
ACID CONJUGATES 
Hippuric
* SUGAR ACIDS*
Ascorbic
Glucuronic
R E T E N T I O N  I N D I C E
tert-Butyl- 
Methylated Silylated Dimethyl-
Derivative Derivative Silylated
Derivative
ND ND
ND ND
ND ND
917 1062 1380
955 1114
<900 1130 1612
990 1307 1846
1104 1396 1949
1202 1513 2063
1311 1610 2169
1516 1804 2379
ND 1747
ND 1345
ND 1083
<900 1060 1576
ND 1499
1179 1656
1414 1839 >2800
1066 1231 1567
1778
1403 1557 2141
1431 1620 2221
1446 1740
1745 1917
1602 1800 2179
ND 1952
ND 2017,2074 -
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hexanoic acid. The methyl ester of hexanoic acid has a 
retention indice of 917, the TMS ester elutes at 1062 and 
the BDMS ester has a retention indice of 1380. The 
increase in retention is further emphasised in the 
dicarboxylic acids when there are two carboxylic groups 
available for derivatisation, as, for example, in the 
three derivatives of adipic acid.
This effect on retention time accounts for the fact 
that glycollic and malic acids were detected as their 
silyl esters but not as their methyl esters; the 
methylated acids eluted too close to the solvent front to 
be detected. Three of the acids, iso-butyric. n-butyric 
and iso-valeric were not detected as either the silyl or 
the methyl derivative as they were also masked by the 
solvent front.
Two unsaturated acids, cis-aconitic and fumarie 
acids, were not detected as their methyl esters but were 
successfully silylated. it is known that acids of this 
type form non-volatile pyrazoline derivatives, when 
reacted with diazomethane, by substitution across the 
double bond [160-162].
The two 'sugar acids' which were examined, ascorbic 
and glucuronic acids, did not chromatograph as their 
methyl esters. These compounds contain several hydroxy 
groups, which would not be methylated and the compounds 
would therefore be too polar to chromatograph under the 
conditions used. Ascorbic acid chromatographed as a 
single peak corresponding to the silyl derivative of the
- 238 -
cyclic compound. Glucuronic acid gave two peaks with very 
similar mass spectra. These two peaks could be due to the 
silyl derivatives of two isomers of glucuronic acid.
(a) MASS SPECTRA OF METHYLATED DERIVATIVES OF ORGANIC
ACID STANDARDS
The principal cleavage of carbonyl compounds is
alpha to the c=o group;
0f
IKr*R —  c — x — - R —  C ^ 0 + + X'
ACYLIUM ION
The formation of acylium ions by loss of H r , R* * , R y O' ,
HO* and H^N * is an important diagnostic feature of the
mass spectra of aldehydes, ketones, esters, acids and
amides, respectively. in the fragmentation of methyl
esters four possible ions can be formed by cleavage alpha 
to the carbonyl group:
°I
f  0C H 3 - R+ CO2CH3 R - C E O + +0CH3
1 2  3 A
2
The formation of the acylium ion by loss of a c h 3o 
radical (m/z 31) and the loss of a CO^CH^ radical
(m/z 59) are two frequently observed fragmentations in the 
spectra of methyl esters and can be seen for many of the 
standard acids listed in Table 3.3.1.
Another useful feature in identifying carbonyl 
compounds is the loss of an alkene from the substituent 
group, with hydrogen transfer to the carbonyl oxygen.
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This fragmentation, is called the McLafferty rearrangement 
since F . w .  McLafferty first observed this reaction when 
studying the mass spectra of a series of aliphatic methyl 
esters in the 1950's. The McLafferty rearrangement is 
illustrated below:
HO1"
R^ < U o t R- 1
“ ,,/c=CH2 +
o c h3 H‘ H2C ^  ^ oc h3
ALKENE ENOL ION
m/z 74
The base peak in the mass spectrum of methyl hexanoate is 
the McLafferty rearrangement ion at m/z 74.
The aromatic methyl esters listed in Table 3.3.1 
all contain a distinctive molecular ion and have an M-31 
ion as the base peak. Another dominant fragmentation seen 
in the mass spectra of the aromatic esters is the M-59 
peak, mentioned earlier.
Benzoyl compounds also give characteristic m/z 105 
and 77 peaks in their mass spectra. These fragmentations 
are illustrated in Figure 3.4.1. Benzyl compounds 
generally afford C7H7 (m/z 9 1 ) and its
decomposition product C5H 5 (ni/z 65), as shown in 
Figure 3.4.2.
indole-3-acetic acid and hippuric acid both follow 
the Nitrogen Rule by having odd molecular weights. A 
discussion of the spectra of methyl esters of amino acid 
conjugates is given in Section 3.4.3.
(b) MASS SPECTRA OF SILYLATED DERIVATIVES OF ORGANIC
ACID STANDARDS
The mass spectra of silylated derivatives often
- 2 4 0  -
FIGURE 3.4.1: The m/z 105 and its decomposition products are
characteristic of benzoyl compounds.
0+
I k  - 0 C H 3 ____
C5H5C^ -OCH3 ----► CgH5C=0
m /z 105
| - C 0
C6H5 
m /z 77
|-C2H2 
C4H3
FIGURE 3.4.2: The m/z 91 ion and its decomposition products are
characteristic of benzyl compounds.
C6H5CH2R"lt C5H5+
m /z 91 m /z 65
TROPYLIUM ION
- 2 4 1  -
contain intense ions at m/z 73 , 74, 75, 76, 147 and 148,
which have low diagnostic significance, the structures of 
the m/z 73 and 75 ions are illustrated in Figure 2.5.20. 
A ubiquitous ion found in compounds with two or more TMS 
groups occurs at m/z 147 and is formed by a rearrangement
reaction [113]; its structure is depicted below:
c h 3 
* ' I 
TMS — 0  =  S(
I
CH3
m/z 147
Table 3.3.2 illustrates that the base peak in the mass 
spectra of silylated compounds is frequently at m/z 73 and 
the 147 ion is seen in many of the mass spectra listed 
including those of aconitie, azalaie, glutaric and pimelic 
acids.
It is evident from Table 3.3.2 that the molecular 
ions of silylated compounds are frequently not detected or 
are of low relative abundance. However, a fragment ion at 
M-15, arising by loss of a methyl radical from a TMS 
function, is always present and serves to indicate the 
molecular weight. A fragment equivalent to the McLafferty 
rearrangement ion at m/z 74 in methyl esters is at m/z 132 
in the spectra of trimethylsilyl esters and is found in 
cases where the gamma hydrogen rearrangement is possible. 
As for the aromatic methyl esters, the aromatic silyl 
esters often contain ions at m/z 77, 91 and 105. The
silyl esters of indole-3-acetic and hippuric acids also 
conform to the Nitrogen Rule and have molecular weights of 
319 and 215, respectively.
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(C ) MASS SPECTRA OF tert-BUTYLDIMETHYLSILYLATED
DERIVATIVES OF ORGANIC ACID STANDARDS 
The BDMS derivative has not previously been used 
for the identification of urinary organic acids. Like the 
silylated derivatives, the spectra of BDMS derivatives 
also contain intense ions at m/z 73, 75 and 147 and
aromatic BDMS esters exhibit ions at m/z 77, 91 and 105.
Table 3.3.3 illustrates that the BDMS esters do not 
normally exhibit a molecular ion. An M-l ion of low 
intensity, however, is often present and indicates the 
molecular weight. A more useful diagnostic ion invariably 
seen at M-57 is due to loss of the tertiary butyl radical.
3.4.2 NORMAL URINARY ACID PROFILE OF THE RACING GREYHOUND 
in order to obtain the average "normal" urinary 
acid profile of the racing greyhound, several attempts 
were made to collect twenty-four hour urine samples. It 
was not always possible to collect a complete twenty-four 
hour urine due to problems encountered with the animals. 
Although the animal was kept in the metabolic cage for a 
twenty-four hour period it frequently would not urinate in 
the cage. on release the animal would urinate and the 
animal nurses would attempt to collect a full sample, but 
this was not always possible. catheterisation was tried 
on a few occasions, but this was thought to be too 
traumatic to the animals and to carry too high a risk of 
infection to carry out on a regular basis. in consequence 
the average profile was taken on pooled urine samples 
collected over an extended period of several days, 
individual samples in this series were analysed separately 
as discussed in section 3.3.2.
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3.4.3 COMPARISON OF DERIVATIVES AND IDENTIFICATION OF
GREYHOUND URINARY ACIDS
The chromatogram of the methylated extract was less 
complex than the other three chromatograms. This is most 
likely due to the fact that various hydroxylated compounds 
were not methylated on the hydroxyl functions and were too 
polar to chromatograph successfully. By contrast, the 
hydroxy groups can be silylated and also tert-butyl- 
dimethylsilylated, giving more complex profiles. When 
several urine extracts were chromatographed in sequence it 
was noted that the injection liner and the top of the 
column became contaminated. As a result, the injection 
liner was frequently cleaned and silylated to prevent 
polar material adsorbing on the inner glass surface. To 
maintain good chromatographic performance the front few 
centimetres of the column were removed when the 
chromatography was observed to have deteriorated. Current 
alternatives to this procedure are washing of the column 
(bonded phases) and incorporation of a retention gap to 
protect the analytical column.
The remainder of this section deals with the 
analysis of greyhound urinary acids as their methyl esters 
and as their trimethylsily1 derivatives.
(a) MASS SPECTRA OF ORGANIC ACIDS FOUND IN A METHYLATED
EXTRACT OF GREYHOUND URINE
The mass spectra of long-chain aliphatic methyl 
esters have been described extensively by Ryhage arid 
Stenhagen [163 and references therein]. The molecular 
ions are present and increase in intensity with increasing
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chain length. The M-31 ion, conversely, decreases in 
intensity with increasing chain length. in addition to 
the m/z 74 base peak (already mentioned in section 3.4.1), 
a dominant ion in methyl ester spectra is found at 
m/z 87. This is the most intense ion in a series which 
corresponds to m/z (59 + 14n), i.e. at 73, 87, 101, 115,
129, 143, 157, etc. The lowest member, m/z 73, is
insignificant, whereas the abundance of m/z 87 is high and 
is favoured by resonance stabilisation. Ryhage and 
Stenhagen point out that in this ion series there is a 
periodic intensity enhancement every four methylene groups 
at m/z 143 , 199 , 255, etc. This can be clearly seen in
the spectrum of methyl stearate (Figure 3.4.3). The other 
long-chain fatty acids identified also show evidence of 
these trends.
The spectra of the methyl esters of dibasic acids 
are more complex and differ considerably from the 
monobasic compounds. They have low-abundance molecular 
ions but usually M-31 peaks are evident. In addition to 
the (59 + 14n) series of ions characteristic of the 
monobasic esters two other series may be evident, i.e. (27 
+ 14n), present in all diesters, and (84 + 14n). Evidence 
of these three series is present in the spectra of suberic 
and azelaic acids (Figure 3.4.3) identified in the extract 
of greyhound urine.
A large number of aromatic compounds was identified 
in the urine extract, about fourteen of them as their 
methyl esters.
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FIGURE 3.4.3: The mass spectra of the methyl esters of stearic,
suberic and azelaic acids obtained from the GC-MS analysis of a
methylated extract of greyhound urine.
BLK3 655 METHYLRTED BLK
CfiL.: UPCfiL S T fi: E .
* 5
13-JUN-86
2 8 :2 3
CbbCCHbhfiC ~ OCH3
10B 208
Stearic Acid Methyl Ester
BLK3 302 METHYLRTED BLK
C fiL :U P C fiL  S T fi:E .
13-JUN-86
1 3 :8
21969-W S9
129 H3CO-C(CH2)6C-OCH397
M
8?29
20010a
Suberic Acid di -  Methyl Ester
BLK3 361 METHYLRTED BLK 
C fiL :U P C fiL  s t r j e .
13—JUN—86
1S:41
ss. ■7=F 7318
1S2 H3CO-C(CH2)7C-OCH3+9 137
8
M
A<D 18S
97
200100
Azelaic Acid d i-M ethy l Ester
- 246 -
The presence of the aromatic ring appears to confer 
great stability on the molecular ions, which are much more
speaking all of the aromatic methyl esters identified did 
show prominent molecular ions. The other ions present in 
the spectra of aromatic compounds, m/z 77, 91 and 105,
already mentioned in Section 3.4.1 are evident in the 
spectra listed in Table 3.3.4. Two examples of the 
spectra obtained for aromatic compounds are given in 
Figure 3.4.4.
The nitrogen-containing acids identified all had
odd molecular weights. An unusual nitrogen-containing 
acid identified in an extract of the greyhound urine was 
2-amino-benzoic acid (peak N o . 5 in Table 3.3.4). This
compound illustrates a phenomena known as the 1 ortho 
effect'. When two substituents are meta or para they 
cannot interact through space, but when they are or tho 
they can exhibit the 1 ortho effect'. For instance, the
base peak in the spectrum of the methyl ester of 
2-amino-benzoic acid is at m/z 119 which is a loss of 32 
(c h ^o h ) , instead of the usual loss of 31 (-o c h 3 ).
This could be explained by the hydrogen transfer
illustrated below:
prominent than for aliphatic compounds. Generally
0 0
I II
+
H m /z 119
m /z 32
A similar ortho effect is seen for mefenamic acid
(Figure 2 .5 .12, pl35).
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FIGURE 3.4.4: The mass spectra of the methyl esters of methoxy
phenylacetic and 3 , 4-dimethoxy-cinnamic acids obtained from the GC-MS 
analysis of a methylated extract of greyhound urine.
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FIGURE 3.4.5: The mass spectrum of the methyl ester of hippuric acid
obtained from the GC—MS analysis of a methylated extract of greyhound
urine.
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it to have the composition CH = +NH [159] and it
2 2
is probably formed as shown below:
0
R - C H 2 - C 0 - N H - ^ C H 2 C 0 2CH3  ► C j N H = C H 2 ------- - NH2 =  CH2
R - C H ^ H  m/z 30
A significant ion in almost all spectra is [M-116]+ and 
this is the base peak in cases where the ion is 
stabilised, for example, phenylacetylglycine.
in addition to glycine conjugates, three 
other conjugates were identified in the urine of
the greyhound, namely, 4-hydroxy-phenylacetyl-alanine,
phenylacetyl-cysteine and N-acety1-tryptophan
(Figure 3.4.6). The spectrum of 4-hydroxy-phenyl­
acetyl-alanine has its base peak at m/z 107. This ion 
arises from M-130, a homologous equivalent to the M-116 
ion in the glycine conjugate spectra. The presence of an 
ion at m/z 34 (H2S) supports the fact that component
number 52 in Figure 3.3.6 is a cysteine conjugate.
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FIGURE 3.4.6. The mass spectra of the methyl esters of 4—hydroxy— 
phenylacetyl— a l a n i n e , phenylacetyl— cysteine and N — acetyl— tryptophan 
obtained from the GC—MS analysis of a methylated extract of greyhound 
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(b) MASS SPECTRA OF ORGANIC ACIDS FOUND IN A SILYLATED 
EXTRACT OF GREYHOUND URINE
As mentioned earlier, the aliphatic acid TMS esters 
give molecular ions of low intensity, although a fragment 
ion at M - 15 is always present and serves to indicate the
molecular weight of the compound. The spectrum of
hydroxy-heptanoic acid TMS ester (Figure 3.4.7) 
illustrates marry of the features common in spectra of 
short-chain hydroxy-acids. The presence of the silyl
ether in the chain results in the alpha cleavage ion 
m /2 131, where the charge has been retained on the 
TMS-ether fragment. Retention of charge on the carboxy
ether gives m/z 117. The fragmentation pattern indicates 
that the hydroxy group is either in the 3- or 5-position.
In long-chain acids, a series of carboxy
ester-containing ions analogous to those in the mass 
spectra of methyl esters is observed at m/z 145, 159, 173,
etc. This series also shows some periodicity, favouring 
ions at 145, 201. 257, etc. In addition, methane is lost
from these to give a second lower-intensity ion series
(m/z 129, 185, 269 ....)•
The M c L a f f e r t y  rearrangement peak, is p r o m i n e n t  at
m/z 132, as previously mentioned.
The mass spectra of diacids show the presence of
additional fragmentation pathways resulting from the
additional silyl group, notably the presence of
rearrangement products such as the ions at m/z 204 and 217
which have t.he structures shown below [164]:-
V ms otms
Ch2 = C-OTMS CH2 = CH-c-otms
m/z 204 m/z 217
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FIGURE 3.4.7: The mass spectrum of the silylated ester of hydroxy—
heptanoie acid obtained from the GC-MS analysis of a silylated extract 
of greyhound urine.
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These ions are considered to be equivalent to the 
hydrogen rearrangement ions at m/z 74 and 87 respectively 
in the spectra of methyl esters. As noted above, the 
additional silyl group also gives rise to a commonly- 
observed ion at m/z 147, which is useful as an indicator 
that at least two silyl groups are present. Finally, the 
spectra of the dibasic acids show the presence of ions 
resulting from decarboxylation (M-44, for example m/z 245 
in the spectrum of pimelic acid), although in the present 
study these did not reach the same degree of prominence as 
in previous work [164].
The fragmentation patterns of aromatic acid silyl 
derivatives are influenced by the presence of the aromatic 
ring which confers the molecule with some stability, 
resulting in visible, and in some cases prominent, M^ 
and M-15* ions. As expected, the fragmentation is 
also directed by the ester moiety, giving rise to 
characteristic ions according to the location of the 
carboxyl group - on the ring or isolated from it by one or 
more methylene carbon atoms. These features are shown by 
the three examples given in Figure 3.4.8. In the spectrum 
of 4-HO-benzoic acid, decarboxylation occurs from the M-15 
ion by a cyclic mechanism [165]:
0 =  c {  SxSi(CH3)2 Si(CH3)2 + Si(CH3)2
R
M-15 M-15-44
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FIGURE 3.4.8: The mass spectra of the silylated esters of 4—hydroxy-
benzoic, 4— hydroxy— phenylacetic and 4—hydroxy-mandelic acids obtained 
from the GC—MS analysis of a silylated extract of greyhound urine.
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When the carboxy group is on an aliphatic carbon 
atom, as in phenyl acetic acid and its analogues, this 
mechanism is no longer possible and decarboxylation occurs 
directly from the molecular ion.
In 4-HO-benzoie acid, loss of the silyloxy group 
gives rise to an M-89 ion rather than the more familiar 
M-90 ion, because the carboxy group is directly 
substituted on the aromatic ring. By contrast, the 
structure of 4-HO-phenylacetic acid allows the possibility 
of loss of trimethylsilanol (M-90) and this ion is indeed 
visible at m/z 206, though at low intensity. The 
preferred mechanism is, instead, loss of the carboxysilyl 
group (M-117), giving rise to the base peak at m/z 179. 
The presence of an additional directing group on the side 
chain, such as the trimethylsilyloxy group in 
4-HO-mandelic acid, further promotes this fragmentation 
and in this instance most of the ion current is carried by 
the M-117 ion at m/z 267.
Differences between aromatic and aliphatic acids 
also exist when these are conjugated with amino acids:- 
the spectra of hippuric acid and N-phenylacetyl-glyeine 
are illustrated for comparison in Figure 3.4.9. under the 
conditons used for silylation, the amide nitrogen was not 
derivatised. In the spectrum of hippuric acid, 
decarboxylation occurs together with loss of a proton, 
giving rise to a product ion which is stabilised by the 
aromatic ring. By the same token, the expected cleavage 
reaction through the amide carbon-nitrogen bond leaves the
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FIGURE 3.4.9: The mass spectra of the silylated esters of hippuric
acid and N-phenylacetyl-glycine obtained from the GC-MS analysis of a 
silylated extract of greyhound urine.
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charge on the aromatic moiety and not on the aliphatic 
residue. in the spectrum of N-phenylacetyl glycine, 
decarboxylation gives rise to an M-44 ion but cleavage of 
the amide is accompanied by further loss of a hydrogen 
atom to give the ion at m/z 118, which is presumably also 
stabilised by delocalisation of the charge into the 
aromatic ring.
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3.5 C O N C L U S I O N
It is apparent from a consideration of Tables
3.3.4-7 that some components in the extracts remain 
unidentified and that the number of unidentified 
substances is greatest in the BDMS and methyl ester/silyl 
ether samples. This reflects the general problem of 
identifying unknown materials purely on the basis of their 
mass spectra, a difficult and skillful task which depends 
greatly on the availability of reference data. in the 
present instance, few data were available for those two 
derivatives and identification of acids was based on a 
knowledge of the types of acid present and on the presence 
of ions in the mass spectra consistent with the proposed 
structures.
It is concluded that, while novel derivatives such 
as the BDMS derivative yield useful mass spectra 
characterised by the presence of valuable diagnostic ions, 
a substantial amount of work requires to be done to enable 
them to be used effectively in screening for unknown 
substances, notably to establish a database of spectra of 
urinary acids derivatives.
Subsequent studies of the metabolism of NSAIDs were 
based on methylated extracts for this reason. Also, 
because the metabolic work was carried out in parallel 
with the urinary acid analysis, an early decision required 
to be taken concerning which derivative to use and the 
methyl derivatives were chosen because of the simpler 
nature of the chromatogram.
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C H A P T E R  F O U R  
DRUG METABOLISM
4 .1 INTRODUCTION
In developing a screening procedure to comply, for 
example, with the International Olympic Committee's 
requirements, it is necessary for the analyst to know:
(a) The structures of the target analytes.
(b) The excretion rates and routes.
(c) The time period over which excretion takes place.
(d) The time period over which the methodology can 
detect the target analytes.
Having established the urinary acid profile for the 
greyhound, and selected derivatisation procedures and 
analytical methods, it was necessary to compile data on 
the metabolism and pharmacokinetics of individual NSAIDs. 
The development of a general screening procedure requires 
GC retention and mass spectral data for the metabolites as 
well as the parent drugs. While some information is 
available on the metabolism of these compounds in humans 
and other mammals, including rats, rabbits and beagle 
dogs, it was expected that both the metabolism and
kinetics would differ in the greyhound, notably because of 
its lean physique and small fat depot.
An additional requirement of the N.G.R.C. is
that drugs and their metabolites must be analysed 
quantitatively in urine to allow an interpretation to be
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made of the significance of drugs detected.
Since the volume of urine excreted varies according 
to the condition of the dog the concentration of drugs
present will also vary. A common method for compensating 
for these differences is to relate the urinary drug level 
to the creatinine concentration. Creatinine is excreted
from the body at a constant rate [166]. This approach was 
used in the present study.
The following sections deal with the metabolism of 
five selected NSAIDs which are amongst the most commonly 
used drugs of this type and which were considered to be 
suitable model compounds. Ibuprofen is readily available 
as a non-proprietary drug and phenylbutazone has been
previously detected in the course of routine race track 
testing.
4.2 GENERAL PHARMACOLOGY OF THE NSAIDs
Non-steroidal anti-inflammatory drugs have been
in use for more than a century. The active ingredient in 
the willow bark, salicin, was first discovered by Leroux 
in 1827 and in November of 1874, Thomas MacLagan [167], a 
Dundee physician first used salicin to treat a patient 
with rheumatic fever. Acetylsalicylic acid (aspirin) was 
synthesised in 1853, but the drug was not used until 
1899. since then it has remained one of the most widely 
employed remedies.
Due to the side effects of salicylic acid-based 
drugs, considerable effort has been expended to develop 
new compounds with similar pharmacological properties.
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but with fewer side effects. In the 1950s the first 
successful alternative was mefenamic acid, followed in 
1963 by indomethacin and in 1964 by ibuprofen. Many
hundreds of analogues of these compounds have been 
synthesised but only about twelve are commonly prescribed 
in the U.K. (Table 1.3.1).
Although the NSAIDs have a wide range of chemical
structures, they share a common set of pharmacological 
effects (anti-inflammatory, anti-pyretic and analgesic) 
which are best understood on the basis of their mechanism 
of action (Figure 4.2.1). This lies in the inhibition of
prostaglandin biosynthesis at the step catalysed by 
cyclo-oxygenase [169]. While the detailed mechanism of 
this effect is not fully understood, available evidence 
suggests that the drugs bind to a site on the enzyme 
which is not the active site but is sufficiently close to
it to inhibit the enzyme's catalytic activity.
Prostaglandins are involved in the pathogenesis of
inflammation and fever [5]. prostaglandins of the E and F 
groups are involved in the mediation of the inflammatory
response [170] and a rise in the concentration of
prostaglandins in the brain is associated with disturbance 
of the thermoregulatory centre in the hypothalmus causing 
an increase in body temperature (PGE^ j^  is one of the most 
potent pyrogens known). The inhibition of prostaglandin 
synthesis in inflamed tissues also results in an analgesic 
affect. NSAIDs are effective against pain of low to
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FIGURE 4.2.1. Mode of action of non-steroidal anti-inflammatory 
drugs. *
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moderate intensity, especially where this is peripheral.
The commonest adverse effects of therapeutic doses 
of NSAIDs are dyspepsia and gastric and intestinal
ulceration with consequent anaemia due to occult blood 
loss. These side effects may also be related to the 
inhibition of prostaglandin biosynthesis. For example, 
the gastric mucosa synthesises PGI2 and the gastric 
erosion caused by indomethacin and other drugs in
experimental animals can be prevented by administration of 
prostaglandins.
An additional side effect, which is used
beneficially in the treatment of patients suffering from 
coronary heart disease, is the inhibition of the formation 
of blood clots because NSAIDs prevent the formation of 
thromboxane , a potent aggregating agent, by the 
platelets.
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4.3 E X P E R I M E N T A L
4.3.1 REAGENTS
In addition to the reagents listed in Section 3.2.1 
the following were used in the drug metabolism work!
1. Anhydrous sodium acetate (BDH Chemicals Limited, 
Poole, England).
2. Glacial acetic acid (BDH Chemicals Limited, Poole, 
England).
3. Helix pomatia enzyme mixture (Uniscience Limited, 
London).
4. 2,3-Dicarboxy-naphthalene (sigma Chemicals, Poole, 
England).
4.3.2 DRUG STANDARDS
The drug standards used were ibuprofen, ketoprofen, 
naproxen, mefenamic acid, phenylbutazone and flurbiprofen 
(as the internal standard). The suppliers of these drugs 
are listed in Section 2.3.2.
4.3.3 DRUG FORMULATIONS
The doses of drug administered to the greyhound 
were as follows:
Brufen (ibuprofen) - 200mg
Orudis (ketoprofen) - 50mg
Naproxyn (naproxen) - 250mg
Ponstan (mefenamic acid) - 250mg
Butazolidin (phenylbutazone) - lOOmg
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4.3.4 PREPARATION OF SODIUM ACETATE BUFFER 
REAGENTS:
0.5M Acetic Acid - 2.9ml of glacial acetic acid in
100ml of distilled water.
0.5M Sodium Acetate - B.203g of anhydrous sodium acetate
in 200ml of distilled water.
Acetic acid (0.5M,l00ml) is mixed with sodium acetate 
(0.5M,150ml) and the pH was adjusted to 4.6 with
concentrated hydrochloric acid.
4.3.5 PREPARATION OF STANDARD SOLUTIONS
About 5mg of drug standard was accurately weighed 
into a 50ml volumetric flask. The drug was dissolved in 
methanol and the solution made up to the mark with
methanol and mixed well. An aliquot (250pl) of the 
appropriate standard solution (ibuprofen, ketoprofen, 
naproxen, mefenamic acid or phenylbutazone) and an aliquot 
(25 op1) of the internal standard solution (flurbiprofen) 
were mixed and to this solution was added a freshly 
prepared solution of diazomethane until the solution 
remained yellow. The solution was then allowed to stand
at room temperature for 15 minutes before evaporating to 
dryness under a stream of oxygen-free nitrogen. The
residue was redissolved in methanol (250)il) and 0.i-0.5^pl 
was used for GC-MS analysis.
4.3.6 CALCULATIONS
Drug concentrations were calculated using the
formula:
^2 x c  = concentration of drug in unknown (jig/jil)
A
1
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where:
A = peak area ratio of drug to internal standard for
the standard solution.
A2 = peak area ratio of drug to internal standard for
the unknown solution.
c = concentration of drug present in the standard
solution (about looyig/ml).
4.3.7 PROTOCOL FOR THE ADMINISTRATION OF DRUGS AND THE 
COLLECTION OF BLOOD AND URINE SAMPLES
Greyhounds were administered with a single 
dose of an anti-inflammatory drug (quantity given in
section 4.3.3) and blood and urine samples were taken 
by licensed kennel nurses according to a specified
protocol. An example of a protocol sheet is given 
in Table 4.3.1.
The timetable for the collection of samples was 
supplied to the kennel nurses along with the drug to be 
administered. The times given were to be used as a guide 
and could be changed to fit in with normal routine in the 
kennels. if, however, the sampling times were changed the 
nurse could make a note of the actual sampling time on the 
sheet.
Blood samples were collected from a vein in
the neck in heparinised tubes and were gently mixed 
immediately after collection. They were then centrifuged
(3500 rpm,15 minutes) and the plasma obtained transferred 
to polypropylene tubes. urine samples were collected in a 
stainless steel jug, then transferred to polypropylene
containers for carriage. All plasma and urine samples
- 268 -
TABLE 4.3.1: Timetable for collection of blood and urine. 
DOG USED:
DRUG ADMINISTERED:
QUANTITY
TIME AND DATE OF DOSING
BLOOD URINE
Proposed time 
after dosing
Actual time Proposed time
after dosing after dosing
Actual time 
after dosing
Clear sample Clear Sample
1 hour(about 1 1  am)
2 hours(about 1 2  noon) 2 hours(about 1 2  noon)
3 hours(about 1 pm)
4 hours(about 2 pm)
6 hours(about 4 pm) 6 hours(about 4 pm)
24 hours(about 10 am 
on day 2 )
24 hours(about 10 am 
on day 2 )
30 hours(about 4 pm 
on day 2 )
48 hours(about 10 am 
on day 3)
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were stored at -20°c until analysed.
A washout period of about three weeks was allowed
before an animal was administered with another drug.
4.3.8 EXTRACTION AND PERIVATISATION OF URINE SAMPLES
Urine samples were extracted and derivatised
according to the following procedure:
1. urine (5-20ml) was acidified with 1M HCl.
2. The acidified urine was loaded on a freshly 
prepared column of XAD-2 resin (preparation of 
column described in section 3.2.5).
3. The column was washed with 200ml distilled water 
(flow rate 4ml/min).
4. The column was allowed to drain.
5. organic material retained on the column was then 
eluted with 100ml ethanol (flow rate 2ml/min).
6. The eluate was evaporated to dryness on a rotary 
evaporator.
7. Sodium acetate buffer (pH 4.6, 20ml) was added and
the tube sonicated for ca 30 seconds. Helix-pomatia 
enzyme mixture (300pl) was then added and incubated 
at 37°c for 24 hours to hydrolyse conjugates.
8. After incubatation was complete the mixture was 
allowed to cool to ambient laboratory temperature 
and then the total extract (including the enzymes 
and buffer) was loaded onto the XAD-2 column.
9. Steps 3-6 were repeated.
10. The residue was quantitatively transferred to a 
vial with methanol and evaporated to dryness with 
oxygen-free nitrogen.
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11. The extract was redissolved in methanol containing
the internal standard (flurbiprofen, looyig/ml,
2 5 0 1 )  and freshly-prepared ethereal diazomethane 
(500pl) was added. The solution was allowed to 
stand at room temperature for 15 minutes, then 
evaporated to dryness under a stream of oxygen-free 
nitrogen.
12. The extract was redissolved in methanol (250jal) and 
0.1-0.5jil was used for GC-MS analysis.
4.3.9 EXTRACTION AND DERIVATISATION OF PLASMA SAMPLES
Plasma samples were extracted and derivatised
according to the following procedure:
1. A iml plasma sample was transferred to an
extraction tube, then internal standard 
(flurbiprofen, loojig/ml, loopl) was added and
vortex-mixed.
2. The mixture was acidified with 1M HC1 (250jil), then
extracted with heptane: ethyl acetate, 4:1 (6ml)
by vortexing for ca 30 seconds.
3. The tube was then centrifuged (3500 rprn, 
10 minutes) .
4. An aliquot (4ml) of the organic layer was removed 
to a fresh tube and evaporated to dryness under a 
stream of oxygen-free nitrogen.
5. The extract was redissolved in methanol and a
freshly prepared solution of diazomethane (500pl) 
was added. The solution was allowed to stand at 
room temperature for 15 minutes, and was then
- 2 7 1  -
evaporated to dryness under a stream of oxygen-free 
nitrogen.
6. The extract was redissolved in methanol (lOOjil) and
0.1-0. 5jil was used for GC-MS analysis.
4.3.10 GAS CHROMATOGRAPHY/MASS SPECTROMETRY CONDITIONS
GC-MS was carried out on a system similar to that 
described in Section 2.5.2.
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4.4 IBU P R O F E N
4.4.1 INTRODUCTION
As mentioned earlier, ibuprofen was the first 
commercially successful drug in the series of substituted 
propionic acid derivatives. Naproxen and ketoprofen are 
also in this category and will be dealt with in 
Sections 4.5 and 4.6. Ibuprofen is readily available and 
can be purchased in Britain without a prescription. Basic 
information about ibuprofen is summarised in Table 4.4.1.
Ibuprofen is rapidly and almost completely absorbed 
from the gastro-intestinal tract following oral 
administration, giving rise to peak plasma levels after 
1-2 hours. Therapeutic concentrations in plasma are 
usually in the range 20-30^ag/ml. A review of the 
literature relating to toxicity of ibuprofen indicates 
that toxic effects in dogs might become apparent following 
single oral doses of I25mg/kg [171] and in humans 
following doses of approximately 200mg/kg [172]. in two 
reports of attempted suicide plasma concentrations of 
ibuprofen in the range 400~840pg/ml were measured. 
Although one subject was comatose all recovered within 24 
hours [173 & 174].
Ibuprofen has an asymmetric carbon and exists as 
r (-) and S( + ) optical isomers. The marketed preparation 
is racemic consisting of equal parts of both isomers. The 
s ( + )  isomer of ibuprofen is much more active than the R(-) 
isomer as an inhibitor of cyclo-oxygenase _in vitro. 
However, ijn vivo the less potent R(-) isomer is converted
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TABLE 4.4.1: Description and basic pharmacokinetic data for ibuprofen.
Chemical Name
<?£-Methyl-4-(2-methylpropyl)benzeneacetic acid
Chemical Abstracts Registry Number
15687-27-1
Non-Proprietary Name 
Ibuprofen
Proprietary Names 
Amersol, Apsifen, Brufen, Ebufac, 
Fenbid, Inabrin, Inflam, 
Librofen, Motin, Nurofen, 
Paxofen, Proflex, Relcofen, 
Seclodin and Uniprofen.
Empirical Formula Structural Formula
c 13h 18°2
ch3
H 3C' Y ^ f V v'C02H
ch3
Molecular Weight Dissociation Constant
206.27 pKa =4.4, 5.2
Physical Properties 
A white crystalline stable solid, 
insoluble in water; soluble 1 in 
and 1 in 2 of ether.
Melting point 75-77°C. 
1.5 of ethanol, 1 in 1 of
Practically
chloroform
Dose Plasma Half-Life
200, 400 and 600mg tablets. 
Total daily dose up to 2400mg, 
although usually 1200-1800mg.
About 2 hours
Protein Binding Volume of Distribution
99% About 0.1 litre/kg
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to the S( + ) isomer; consequently, it is difficult to 
detect differences in the pharmacological activity of the 
two isomers in whole-animal studies [175]. The half-life 
of the active S( + ) isomer is longer than that of the R(-) 
isomer [176].
4.4.2 METABOLISM AND EXCRETION
The metabolism of ibuprofen in mammals has been 
described by Mills and Co-workers [177]. in this and 
subsequent sections only humans and dogs will be 
considered.
Four metabolites have been identified in the urine 
of both species (Figure 4.4.1) although the relative 
proportions differ as shown in Table 4.4.2 [178-180]. 
Although ibuprofen disappears more slowly from plasma in 
dogs than in other species, the metabolites have not been 
detected in dog plasma suggesting that the metabolites are 
formed slowly and excreted rapidly. It has also been 
found that bile is an important route of excretion in the 
dog and about 25% of a dose is excreted in bile in the 
first three hours.
The literature data suggested the probable 
structures of ibuprofen metabolites in the greyhound but 
also that the relative proportions and excretion would be 
subject to species variation. In the present study 
published information concerning retention data and mass 
spectra of the known metabolites (Table 4.4.3) were used 
to search for the metabolites in greyhound urinary 
extracts.
- 2 7 5  -
FIGURE 4.4.1: The metabolism of ibuprofen.
Metabolites A and B have been characterised as the dextrorotatory (-f) 
isomers (Reference 180).
C 02H
Ibuprofen
OH
C02H
h o h 2c
c o2h
h o 2c
Metabolite A
C02H
Metabolite C Metabolite B
- 276 -
TABLE A.A.2: Excretion of ibuprofen and its metabolites in urine.*
Percentage of Dose Excreted
Man Dog
Ibuprofen 1 1
Unconjugated Metabolite A 15 9
Metabolite B A2 1
Ibuprofen 8 7
Conjugated Metabolite A 2 0 23
Metabolite B 9 13
TOTAL 95 5A
* taken from reference [172]
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4.4.3 R E S ULTS
Blood samples were collected from one greyhound and 
urine samples from two dogs according to the protocol 
described (Section 4.3.7). The samples were analysed 
according to the methods in section 4.3. The results 
obtained from the analysis of ibuprofen in the plasma of 
animal 1 are given in Table 4.4.4 and are illustrated as 
concentration versus time in Figure 4.4.2 and as log 
concentration versus time in Figure 4.4.3. The results 
obtained for the analysis of ibuprofen in urine samples 
(expressed as jig/mL urine and ^ig/mg creatinine) are 
summarised in Table 4.4.5 and are illustrated in 
Figure 4.4.4.
Metabolites A and B were identified in samples 
of greyhound urine, their mass spectra are given 
in Figure 4.4.6. Metabolite A was detected in urine 
samples taken from animal 2 at 2, 6, 24 and 30 hours after 
administration. Metabolite B was detected in urine samples 
taken from animal 2 at 6 and 24 hours. Metabolites c  
and D were not detected. Relative concentrations of the 
metabolites in each sample were calculated from the peak 
areas of selected mass chromatograms for the metabolites 
and the internal standard. Estimated real concentrations 
were calculated by assuming that the total ion 
chromatogram (TIC) response ratios for the metabolites 
were the same as that for ibuprofen, which was quantified 
using an authentic standard (Table 4.4.6). Figure 4.4.5 
illustrates the excretion of ibuprofen and its two 
metabolites.
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The total ion current chromatograms obtained from 
extracts of greyhound urine taken at 2, 6, 24 and 30 hours 
after the administration of 200mg of ibuprofen are 
illustrated in Figure 4.4.7. These 4 chromatograms allow 
a comparison of the relative amounts of parent and 
metabolites present and also illustrates the compounds 
which may interfere in the analysis for ibuprofen and its 
metabolites.
Figure 4.4.8 illustrates the total ion chromatogram 
obtained from an extract of greyhound urine (6 hour 
sample) along with 4 mass chromatograms showing the 
positions of ibuprofen (m/z 205), metabolite A (m/z 178), 
metabolite B (m/z 205) and flurbiprofen, the internal 
standard (m/z 199).
4.4.4 DISCUSSION
In this study, a single 200mg dose of ibuprofen was 
administered to greyhounds of body weight 30kg, a dose of 
6-7mg/kg and therefore higher than the normal adult dose 
in man of about 4mg/kg. The peak plasma level was 
observed 2 hours after dosage and was measured as 
49pg/ml. This was consistent with the normal therapeutic 
range in man of 20-30pg/ml, considering the higher dosage 
level administered to the greyhounds. From the plasma 
data available for one greyhound (Figure 4.4.4, 
Table 4.4.3) a plasma half-life of about l hour can be 
estimated for the parent drug, using a single-exponential 
model to describe tbe fall in level as the small number of 
data points does not allow a more complex analysis to be
- 2 8 0  -
carried out. This half-life value indicates that 
ibuprofen may be cleared more rapidly in the greyhound 
than in man (half-life 2 hours) although a statistically 
significant number of trials would be necessary to make 
this conclusion valid. Nevertheless, if the drug is
cleared rapidly, this may reflect the absence of a 
significant body fat depot, one of the expected features 
of greyhound metabolism.
In man, the literature suggests [172] that a total
of about 8% of a dose of ibuprofen is excreted in the 
urine as either the parent drug or as its glucuronide 
conjugate. The present study indicates that a much lower 
fraction (0.1% of the dose) is excreted in urine as the 
parent drug or its conjugate in the first 24 hours. As 
mentioned below, it has not been possible to obtain a
quantitative measurement of the total fraction of dose 
excreted in the urine as either the parent or metabolites: 
these measurements normally require the use of 
radiolabelled compounds which were not available in this 
study. The other major route of excretion via the bile 
and faeces was not examined.
Urinary concentrations are sometimes difficult to
interpret because of variations in the urinary output and 
are often corrected using creatinine as an internal 
standard to allow for fluctuations in urinary output. The 
curves shown in Figure 4.4.4 for corrected and uncorrected 
concentrations of ibuprofen have the same shape, 
indicating that the urinary output was regular during the
- 2 8 1  -
course of the study. This was not true for all the
metabolic experiments carried out (see below). in
addition, a comparison of the curves for the two dogs used 
in the study indicates a significant variation between 
individuals during the absorption and excretion phases.
These are influenced by many factors, including the
concurrent diet, gastric pH and urinary pH. However, the 
latter was regularly monitored in the course of this work 
and was not found to vary sufficiently to affect urinary 
excretion to a significant extent. After about 30 hours, 
extremely small concentrations of ibuprofen (oa iong/mL 
urine) were present. The small levels were detected
because the analysis was targeted for the drug using mass 
chromatograms i.e. for m/z 220 to locate methyl
ibuprofen. However, in a general screening procedure, 
these peaks could have been easily missed or, if detected, 
the identification of the drug might remain uncertain.
Two known metabolites of ibuprofen were identified 
in greyhound urine by comparison of their mass spectra and 
gas chromatographic data with those published in the
literature [176]. Their structures and mass spectra are 
shown in Figure 4.4.6. in the absence of authentic 
standards of the metabolites, accurate quantification of 
the metabolites was not possible. However, estimated 
concentrations were calculated using the (non-selective)
TIC chromatogram by assuming that the metabolites had the
same detector response as ibuprofen, which was 
independently quantified using a standard solution. on
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this basis, metabolite A was present at a peak 
concentration 6 hours after dosage, of about 5 times that 
of ibuprofen and metabolite B was present at approximately 
half that of ibuprofen. Both metabolites were excreted 
over the same time interval as the parent drug. The
implications of these results for a screening programme 
are:
(a) The time limit for detection of ibuprofen and its 
metabolites is 24-30 hours and this is not improved by 
using either metabolite as the target analyte instead of 
the parent drug.
(b) The detection of ibuprofen can be confirmed by
including metabolite A, at least, in the list of target
analytes in the screen. As both compounds are excreted 
together, both should be detected if the drug has been
administered to the dog providing the sample.
The I.O.C. Medical Commission have ruled that, "the 
detection of a prohibited substance and/or one of its 
metabolites shall constitute an offence." This ruling is 
accepted by the N.G.R.C. provided it has been shown by the 
testing laboratory that the detected metabolite can be 
unequivocally related to the administration of the parent 
drug and that the concentration of the detected substance 
indicates that the performance of the dog would have been 
affected. The results indicate that if ibuprofen is 
detected it would have been administered in the 24 hours 
prior to the race meeting at which the sample was 
collected, and would constitute an offence under the rules 
of the N.G.R.C.
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TABLE 4.4.A: Results obtained for the analysis of ibuprofen in plasma
samples taken from greyhound 1 following the oral administration of
ibuprofen 20 0mg.
Concentration 
Ibuprofen 
In Plasma Sample 
(jig/ml)
0 0.00
1  9.08
2 49.32
3 22.54
4 21.39
6 4.38
24 0.00
T I M E  
(hours)
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TABLE 4.4.5: Results obtained for the analysis of ibuprofen in urine
samples taken from two greyhounds following the oral administration of
ibuprofen 200mg.
T I M E
(hours)
Concentration 
Ibuprofen 
In Urine Sample 
(}ig/ml)
Concentration 
Ibuprofen 
In Urine Sample 
(jig/ml)
Greyhound 1 Greyhound 2 Greyhound 1 Greyhound 2
0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0
2 1.55 0 . 0 0 1.25 0 . 0 0
6 0.70 1.65 0.44 0.65
24 0.03 0.15 0 . 0 2 0.06
30 0 . 0 1 0.05 0 . 0 1 0.03
48 0 . 0 0 0.05 0 . 0 0 0.03
54 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0
72 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0
TABLE 4.4.6: Results obtained for the analysis of metabolites A and B 
of ibuprofen in urine samples taken from greyhound 1 following the 
oral administration of ibuprofen 2 0 0 mg.
T I M E
(hours)
Estimated 
Concentration 
of Metabolite A 
In Urine Sample 
tpg/ml)
Estimated 
Concentration 
of Metabolite B 
In Urine Sample 
(jig/ml)
0 0 . 0 0 0 . 0 0
2 0 . 1 0 0 . 0 0
6 7.14 0.71
24 1.80 0.26
30 0 . 2 2 0 . 0 0
48 0 . 0 0 0 . 0 0
54 0 . 0 0 0 . 0 0
72 0 . 0 0 0 . 0 0
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FIGURE 4.4.2: Concentration versus time
levels obtained for greyhound 1 following 
ibuprofen 2 0 0 mg.
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FIGURE 4.4.3: Log concentration versus time for the plasma ibuprofen
levels obtained for greyhound 1  following the oral administration of 
ibuprofen 2 0 0 mg.
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FIGURE 4.A.4: Excretion of ibuprofen in the urine of two greyhounds
following the oral administration of ibuprofen 200mg.
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FIGURE 4.4.5: Excretion of ibuprofen and its two metabolites in the
urine of greyhound 1 following the oral administration of ibuprofen 
2 0 0 mg.
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FIGURE 4. A.6 : The mass spectra of the methylated esters of
metabolite A and metabolite B obtained from the GC-MS analysis of a 
methylated extract of greyhound urine ( 6 hours after the
administration of 2 0 0 mg of ibuprofen).
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FIGURE 4.4.7: Chromatograms obtained from the GC-MS analysis of
methylated extracts of greyhound urine (2 and 6 hours after the oral 
administration of 2 0 0 mg ibuprofen).
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FIGURE A. 4.7 (Continuation a): Chromatograms obtained from the GC-MS
analysis of methylated extracts of greyhound urine (24 and 30 hours
after the oral administration of 200mg ibuprofen).
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FIGURE A.4.8 : Total ion chromatogram and mass chromatograms
(m/z 220, 178,205 and 199) obtained from the GC-MS analysis of a 
methylated extract of greyhound urine (6 hours after the oral 
administration of 2 0 0 mg ibuprofen).
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4 * 5 NAPROXEN
4.5.1 INTRODUCTION
Naproxen is the second member in the series 
of substituted propionic acid derivatisves which was
administered to greyhounds. Basic information about 
naproxen is summarised in Table 4.5.1. Naproxen is the 
active D( + ) isomer of 6-methoxy-o£-methyl-2-naphthalen- 
acetic acid. The inactive L(-) isomer is not contained in 
naproxen. Naproxen is completely absorbed from the
gastro-intestinal tract, and peak plasma levels are
reached in 2-4 hours. After a single oral dose of 250mg, 
peak plasma levels of 30-40pg/ml are achieved [181]. The 
biological plasma half-life, independent of dose, is 
10-17 hours. The area under the plasma concentration 
versus time curve increases linearly with dosage up to 
500mg twice a day, but with higher doses the plasma 
response is non-linear [182]. This non-linear response 
at high doses can be attributed to accelerated renal 
clearance as a result of a rise in levels in free naproxen 
when plasma protein binding capacity is exceeded. It has 
been suggested [181] that this self-regulating mechanism, 
which limits naproxen plasma levels in man, may well limit 
toxic effects should an overdose of naproxen be taken.
Frey and Rieh reported in 1981 [183] the pharmaco­
kinetics of naproxen in mongrel dogs. After oral 
administration, of 5mg/kg, the drug was rapidly 
absorbed and maximal plasma concentrations were found at 
0.5-3 hours after administration. The elimination
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TABLE 4.5.1: Description and basic pharmacokinetic data for naproxen.
Chemical Name
(s)-6-methoxy-£<.-methyl-2-naphthaleneacetie acid
Chemical Abstracts Registry Number 
22204-53-1
Non-proprietary Name 
Naproxen
Proprietary Names 
Equiproxen, Floginax, Laser, 
Naixon, Naprosyn(e), Naprix, 
Naxen, Proxen and Xenar
Empirical Formula 
c14h14°3
Structural Formula
h3co
co2h
Molecular Weight D issociation Constant
230.26 pKa = 4.2
Physical Properties
A white crystalline powder. Melting point about 156°C. Practically 
insoluble in water; soluble 1 in 25 of ethanol, 1 in 15 of chloroform 
and 1 in 40 of ether.
Dose Plasma Half-Life
250 and 500mg tablets. 10 to 20 hours (mean 14)
Total daily dose of about
500-1000mg
Protein Binding 
More than 99%
Volume of Distribution 
About 0.1 litre/kg
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half-life ranged from 45-92 hours.
Fredell and strand [184] described the clinical 
course of a patient who was thought to have ingested 
25g of naproxen. The patient developed mild transient 
nausea and indigestion. The serum naproxen concentration, 
obtained approximately is hours after ingestion, was 
4l4jig/ml. Waugh and Keatinge [185] have reported the 
development of hypoprothombinaemia in a patient who 
ingested log of naproxen. in addition to the coagulation 
abnormality, the patient also experienced nausea which 
persisted for several days.
4.5.2 METABOLISM AND EXCRETION
The main metabolite in human urine is 6-hydroxy-ad - 
methyl-2-naphthylacetic acid (Figure 4.5.1) and is 
excreted, like naproxen, to a large extent as the 
glucuronide conjugate [186]. A glycine conjugate of 
naproxen has also been identified.
Runkel and his colleagues [187] studied the 
absorption, distribution, metabolism and excretion of 
naproxen in various laboratory animals and human 
subjects. He reported that with the exception of the dog, 
all of the species studied excreted naproxen and its 
metabolites predominantly in the urine. in the dog the 
major route was faecal excretion. in the human 94% of the 
dose administered appeared in the urine after 5 days, with 
only 1-2% in the faeces. only 5-6% of the drug appeared 
as unchanged naproxen, 28% as the demethylated naproxen 
and the remainder was in the form of conjugates of the 
drug (predominantly the glucuronide ester).
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FIGURE 4.5.1: The metabolism of naproxen.
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4.5.3 RE S U L T S
A single 250mg dose of naproxen was administered to 
a greyhound and urine samples were collected according to 
the protocol described (Section 4.3.7). The samples were
analysed according to the methods in section 4.3. The
results obtained for the analysis of naproxen in urine
samples (expressed as pg/ml urine and pg/rng creatinine)
are summarised in Table 4.5.2 and are illustrated in 
Figure 4.5.2.
The 6-0-des-methyl-naproxen metabolite was 
indentified in samples of greyhound urine: the mass
spectrum obtained is given in Figure 4.5.3. The 
metabolite was detected in urine samples taken 24 and 48 
hours after the administration of the drug but was not
detected in the remaining urine samples. Relative
concentrations of the metabolite in each sample were
calculated as l.04pg/ml in the 24 hour sample and
1.12pg/ml in the 48 hour sample from the peak areas of 
selected mass chromatograms for the metabolite and the 
internal standard. Estimated real concentrations were 
calculated by assuming that the Tic response ratio for the 
metabolite was the same as that for naproxen, which was 
quantified using an authentic standard.
The total ion current chromatograms obtained from 
extracts of grehound urine taken at 6, 24, 30 and 48
hours after the administration of 250mg of naproxen are
illustrated in Figure 4.5.4. These 4 chromatograms 
illustrate the relative amounts of naproxen and its
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metabolite present with time and also the compounds which 
may interfere in the analysis.
Figure 4.5.5 illustrates the TIC and 3 
mass chromatograms obtained from an extract of 
greyhound urine (48 hour sample). The mass chromatograms 
show the positions of naproxen (m/2 185), the 
6-o-des-methyl-naproxen metabolite (m/z 171) and 
flurbiprofen, the internal standard (m/z 199).
4.5.4 DISCUSSION
The limited data available from this study of 
naproxen in the greyhound are of value for the detection 
of the drug in future as part of a screening process. In 
several ways, naproxen differs from ibuprofen, in terms of 
its metabolism, excretion and the interpretation of 
observed levels in urine.
Naproxen is a more lipophilic drug than ibuprofen, 
due to the presence of the naphthalene ring in its 
structure, and in common with many other drugs with a 
lipophilic moiety, it persists in the circulation for a 
relatively long time. The biological half lives of 
naproxen and ibuprofen (10-17 hours and 2-4 hours 
respectively) illustrate this effect. This observation in 
humans appears to be upheld for the greyhound also, and 
the drug was readily observed in urine for the duration of 
the period of observation in this study, 72 hours, and 
would continue to be measurable for some time afterwards. 
The drug was absorbed well orally and could be observed in 
urine 2-6 hours after dosing, peaking during the period
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6-24 hours after dosing. The importance of parallel 
measurements of urinary creatinine is well-illustrated in 
this study: examination of Figure 4.5.2 shows that the
corrected and uncorrected graphs of urinary naproxen 
concentrations are different and that the concentrations 
of naproxen in the samples taken at 6, 24 and 72 hours are 
significantly different after correction.
The results indicate that naproxen is easily 
detected in greyhound urine. The urinary concentration 
rises to several microgrammes per millilitre (uncorrected) 
even after a single dose. Faecal excretion may be the 
predominant route in at least some species of dog [187] 
but appears not to pose a problem in this instance: as
with ibuprofen, faecal excretion of naproxen was not 
examined in the study. The known metabolite of naproxen 
(O-desmethyl naproxen) was observed in the study at lower 
concentrations than naproxen, but not in all samples, 
suggesting that the parent drug is the target analyte of 
choice: the presence of the metabolite may be helpful in
confirmation of the presence of naproxen but is not 
essential for a positive result in a urinary drug screen. 
The mass spectra of naproxen and its desmethyl metabolite 
show the presence of strong, characteristic ions, which 
also aids the detection and confirmation of their presence 
in urine. It is the presence of the naphthalene ring 
which imparts stability to the structures and influences 
the fragmentation reactions. in addition, there are no 
major interferences in the urinary acid profile to hinder
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the detection and quantification of either the drug or 
its metabolite (Figure 4.5.5). Even the non-selective TIC 
trace appears to be free from significant interference, 
suggesting that naproxen might be amenable to analysis by 
GC with FID detection.
No other conjugates of naproxen were detected in 
this study, although the occurrence of a glycine conjugate 
of the parent has been reported in the literature [186]. 
in the absence of mass spectral and chromatographic 
data concerning this conjugate, the probable retention 
time and fragmentation pattern were predicted from those 
of components in the urinary acid profile (delta-i = 535, 
301, major fragments at m/z 242, 213 and 185 corres­
ponding to loss of the carboxymethyl group and subsequent 
side-chain cleavages). However, examination of each of 
the urinary extracts failed to show the presence of this 
metabolite.
The creation in future of reliable criteria by 
which a urine sample will be considered to be positive for 
naproxen will clearly depend on the compilation of more 
data relating to a statistically significant number of 
dogs. Both plasma and urinary analysis will be required 
for this purpose. However, the present results have 
several implications for the screening process and 
interpretation of analytical results. Naproxen can be 
detected for several days following administration of even 
a single dose and it is likely that the drug will be 
detected long after it is significant to the performance
of the dog concerned in the race meeting at which the 
sample was collected. An interpretation will need to be 
made with respect to when the drug was administered and 
the intention of the dog's owner. simple measurements of 
urinary concentration with creatinine correction may be 
sufficient if a threshold level is set, drawing from 
experience in dealing with caffeine, which poses a similar 
problem. For example, if the offence is defined as 
administration of naproxen less than three days prior 
to a race, then a suitable threshold level would be 
approximately 1 microgramme of naproxen per milligramme of 
creatinine.
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TABLE 4.5.2: Results obtained for the analysis of naproxen in urine 
samples taken from a greyhound following the oral administration of 
naproxen 250mg.
T I M E  
(hours)
Concentration 
Naproxen 
In Urine sample 
(pg/ml)
Concentration 
Naproxen 
In Urine Sample 
(^ tg/mg creatinine)
0 . 0 0 0 . 0 0
2 0 . 0 0 0 . 0 0
6 5.00 8.18
24 6.30 1.92
30 2.80 1.53
48 1.43 0 . 8 8
54 1.23 0.99
72 1.58 0.74
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FIGURE A.5.2: Excretion of naproxen in the urine of
following the oral administration of naproxen 250mg.
0 raI Pam i n i s t ra t i on o f Nap roxen 250mg
^jg/mg C reat i n i ne
Qa-a-
TIME CHours)
greyhound
- 302 -
FIGURE 4.5.3: The mass spectra of the methyl ester of the
6 -o-des-methyl-naproxen metabolite obtained from the GC-MS analysis of 
a methylated extract of greyhound urine (48 hours after the
administration of 250mg of naproxen).
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FIGURE 4.5.4: Chromatograms obtained from the GC-MS analysis of
methylated extracts of greyhound urine (6 and 24 hours after the oral
administration of 250mg naproxen).
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FIGURE 4.5.4 (Continuation a): Chromatograms obtained from the GC-MS
analysis of methylated extracts of greyhound urine (30 and 48 hours
after the oral administration of 250mg naproxen).
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FIGURE 4.5.5: Total ion chromatogram and mass chromatograms
(m/z 185, 171 and 199) obtained from the GC-MS analysis of a 
methylated extract of greyhound urine (48 hours after the oral 
administration of 250mg naproxen).
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4.6 KETOPROFEN
4.6.1 INTRODUCTION
Basic information about ketoprofen, a propionic 
acid derivative, is summarised in Table 4.6.1.
Pharmacokinetic studies on ketoprofen [188] have 
shown that maximum concentrations of ketoprofen in plasma 
occur 30 minutes to two hours after oral dosing, in man, 
therapeutic concentrations in plasma are in the range 
3~23pg/ml. The plasma disappearance curve of ketoprofen 
is multi-exponential, with a slower terminal phase of 
elimination [189]. Jolou and co-workers [190] have 
studied the acute toxicity of ketoprofen administered 
orally and subcutaneously in various animals, including 
the dog. The average lethal dose in the different animals 
ranged between 100 to 200mg/kg. court and volans [191] 
have summarised data on 20 suspected cases of overdose 
with ketoprofen where the only clinical features were 
drowsiness, abdominal pain and vomiting.
4.6.2 METABOLISM AND EXCRETION
After oral administration of ketoprofen, in man, 
excretion varied greatly amongst patients, 30-90% of the 
dose being excreted in 24 hours, but mostly during the 
first 6 hours [192]. in the dog, urinary excretion was 
relatively low, only 60% being excreted in 6 days [188]. 
Although ketoprofen is excreted in the bile, essentially 
all is reabsorbed, and little drug is present in the 
faeces [193]. Ketoprofen excretion in the faeces only 
accounted for about 1% of a dose in man.
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TABLE 4.6.1: Description and basic pharmacokinetic
ketoprofen.
Chemical Name
3-Benzoyl-<?C -methyl-benzeneacetic acid
Chemical Abstracts Registry Number 
22071-15-4
Mon-Proprietary Name 
Ketoprofen
Proprietary Names 
Alrheumat, Capisten
Ketopron, Meprofin
Oruvail and Profenid.
Empirical Formula 
C16H14°3
Molecular Weight 
254.29
Structural Formula
CH3
co2h
Dissociation Constant 
not known
Physical Properties
A white, crystalline powder. Melting point 93-96cC. 
insoluble in water; freely soluble in ethanol, chloroform
Dose
50 and lOOmg capsules. 
Total daily dose of 
1 0 0  to 250mg
Plasma Half-Life 
1-4 hours.
data for
Kefenid, 
Orudis,
Practically 
and ether.
Protein Binding 
about 95%
Volume of Distribution 
About 0.1 to 0.2 litre/kg.
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Ketoprofen is largely excreted as its glucuronide 
conjugate in most species. A minor metabolic route 
involves hydroxylation to form phenolic derivatives. The
detailed structures of the hydroxylated metabolites have 
not been reported in the literature.
4.6.3 RESULTS
A single 50mg dose of ketoprofen was administered
to a greyhound and urine samples were collected according 
to the protocol described (Section 4.3.7). The samples 
were analysed according to the methods in Section 4.3. 
The results obtained for the analysis of ketoprofen in
urine are summarised in Table 4.6.2. (Creatinine 
measurements were not available in this study).
Figure 4.6.1 illustrates the TIC and 3 mass 
chromatograms obtained from an extract of greyhound urine 
(6 hour sample). The mass chromatograms show the 
positions of ketoprofen (m/z 268 and 209) and
flurbiprofen, the internal standard (m/z 199).
Figure 4.6.2 illustrates the mass spectra of an 
interfering peak, observed immediately before ketoprofen, 
and that of a large peak which elutes just after
ketoprofen. These two peaks remain unidentified but, on 
the basis of the ions present in their mass spectra, they 
could be ketoprofen metabolites or diazomethane artefacts 
(see also chapter 2).
4.6.4 DISCUSSION
in this study a single oral dose of 50mg of
ketoprofen was administered to a greyhound (ca. l.5mg/kg).
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Ketoprofen was detected at a high concentration in the 
6-hour urine sample but thereafter relatively small 
amounts (2pg/ml) were detected up to 30 hours after 
administration, it has been reported [188] that urinary 
excretion of Ketoprofen in the dog (most likely a beagle) 
is low but, in man, up to 90% of the dose could be 
excreted within 24 hours and mostly in the first 
6 hours [192]. In this study about 46% of the dose 
administered to the greyhound was excreted in the first 
6 hours (taking into account the total volume of urine 
collected in this period). The drug could not be detected 
after 48 hours.
The mass spectra in Figure 4.6.2 contain ions which 
are similar to the ketoprofen spectrum (Figure 2.5.10). 
The later-eluting peak has a molecular ion at m/z 282 
(i.e. ketoprofen + 14) which suggests the addition of a
CH2 group. The identities of these peaks remain
uncertain but could be due to a ketoprofen metabolite or a 
diazomethane artefact (see DISCUSSION, Section 2.5). if 
one or both of these peaks were due to a diazomethane 
artefact then the quantification of ketoprofen using 
diazomethane methylation would be difficult. it is 
undesirable to have such products which could further 
complicate a screening procedure. The limited data
available in this study serve as a starting point for 
further investigation. However, it appears that 
ketoprofen is rapidly eliminated in the urine of the
greyhound with peak levels at 6 hours after a single oral
dose. If ketoprofen was detected during a screening 
procedure in the urine of a greyhound at a race meeting 
then the animal must have been administered with the drug 
within the previous 24-30 hours. It is uncertain in this 
case whether or not metabolites were detected: further
work would be necessary to ascertain these facts.
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TABLE A.6 .2: Results obtained for 
samples taken from a greyhound 
ketoprofen 50mg.
the analysis of ketoprofren in urine 
following the oral administration of
Concentration
T I M E Ketoprofen
(hours) In Urine Sample
(}ig/ml)
0 0 . 0
2 1 . 0
6 291.0
24 6 . 0
30 2 . 0
48 0 . 0
54 0 . 0
72 0.0
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FIGURE 4.6.1: Total ion chromatogram and mass chromatograms (m/z 268,
209 and 199) obtained from the GC-MS analysis of a methylated extract 
of greyhound urine ( 6 hours after the oral administration of 50mg 
ketoprofen). The mass spectra of the unidentified components A and B 
are given in Figure 4.6.2.
Ketoprofen
Peak B
(Mass spectra 
in Figure
Peak A 
(Mass spectra 
in Figure
Ocfadecanoic
"Acid
Ocfadecadienoic 
Acid \
Flurbiprofen
TIC
m/z 268 
m/z 209 
m/z 199
- 313 -
FIGURE 4.6.2: Mass spectra of two substances co-extracted with
ketoprofen from greyhound urine (components A and B in Figure 4.6.1).
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4.7 MEFENAMIC ACID
4.7.1 INTRODUCTION
Mefenamic acid is one of a series of substituted
N-phenyl anthranilic acid derivatives (or fenamates) and 
has been marketed since the 1960s. Basic information 
about mefenamic acid is summarised in Table 4.7.1.
In a review of the metabolism of mefenamic acid by 
Glazko [194] it was shown that, after oral administration, 
mefenamic acid is rapidly absorbed and that blood levels 
reach a maximum in 2-4 hours. Following a single oral 
dose of lg to 6 subjects a mean plasma concentration of 
lOpg/ml of free, unconjugated drug was attained which 
dropped to a O.ljig/ml in 24 hours. Two metabolites have
been isolated from plasma and identified as the
3'-hydroxymethyl derivative (Metabolite I), and 
3'-carboxyl derivative (Metabolite II) (Figure 4.7.1). 
Metabolite I (present mainly as the glucuronide) attained 
peak plasma concentrations of about lOpg/ml after 3 hours, 
but disappeared from the plasma more slowly than the
parent. Metabolite II formed more slowly, with peak 
plasma levels of about lOpg/ml occurring 6-8 hours after 
administration; approximately 50% of this metabolite was 
conjugated.
court and volans [191] have reported 73 mefenamic 
acid overdose cases and concluded that, unlike poisoning 
with other NSAIDs, mefenamic acid overdose appears to 
cause convulsions. Bala1i-Mood and co-workers [195] 
reported 54 mefenamic overdose cases over a period of 11
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TABLE 4 .7 .1 : Description and basic pharmacokinetic data for mefenamic
acid.
Chemical Name
2-[(2,3-Dimethylpropyl)amino-benzoic acid
Chemical Abstracts Registry Number 
61-68-7
Non-Proprietary Name 
Mefenamic Acid
Proprietary Names
Coslan, Lysalgo, Parkemed,
Ponstan, Ponstel, Ponsyl, Tanston 
and Vialidon.
Empirical Formula 
c15h15no2
Molecular Weight 
241.28
Structural Formula
Dissociation Constant 
pKa - 4.2
Physical Properties
A white to greyish-white microcrystalline powder. Melting point 
230-231°C with effervescence. Practically insoluble in water;
soluble in 1 in 185 of ethanol, 1 in 150 of chloroform and 1 in 80 of 
ether; soluble in solutions of alkali hydroxides.
Dose Plasma Half-Life
250mg tablets. About 3-4 hours
750-1500mg daily
Protein Binding 
About 99%
FIGURE 4
(
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7.1: Metabolic disposition of mefenamic acid in humans
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years. Twenty-nine patients had plasma concentrations 
above the therapeutic range (lcyig/ml) on admission; 14 of 
these patients were asymptomatic (plasma concentration 
range 14-62^ig/ml), 15 had muscle twitching and 11
progressed to grand mal convulsions (plasma concentration 
range 27-H9^ig/ml).
Metabolic studies [196] have shown that mefenamic 
acid is also rapidly absorbed in dogs and peak plasma 
levels are achieved in 2-4 hours after oral 
administration. When mefenamic acid was administered to 
dogs in long term studies at a daily dose of 50mg/kg, no 
adverse clinical or tissue reactions were observed, but at 
a daily dose of lOOmg/kg slight hepatic damage was
revealed on histological examination.
4.7.2 METABOLISM AND EXCRETION
In man about 52% of a dose is excreted in the
urine in 48 hours (of this 6% is mefenamic acid, 25% is 
Metabolite I and 21% is Metabolite II). The maximum 
excretion rate for mefenamic acid was found in the 
2-4 hour period after dosing, occurring mainly as the 
glucuronide. Metabolite I excretion peaked in the 4-8
hour period appearing almost entirely as the glucuronide 
and Metabolite II excretion peaked in the 6-8 hour period, 
with only about 30% conjugated. About 10-20% of a dose is 
excreted in the faeces over a 3 day period, mostly as 
unconjugated Metabolite II.
The major route of excretion of mefenamic acid in 
the dog is the faeces (appearing mainly as conjugated
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mefenamic acid), with only small amounts appearing in the 
urine [194]. it appears that dog liver lacks the enzyme 
systems required for the oxidation of the 3 ‘-methyl group 
to the hydroxymethyl.
in all species a high percentage of the 
administered dose is initially excreted in the bile but
reabsorption from the intestine occurs (i.e. enterohepatic
recycling) to varying extents in different species. The
literature has suggested the possible structures of the 
mefenamic metabolites in the greyhound [194]. However, 
mass spectral data and GC retention times of the 
derivatives are not available.
4.7.3 RESULTS
A single oral dose of 250mg of mefenamic acid was 
administered to a greyhound. Blood and urine samples were 
collected and analysed according to the methods described 
in Section 4.3. The results obtained for the analysis of 
mefenamic acid in plasma are given in Table 4.7.2 and are 
illustrated as concentration versus time in Figure 4.7.2. 
The results obtained for the analysis of mefenamic acid in 
urine samples (expressed as ^ig/ml urine and jag/mg 
creatinine) are summarised in Table 4.7.3 and are
illustrated in Figure 4.7.3.
Neither Metabolite I or II (Figure 4.7.1) were 
detected in any of the urinary extracts.
The TIC chromatogram obtained from an extract of 
greyhound urine (6 hour sample) along with 2 mass 
chromatograms showing the positions of mefenamic acid
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(m/z 255) and 2,3-dicarboxy-naphthalene acetic acid, the 
internal standard (m/z 213) are illustrated in 
Figure 4.7.4.
4.7.4 DISCUSSION
Mefenamic acid appeared to be well absorbed orally 
in the greyhound, giving peak plasma concentrations of 
unconjugated mefenamic acid of about 3 jig/ml after 
2-3 hours, following a dose of 250 mg (approximately 
8 mg/kg). This compares well with clinical data in man 
which indicated an average plasma concentration of 
10 pg/ml after a single oral dose of 1 gram (approximately 
20 mg/kg). However, in the present study, the plasma 
level fluctuated markedly during the period up to 48 hours 
after dosing and a plasma half-life was not measured: in
human subjects this was reported as 3-4 hours. The reason 
for the changes in concentration which took place was not 
established in this single experiment but is thought to be 
the result of enterohepatic circulation, which is known 
from the literature to be a prominent feature of the 
pharmacology of mefenamic acid.
Urinary concentrations of mefenamic acid were low 
throughout the course of the study, maximising at 
0.5 ^ig/ml after 6 hours. Towards the end of the 
observation period, levels approaching the limit of 
detection were found. This is consistent with the major 
route of excretion being via the faeces. in this 
experiment, the creatinine concentrations in all samples 
were similar, and creatinine correction did not alter the
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shape of the urinary excretion curve (Figure 4.7.3).
These results suggest that during a screening 
procedure mefenamic acid could be detected for 24-30 hours 
following a single dose, despite the fact that the drug is 
excreted in urine to a very small extent. The mass 
spectrum of the methyl ester of mefenamic provides salient
diagnostic ions which permit the drug to be detected even
in the presence of a large interference (methyl linoleate. 
Figure 4.7.4). No metabolites were observed in greyhound 
urine, leaving the parent drug as the target analyte.
Interpretation of measured levels within a drug control 
programme will depend on the minimum period allowed
between dosing an animal and a race: for example, a level 
above 0.1 }ig/ml (uncorrected) would suggest that the dog 
had been given mefenamic acid within 24 hours of the race 
meeting at which the sample was collected.
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TABLE 4.7.2: Results obtained for the analysis of mefenamic acid in
plasma samples taken from a greyhound following the oral
administration of mefenamic acid 250mg.
T I M E
(hours)
Concentration 
Mefenamic Acid 
In Plasma Sample 
(jig/ml)
0 0 . 0 0
1 2 . 0 1
2 1.74
3 3.04
4 1 . 1 2
6 1.09
24 2.60
48 1.39
TABLE 4.7.3: Results obtained for the analysis of mefenamic acid in
urine samples taken from a greyhound following the oral administration 
of mefenamic acid 250mg.
T I M E
(hours)
Concentration 
Mefenamic Acid 
In Urine sample 
(ug/ml)
Concentration 
Mefenamic Acid 
In Urine Sample 
(jig /ml)
0 0 . 0 0 0 0 . 0 0 0
2 0.044 0.026
6 0.498 0.377
24 0.158 0.132
30 0.085 0.71
49.5 0.003 0 . 0 0 2
70.5 0 . 0 0 2 0 . 0 0 1
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FIGURE 4.7.2: Concentration versus time for the plasma mefenamic acid
levels obtained from a greyhound following the oral administration of 
mefenamic acid, 250mg.
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FIGURE 4.7.3: Excretion of mefenamic acid in the urine of a greyhound
following the oral administration of mefenamic acid, 250mg.
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FIGURE 4.7.4: Total ion chromatogram and mass chromatograms (m/z 255
and 213) obtained from the GC-MS analysis of a methylated extract of 
greyhound urine ( 6 hours after the oral administration of 250mg 
mefenamic acid).
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4.8 PHENYLBUTAZONE
4.8.1 INTRODUCTION
Phenylbutazone, the active ingredient of 
butazolidin, possesses anti-inflammatory, analgesic and 
anti-pyretic properties and has been used since 1949 in 
the treatment of rheumatic diseases. Due to serious
toxicity (aplastic anaemia and agranulocytosis), mainly in 
the elderly, its use has been limited, since 1984 to the 
clinical treatment of ankylosing spondylitis. Phenyl­
butazone is one of a series of pyrazolone derivatives; 
basic information about this drug is summarised in 
Table 4.8.1.
Phenylbutazone is almost completely absorbed after 
oral administration. Following single oral doses of 100, 
300 and 600mg to 6 subjects, peak plasma concentrations 
of about 14, 38 and 75pg/ml, respectively, were obtained 
in 1 to 7 hours (197] . Bruce and co-workers have 
reported [198] the pharmacokinetics of phenylbutazone in
the dog. After oral administration of a single I50mg dose 
a maximum plasma concentration of 30.5pg/ml is achieved 
after l hour. The plasma half-life was 2.5 hours.
However other workers have reported [199] that the plasma 
half-life increases with the size of the dose, for 
example, after 10 and 50mg doses the mean half-lives were
2.8 and 8.1 hours, respectively. Repeated dosing of 
phenylbutazone appears to cause induction of enzymes 
responsible for its metabolism in dogs but not in man, 
except to a moderate extent, resulting in a decrease in
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TABLE 4.8.1: Description and basic pharmacokinetic data for
phenylbutazone.
Chemical Name
4-Butyl-l,2-diphenyl-3,5-pyrazolidinedione
Chemical Abstracts Registry Number 
50-33-9
Non-Proprietary Name 
Phenylbutazone
Proprietary Names
Algoverine, Artrizin, Azolid, 
Butacote, Butagesic, Butazol- 
idin(e), Butazone, Intrabutazone, 
Malgesic, Nadozone, Neo-Zoline, 
Phenbutazone and Tibutazone.
Empirical Formula 
c19h 20n 2°2
Structural Formula
(CH2)3CH3
Molecular Weight Dissociation Constant
308.37 pKa = 4.4
Physical Properties
A fine, white, crystalline powder. Melting point about lOS^C. 
Practically insoluble in water; soluble 1 in 28 of ethanol, 1 in 1.25 
of chloroform and 1 in 15 of ether.
Dose Plasma Half-Life
100 and 200 mg tablets. About 2-5 days.
400-600mg daily.
Protein Binding 
about 99%
Volume of Distribution
0.18 litre/kg.
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plasma concentration of the drug [200].
The estimated minimum lethal dose of phenylbutazone
is 5g. Toxic effects during treatment are frequent and
may occur even when the daily dose does not exceed 400mg.
These side effects are usually associated with plasma 
concentrations above lOOjig/ml [BO]. Court and Volans have 
reported [191] a fatal dose of phenylbutazone as 2g in a 
1-year-old, 2.9g in a child aged 15 and 5g in one of 
4 years. Adults have suffered serious symptoms following 
the ingestion of between 4 and 40g of phenylbutazone and 
one adult who ingested between 14 and 28g of the drug
developed pulmonary oedema 25 hours after the first dose 
and died 2 hours later.
4.8.2 METABOLISM AND EXCRETION
Phenylbutazone is extensively metabolised in man 
(Figure 4.8.1). The major routes involve side-chain
oxidation, ring oxidation, combination of these and 0- and 
C-glueuronidation [200,201]. Glucuronidation at a carbon 
atom, i.e. direct coupling of the pyrazolidine ring of 
phenylbutazone to glucuronic acid via a C-C bond, is an 
unusual metabolic transformation, first observed for 
phenylbutazone. carbon glucuronidation has also been
observed in sulphinpyrazone [112]. After a single dose, 
C-glucuronidation seems to be the dominant reaction, while 
oxidation becomes increasingly important after repeated 
administration. in plasma the pharmacologically active
product of ring oxidation (p-hydroxy-phenylbutazone, 
oxyphenbutazone) is the major metabolite, whereas in
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FIGURE 4.8.1 Major metabolites of phenylbutazone in man.
I = oxphenbutazone,
II = Y-hydroxyphenbutazone,
III = p,V -dihydroxyphenbutazone,
IV = C-glucuronide of phenylbutazone,
V = C-glucuronide of metabolite II.
Broken lines indicated that the metabolic pathway is suggested 
by the structure of the metabolites, but that it has not been 
proven experimentally in man.
Glue = glucuronic acid.*
IT
N N
glue  CH2C H2CH ,C H3 ' '  %
O x id a t i  on C- glucuronidation N N
0
glue CH2CH2CHCH3 
CH
31 OH
P h en y l b u taz  one
‘c h 2c h2c h 2c h 3H
O -g lucuron idation
O-giuc
N N
H CH2CH2CH2CH3
* Reproduced from reference 201.
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urine metabolites resulting from side-chain oxidation and 
C-glucuronidation predominate [202]. in both man and dog 
plasma decay of phenylbutazone is mostly due to metabolism 
as both urinary and biliary excretion are low [199]. Only 
about 1% of a dose is excreted unchanged in the urine.
4.8.3 RESULTS
A single oral dose of loomg of phenylbutazone was 
administered to a greyhound. Urine samples were collected 
and analysed according to the methods described in 
Section 4.3. About 0.12 and 1.84^ig/ml of phenylbutazone 
were detected in the 2- and 6-hour urine samples 
respectively, but not in any of the subsequent samples
obtained. Figure 4.8.2 illustrates the total ion 
chromatogram along with 2 mass chromatograms showing the 
presence of phenylbutazone (m/z 308) and the internal
standard, 2,3-dicarboxy-naphthalene (m/z 213). Neither 
oxphenylbutazone or any of the other oxidised metabolites 
were detected. In the absence of radio-labelled
phenylbutazone it was not possible to monitor for the
formation of C-glucuronides.
4.8.4 DISCUSSION
Following a single oral dose of loomg of phenyl­
butazone it was possible to detect the drug in urine up to 
6 hours after administration. After this time the 
concentration of the drug fell below the detection limit 
in agreement with the literature reports that less than 1% 
of a dose is excreted in the urine. The dosage schedule 
used with the greyhounds allowed a sufficient interval
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(4 weeks) to avoid significant induction of liver 
microsomal enzymes [198]. None of the known metabolites 
of phenylbutazone were observed. although it was 
recognised that C-glucuronides would not be sufficiently 
stable to be eluted through the GC column.
This study was carried out towards the end of the 
project. The difficulties in detecting phenylbutazone 
prompted the examination of possible reactions occurring 
between phenylbutazone and diazomethane. in this study 
the extracts had been methylated as it would be in a 
screening procedure. The results of this examination are 
given in section 2.5 and showed that several products are 
in fact formed from phenylbutazone. Time did not permit 
the study to be repeated.
in conclusion phenylbutazone can be detected as the 
parent drug for short periods following administration in 
urine using the screening procedure developed during the 
course of this project. The detection of the drug in a 
race test sample would automatically imply that 
phenylbutazone had been administered shortly before the 
race. However, further investigation of the methylated 
products of phenylbutazone may extend the detection time 
although the drug appears to be excreted more rapidly in 
the greyhound than in man.
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FIGURE 4.8.2: Total ion chromatogram and mass chromatogram#
(m/z 308 and 213) obtained from the GC-MS analysis of a methylated 
extract of greyhound urine (6 hours after the oral administration of 
lOOmg phenylbutazone).
S72
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C H A P T E R  F I V E  
CONCLUSIONS
The aim of this study was to develop suitable 
analytical methods for the detection and measurement of 
non-steroidal anti-inflammatory drugs in urine from the 
racing greyhound. The study was conducted in three parts, 
dealing with the evaluation of analytical methodologies, 
the investigation of the greyhound urinary acid profile 
and the metabolism of non-steroidal anti-inflammatory 
drugs in the greyhound, respectively.
The development of a screening procedure for 
non-steroidal anti-inflammatory drugs (NSAIDs) in urine is 
a complex problem because, although the drugs have similar 
pharmacological effects they encompass a wide range of 
chemical types which are extensively metabolised to form 
acidic products in urine and faeces. in urine especially 
the problem of detecting drugs and their metabolites is 
complicated by the presence of many other organic acids 
similar in structure to the compounds of interest. 
However, the administered dose of anti-inflammatories is 
relatively high and it is often possible to detect small 
quantities of the parent drug in urine. screening 
procedures are therefore particularly required to overcome 
the problems of specificity rather than sensitivity.
in the present work only chromatographic procedures 
were considered. Another viable approach would be a
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series of immimo-assays. These procedures, however, are 
time-consuming and expensive to develop for a diverse
group of compounds and are unlikely to satisfy either the
analytical or medico-legal requirements for specificity.
HPLC was found to be unsuitable as a screening 
procedure for NSAIDs. Isocratic systems such as the one 
used in this evaluation are suitable for the analysis of 
specific or known groups of compounds but are unable to 
resolve completely all of the twelve test drugs. it 
should also be noted that there are many other NSAIDs on 
the market which, in the presence of their metabolites and 
other urinary components, pose an insurmountable problem 
with respect to specificity. This problem could be 
reduced by the use of a gradient system to improve 
resolution, although these systems have in the past been 
unreliable and non-reproducible. Alternatively, increased 
specificity could be achieved by using different detectors 
in series thereby increasing the amount of information 
available on the compounds eluted from the column.
careful use of pre- and post-column derivatisation 
reactions may also offer increased specificity and 
sensitivity, for example, hydroxylated metabolites might 
be distinguished from the parent drug or fluorescent 
derivatives might be prepared from compounds with no 
inherent fluorescence. GC is more suitable as the basis
for a screening procedure because of the ready
availability of high resolution capillary columns and 
reproducible temperature programming. The main drawback.
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however f is the lack of thermal stability of some NSAIDs 
even following derivatisation of the acid function. As 
with HPLC, the problems of specificity can still arise and 
are amenable to the same approach of using multiple 
detectors or they can be largely overcome by the 
effective, though expensive, use of a mass spectrometer as 
the GC detector. From experience, a single capillary 
column is unlikely to be able to resolve the complex 
mixture of components present in acidic urinary extracts: 
an additional * dimension’ is required, supplied either by 
mass spectrometry or column switching techniques.
The screening procedure developed was based on 
capillary GC-MS. This is still the only readily available 
method with sufficient resolution, specificity and 
sensitivity to detect a diverse group of target analytes 
in a complex matrix which contains many endogenous masking 
agents. One possible alternative to GC-MS would be 
gradient HPLC-MS, but this technique has not yet been 
sufficienty developed to provide a robust procedure. 
Nevertheless a need remains for a preliminary screening 
procedure capable of dealing with large numbers of samples 
in which tentative positives could be confirmed by GC-MS. 
None of the common screening methods based on immunoassay 
or TLC are likely to provide a solution, until an 
alternative is found, control of the abuse of 
non-steroidal anti-inflammatories must depend on the 
deterrent effect of random testing.
The greyhound urinary acid profile differed from
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the human profile in both qualitative and quantitative 
composition. Despite the extensive research on urinary 
acids in the clinical context many of the compounds found 
in the urine of the greyhound remain unidentified. 
However, the mass spectra of many of the constituents have 
been tabulated and have proven to be a valuable reference 
collection during studies of drug metabolism. Further 
characterisation of the endogenous components and of 
factors affecting the profile will be required to allow 
more of the drugs and their metabolites to be detected.
The derivative of choice for the metabolic study 
was the methyl derivative because the mass spectra of many 
of the methyl derivatives of urinary acids have previously 
been recorded, reducing the number of unknown components 
in the analysis. However, the butyl-dimethylsilyl 
derivatives provided mass spectra with excellent 
diagnostic ions for the detection of target analytes. 
These derivatives might form a valuable alternative to the 
methyl derivatives or the trimethylsilyl derivatives used 
in clinical chemistry.
The analytical procedure developed during this
project was able to detect five representative NSAIDs 
which had been administered to greyhounds and initial
pharmacokinetic data was obtained with implications for 
the time intervals over which the drugs might be 
detected. information was also obtained on metabolic
routes of some of the drugs examined and possible cut-off 
levels were suggested. Future work would require a
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statistically significant number of animals to be studied 
using different dosing regimens to establish a normal 
range of pharmacokinetic parameters of each drug of 
interest in the greyhound population.
Of the five drugs examined in this project 
phenylbutazone presented the most serious problems of 
detection due to formation of multiple products with 
diazomethane. This could be avoided with the use of the 
butyl-dimethylsilyl derivative.
The work carried out in this project has provided 
the N.G.R.C. with some of the information needed to 
control the abuse of drugs in its sport. Another aspect 
of control concerns the interpretation of the significance 
of drugs detected and their probable effects on 
performance. This problem will be addressed in future 
work by concurrent observations of the racing form of the 
dogs during the course of metabolic studies.
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